Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJHM1624

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 3	MAR 16	CASREACT coverage extended
NEWS 4	MAR 20	MARPAT now updated daily
NEWS 5	MAR 22	LWPI reloaded
NEWS 6	MAR 30	RDISCLOSURE reloaded with enhancements
NEWS 7	APR 02	JICST-EPLUS removed from database clusters and STN
NEWS 8	APR 30	GENBANK reloaded and enhanced with Genome Project ID field
NEWS 9	APR 30	CHEMCATS enhanced with 1.2 million new records
NEWS 10	APR 30	CA/CAplus enhanced with 1870-1889 U.S. patent records
NEWS 11	APR 30	INPADOC replaced by INPADOCDB on STN
NEWS 12	MAY 01	New CAS web site launched
NEWS 13	MAY 08	CA/CAplus Indian patent publication number format defined
NEWS 14	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS 15	MAY 21	BIOSIS reloaded and enhanced with archival data
NEWS 16	MAY 21	TOXCENTER enhanced with BIOSIS reload
NEWS 17	MAY 21	CA/CAplus enhanced with additional kind codes for German patents
NEWS 18	MAY 22	CA/CAplus enhanced with IPC reclassification in Japanese patents
NEWS 19	JUN 27	CA/CAplus enhanced with pre-1967 CAS Registry Numbers
NEWS 20	JUN 29	STN Viewer now available
NEWS 21	JUN 29	STN Express, Version 8.2, now available
NEWS 22	JUL 02	LEMBASE coverage updated
NEWS 23	JUL 02	LMEDLINE coverage updated
NEWS 24	JUL 02	SCISEARCH enhanced with complete author names
NEWS 25	JUL 02	CHEMCATS accession numbers revised
NEWS 26	JUL 02	CA/CAplus enhanced with utility model patents from China
NEWS 27	JUL 16	CAplus enhanced with French and German abstracts
NEWS 28	JUL 18	CA/CAplus patent coverage enhanced
NEWS 29	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification

NEWS EXPRESS 29 JUNE 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:44:44 ON 26 JUL 2007

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 11:44:56 ON 26 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 25 JUL 2007 HIGHEST RN 943407-83-8
DICTIONARY FILE UPDATES: 25 JUL 2007 HIGHEST RN 943407-83-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10 series\10531889\10531889a.str





chain nodes :
7 14 15 16 17 18 19 23 25
ring nodes :
1 2 3 4 5 6 8 9 10 11 12 13
chain bonds :
1-18 2-19 3-15 4-16 5-17 6-7 7-8 9-25 10-23 12-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13
exact/norm bonds :
1-18 2-19 3-15 4-16 5-17 6-7 7-8 10-23 12-14
exact bonds :
9-25
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13

G1:H,X,CN

G2:H,Cl,F

G3:H,OH,X,CF3,Ak,Cb

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 23:CLASS 25:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 H,X,CN

G2 H,Cl,F

G3 H,OH,X,CF3,Ak,Cb

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 11:45:17 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 416 TO ITERATE

100.0% PROCESSED 416 ITERATIONS 18 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 7097 TO 9543
PROJECTED ANSWERS: 106 TO 614

L2 18 SEA SSS SAM L1

=> d scan

L2 18 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(3,4-dichlorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI)
MF C22 H16 Cl2 N6 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 18 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-[4-(dimethylamino)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI)
MF C24 H21 N7 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

```
=> s l1 sss full
FULL SEARCH INITIATED 11:45:59 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     8199 TO ITERATE

100.0% PROCESSED     8199 ITERATIONS                                411 ANSWERS
SEARCH TIME: 00.00.01

L3          411 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     172.55     172.76

FILE 'CAPLUS' ENTERED AT 11:46:03 ON 26 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 26 Jul 2007  VOL 147 ISS 5
FILE LAST UPDATED: 25 Jul 2007  (20070725/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4          35 L3

=> d scan
```

L4 35 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
IC ICM C07D
CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63
TI Preparation of diaminopyrimidines as anticancer drugs.
ST aminopyrimidine prepn anticancer; pyrimidinamine pyridyloxyphenylamino indolyl prepn cancer treatment
IT Antitumor agents
Drug delivery systems
Human
(preparation of diaminopyrimidines as anticancer drugs)
IT Neoplasm
(treatment; preparation of diaminopyrimidines as anticancer drugs)
IT 912471-74-0P 912471-75-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of diaminopyrimidines as anticancer drugs)
IT 56-05-3, 4,6-Dichloropyrimidin-2-amine 110-91-8, Morpholine, reactions 123-30-8, 4-Aminophenol 19235-89-3, 4-Chloropyridine-2-carbonitrile 144104-59-6, 1H-Indol-5-ylboronic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of diaminopyrimidines as anticancer drugs)
IT 630125-69-8P 850250-76-9P 871240-10-7P 912471-76-2P 912472-79-8P 912472-80-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of diaminopyrimidines as anticancer drugs)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

```
=> s l4 ibib abs hitstr
MISSING OPERATOR L4 IBIB
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> d l4 1-35 ibib abs hitstr
```

L4 ANSWER 1 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:510223 CAPLUS
DOCUMENT NUMBER: 146:501071
TITLE: Preparation of bi-aryl 2,4-pyrimidinediamines as inhibitors of kinases
INVENTOR(S): Cao, Jon Jianguo; Hood, John; Lohse, Dan; Mak, Chi Ching; McPherson, Andrew; Noronha, Glenn; Pathak, Ved; Renick, Joel; Soll, Richard M.; Zeng, Binqi
PATENT ASSIGNEE(S): Targegen, Inc., USA
SOURCE: PCT Int. Appl., 336pp., which
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007053452	A1	20070510	WO 2006-US42044	20061026
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: US 2005-732629P P 20051101
US 2006-838003P P 20060815
OTHER SOURCE(S): MARPAT 146:501071
GI



I



II

L4 ANSWER 1 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

AB The title compds. I [X = a bond, C(O), SO2, CH2; Y = a bond, NR9; or X and Y taken together is a bond; R1, R2 = H, alkyl, cycloalkyl, etc.; or R1 and R2 taken together is a bond; or R1 and R2 taken together form (CH2)m, (CH2)rS(CH2)m, (CH2)rO(CH2)m, etc.; p, q, r, n, m = 0-6; R9 = H, alkyl, cycloalkyl, etc.; G0 = N, O, H, CH; R3, R4 = H, alkyl, hydrocyalkyl, etc.; G = N or CR6; R5 = Me; Q = (un)substituted Ph, indolyl, indazolyl, etc.; with provisos] that are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non receptor kinases, were prepared E.g., a 2-step synthesis of II, starting from 4-chloropyrimidin-2-ylamine and 4-methoxyphenylamine, was given. Exemplified compds. I were tested for inhibition of JAK2 kinase (data given). The invention also relates to pharmaceutical composition comprising the compound I alone or in combination with other therapeutic agents.

IT 500863-19-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of bi-aryl 2,4-pyrimidinediamines as inhibitors of JAK kinases
for treating diseases)

RN 500863-19-4 CAPLUS
CN 2,4-Pyrimidinediamine, N4-(4-methoxyphenyl)- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:1097641 CAPLUS
DOCUMENT NUMBER: 145:419172
TITLE: Preparation of diaminopyrimidines as anticancer drugs.
INVENTOR(S): Nagarathnam, Dhanapalan; Chen, Yuanwei; Fu, Wenlang; Wang, Ming; Bierer, Donald; Brands, Michael; Wang, Yamin; Bear, Brian R.
PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 42pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006110447	A2	20061019	WO 2006-US12828	20060407
WO 2006110447	A3	20070118		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: US 2005-669461P P 20050408
OTHER SOURCE(S): MARPAT 145:419172
GI



I

AB Title compds. [I; A = O, NRa; Ra = H, alkyl; D = N, CH; R2 = (substituted) bicyclic aryl; R3 = Cl, Br, cyano, aminocarbonyl, alkylaminocarbonyl, alkyl, CF3; R4 = H, alkyl; R5 = H, halo], were prepared Thus, 6-chloro-N4-(4-[[2-(trifluoromethyl)pyridin-4-yl]oxy]phenyl]pyrimidine-2,4-diamine (preparation given), 1H-indol-5-ylboronic acid, PdCl2(dppf), dimethylacetamide, and aqueous K2CO3 were heated together at 120° overnight to give 6-(1H-indol-5-yl)-N4-[4-[[2-(trifluoromethyl)pyridin-4-

L4 ANSWER 2 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
yl]oxy]phenyl]pyrimidine-2,4-diamine. The latter showed an IC50 ≤500 nM in the HCT116 cytotoxic activity assay.

IT 850250-76-9P 871240-10-7P 912471-76-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of diaminopyrimidines as anticancer drugs)

RN 850250-76-9 CAPLUS
CN 2,4-Pyrimidinediamine, 6-chloro-N4-[4-[(2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 871240-10-7 CAPLUS
CN 2,4-Pyrimidinediamine, 6-chloro-N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 912471-76-2 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[(2-amino-6-chloro-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:977961 CAPLUS
DOCUMENT NUMBER: 145:356802
TITLE: Preparation of pyrimidine derivatives for treatment of hyperproliferative disorders
INVENTOR(S): Dixon, Julie A.; Nagarathnam, Dhanapalan; Zhang, Lei; Wang, Chunguang; Yi, Lin; Chen, Yuanwei; Chen, Jianqing; Bear, Brian R.; Brands, Michael; Hillisch, Alexander; Bierer, Donald; Wang, Ming; Fu, Wenlang; Hentemann, Martin F.; Bullion, Ann-Marie; Patel, Manoj
PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 100pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006099231	A1	20060921	WO 2006-US8779	20060309

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2005-660561P P 20050310
OTHER SOURCE(S): MARPAT 145:356802
GI

L4 ANSWER 3 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I



II

AB Title compds. represented by the formula I [wherein R1 = H; R2 = NH2; L = O; M = CH, m = 1; n = 0-2; G = Me or CF3; G' = Me or NH2; J = pyridinyl or pyrimidyl; Y = Ph, pyridinyl or pyrimidyl; and pharmaceutically acceptable salts thereof] were prepared for treatment of hyperproliferative disorders. For example, II was provided in a multi-step synthesis starting from the reaction of guanidine carbonate with Et 3-oxo-3-phenylpropanoate. Selected I were tested for cytotoxic activity using human HCT-116 cell line with IC50 values of 3 - 135 nM. Thus, I and their pharmaceutical comprns. are useful for the treatment of hyperproliferative diseases, such as cancer.

IT 850247-06-2P, 4-[4-[(2-Amino-6-phenylpyrimidin-4-yl)amino]phenoxy]pyridine-2-carbonitrile 850247-12-0P, 4-[4-[(2-Amino-6-phenylpyrimidin-4-yl)amino]phenoxy]pyridine-2-carboxylic acid 850247-15-3P, 4-[4-[(2-Amino-6-phenylpyrimidin-4-yl)amino]phenoxy]-N-(2-methoxyethyl)pyridine-2-carboxamide 850247-26-6P, 6-Phenyl-N'-[4-[[2-(trifluoromethyl)pyridin-4-yl]oxy]phenyl]pyrimidine-2,4-diamine 850247-28-8P, N'-[4-[[2-(Aminomethyl)pyridin-4-yl]oxy]phenyl]-6-phenylpyrimidine-2,4-diamine 850247-38-0P, N'-[4-[(2-Chloropyridin-4-yl)oxy]phenyl]-6-phenylpyrimidine-2,4-diamine 850247-41-5P, 4-[2-Amino-6-[[4-[[2-(trifluoromethyl)pyridin-4-yl]oxy]phenyl]amino]pyrimidin-4-yl]phenol
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrimidine derivs. for treatment of hyperproliferative disorders)

RN 850247-06-2 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 850247-12-0 CAPLUS
CN 2-Pyridinecarboxylic acid, 4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850247-15-3 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 850247-26-6 CAPLUS
CN 2,4-Pyrimidinediamine, 6-phenyl-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850247-28-8 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-(aminomethyl)-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 850247-38-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-chloro-4-pyridinyl)oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-41-5 CAPLUS
CN Phenol, 4-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



IT 850246-99-0P, N'-[4-[(2-Ethylpyridin-4-yl)oxy]phenyl]-6-phenylpyrimidine-2,4-diamine 850247-00-6P, N'-[4-[(2-Methylpyridin-4-yl)oxy]phenyl]-6-phenylpyrimidine-2,4-diamine 850247-03-9P, N'-[4-[(3,5-Difluoropyridin-4-yl)oxy]phenyl]-6-phenylpyrimidine-2,4-diamine 850247-04-0P, N'-[4-(4-Nitrophenoxy)phenyl]-6-phenylpyrimidine-2,4-diamine 850247-05-1P, N'-[3-Fluoro-4-[(2-methylpyridin-4-yl)oxy]phenyl]-6-phenylpyrimidine-2,4-diamine 850247-09-5P, N'-[4-(4-Chlorophenoxy)phenyl]-6-phenylpyrimidine-2,4-diamine 850247-10-8P, N'-[4-(4-Methoxyphenoxy)phenyl]-6-phenylpyrimidine-2,4-diamine 850247-11-9P, Methyl 4-[4-[(2-amino-6-phenylpyrimidin-4-yl)amino]phenoxy]pyridine-2-carboxylate 850247-13-1P, N'-[4-[[2-(Morpholin-4-ylcarbonyl)pyridin-4-yl]oxy]phenyl]-6-phenylpyrimidine-2,4-diamine 850247-16-4P, N'-[4-[[2-[(4-Methylpiperazin-1-yl)carbonyl]pyridin-4-yl]oxy]phenyl]-6-phenylpyrimidine-2,4-diamine 850247-21-1P, N'-[4-[[2-[2-(Morpholin-4-yl)ethoxy]pyridin-4-yl]oxy]phenyl]-6-phenylpyrimidine-2,4-diamine 850247-27-7P, N'-[4-[[1-Oxido-2-(trifluoromethyl)pyridin-4-yl]oxy]phenyl]-6-phenylpyrimidine-2,4-diamine 850247-29-9P, N-[[4-[4-[(2-Amino-6-phenylpyrimidin-4-yl)amino]phenoxy]pyridin-2-yl]methyl]methanesulfonamide 850247-31-3P, N-[[4-[4-[(2-Amino-6-phenylpyrimidin-4-

yl)amino]phenoxy]pyridin-2-yl]methyl]-4-fluorobenzamide 850247-32-4P, 3-[[4-[4-[(2-Amino-6-phenylpyrimidin-4-yl)amino]phenoxy]pyridin-2-yl]methyl]-1,1-diethylurea 850247-33-5P 850247-34-6P, N'-[4-[[2-[(Isopropylamino)methyl]pyridin-4-yl]oxy]phenyl]-6-phenylpyrimidine-2,4-diamine 850247-35-7P, 4-[4-[(2-Amino-6-phenylpyrimidin-4-yl)amino]phenoxy]pyridine-2-carboxylic acid (2-hydroxyethyl)amide 850247-36-8P, 6-Phenyl-N'-[4-[[2-(1H-tetrazol-5-yl)pyridin-4-yl]oxy]phenyl]pyrimidine-2,4-diamine 850247-37-9P, N'-[4-[[2-(4,5-Dihydro-1H-imidazol-2-yl)pyridin-4-yl]oxy]phenyl]-6-phenylpyrimidine-2,4-diamine 850247-39-1P, (S)-N'-[4-[[2-(2-Methoxymethylpyrrolidin-1-yl)pyridin-4-yl]oxy]phenyl]-6-phenylpyrimidine-2,4-diamine 850247-42-6P 850247-43-7P, N'-[4-[(2-Aminopyridin-4-yl)oxy]phenyl]-6-phenylpyrimidine-2,4-diamine 850247-44-8P, 4-[2-Amino-6-[[4-[(2-chloropyridin-4-yl)oxy]phenyl]amino]pyrimidin-4-yl]phenol 850247-45-9P, (3E)-4-[4-[4-[(2-Amino-6-phenylpyrimidin-4-yl)amino]phenoxy]pyridin-2-yl]but-3-en-1-ol 850247-48-2P 850252-00-5P, 4-[4-[(2-Amino-6-phenylpyrimidin-4-yl)amino]-3-fluorophenoxy]pyridine-2-carbonitrile hydrochloride 871240-05-0P, 6-(2,6-Dimethylphenyl)-N'-[4-[[2-(trifluoromethyl)pyridin-4-yl]oxy]phenyl]pyrimidine-2,4-diamine 871240-08-3P, 6-Phenyl-N'-[4-[[2-(trifluoromethyl)pyrimidin-4-yl]oxy]phenyl]pyrimidine-2,4-diamine 910215-42-8P, 2-Amino-N-[4-[2-amino-6-[[4-[(2-trifluoromethylpyridin-4-yl)oxy]phenyl]amino]pyrimidin-4-yl]phenyl]-3-hydroxypropionamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyrimidine derivs. for treatment of hyperproliferative disorders)

RN 850246-99-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-ethyl-4-pyridinyl)oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-00-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-03-9 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(3,5-difluoro-4-pyridinyl)oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-11-9 CAPLUS
CN 2-Pyridinecarboxylic acid, 4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 850247-13-1 CAPLUS
CN Morpholine, 4-[[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 850247-16-4 CAPLUS
CN Piperazine, 1-[[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 850247-21-1 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-[2-(4-morpholinyl)ethoxy]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-04-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-(4-nitrophenoxy)phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-05-1 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[3-fluoro-4-[(2-methyl-4-pyridinyl)oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-09-5 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-(4-chlorophenoxy)phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-10-8 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-(4-methoxyphenoxy)phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-27-7 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[1-oxido-2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-29-9 CAPLUS
CN Methanesulfonamide, N-[[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 850247-31-3 CAPLUS
CN Benzamide, N-[[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]methyl]-4-fluoro- (9CI) (CA INDEX NAME)



RN 850247-32-4 CAPLUS
CN Urea, N'-[[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]methyl]-N,N-diethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 850247-33-5 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[4-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-2-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 850247-34-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-[[(1-methylethyl)amino]methyl]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-35-7 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 850247-43-7 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-amino-4-pyridinyl)oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-44-8 CAPLUS
CN Phenol, 4-[2-amino-6-[[4-[(2-chloro-4-pyridinyl)oxy]phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 850247-45-9 CAPLUS
CN 3-Buten-1-ol, 4-[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]-, (3E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 850247-48-2 CAPLUS
CN 2-Pyridinemethanol, 4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-,

L4 ANSWER 3 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 850247-36-8 CAPLUS
CN 2,4-Pyrimidinediamine, 6-phenyl-N4-[4-[[2-(1H-tetrazol-5-yl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850247-37-9 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-(4,5-dihydro-1H-imidazol-2-yl)-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-39-1 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850247-42-6 CAPLUS
CN Sulfamic acid, 4-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]phenyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 850247-47-1
CMF C22 H19 N5 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 850252-00-5 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]-3-fluorophenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 871240-05-0 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(2,6-dimethylphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 871240-08-3 CAPLUS
CN 2,4-Pyrimidinediamine, 6-phenyl-N4-[4-[[2-(trifluoromethyl)-4-pyrimidinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 910215-42-8 CAPLUS
CN Propanamide, 2-amino-N-[4-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]phenyl]-3-hydroxy- (9CI) (CA INDEX NAME)



IT 850247-52-8, N'-[4-[(4-Bromopyridin-2-yl)oxy]phenyl]-6-phenylpyrimidine-2,4-diamine 850248-80-5, 6-(4-Aminophenyl)-N'-[4-[[2-(trifluoromethyl)pyridin-4-yl]oxy]phenyl]pyrimidine-2,4-diamine
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrimidine derivs. for treatment of hyperproliferative disorders)
RN 850247-52-8 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(4-bromo-2-pyridinyl)oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850248-80-5 CAPLUS

L4 ANSWER 3 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 2,4-Pyrimidinediamine, 6-(4-aminophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



IT 850250-76-9P, 6-Chloro-N'-[4-[[2-(trifluoromethyl)pyridin-4-yl]oxy]phenyl]pyrimidine-2,4-diamine 871240-10-7P, 6-Chloro-N'-[4-[[2-methylpyridin-4-yl)oxy]phenyl]pyrimidine-2,4-diamine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrimidine derivs. for treatment of hyperproliferative disorders)
RN 850250-76-9 CAPLUS
CN 2,4-Pyrimidinediamine, 6-chloro-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 871240-10-7 CAPLUS
CN 2,4-Pyrimidinediamine, 6-chloro-N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:600888 CAPLUS
DOCUMENT NUMBER: 145:83219
TITLE: Preparation of 4-phenoxy-7-azaindoles as rho kinase II inhibitors
INVENTOR(S): Schirok, Hartmut; Stasch, Johannes-Peter; Kast, Raimund; Figueroa Perez, Santiago; Muenter, Klaus; Gnoth, Mark Jean; Radtke, Martin; Lang, Dieter; Mittendorf, Joachim
PATENT ASSIGNEE(S): Bayer Healthcare A.-G., Germany
SOURCE: Ger. Offen., 24 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 102004060752	A1	20060622	DE 2004-102004060752	20041215
PRIORITY APPLN. INFO.:			DE 2004-102004060752	20041215

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = CF3; R2 = H, F; R3 = H, Cl, CF3, etc.] and their pharmaceutically acceptable salts and formulations were prepared For example, coupling of 2-amino-4-chloropyrimidine and aniline II afforded phenoxyazaindole III in 53% yield. In rho kinase II inhibition assays, 4-examples of compds. I exhibited IC50 values ranging from 0.7-0.9 nM.

IT 892414-37-8P 892414-38-9P 892414-39-0P
892414-40-3P 892414-41-4P 892414-42-5P
892414-43-6P 892414-44-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4-phenoxy-7-azaindoles as rho kinase II inhibitors)
RN 892414-37-8 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[3-fluoro-4-[[3-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 892414-38-9 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[3,5-difluoro-4-[[3-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 892414-39-0 CAPLUS
CN 2,4-Pyrimidinediamine, 6-chloro-N4-[3,5-difluoro-4-[[3-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 892414-40-3 CAPLUS
CN 2,4-Pyrimidinediamine, 6-cyclopropyl-N4-[3,5-difluoro-4-[[3-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 892414-41-4 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[3,5-difluoro-4-[[3-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 892414-44-7 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[3,5-difluoro-4-[[3-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-6-(1-methylethyl)- (9CI) (CA INDEX NAME)





RN 892414-42-5 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[3,5-difluoro-4-[[3-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 892414-43-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[3,5-difluoro-4-[[3-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-6-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

ACCESSION NUMBER: 2006:301346 CAPLUS
DOCUMENT NUMBER: 144:350708
TITLE: Novel pyrimidine compounds, process for their preparation, pharmaceutical compositions, and their use as antiinflammatory, cytotoxic, rheumatic, immunosuppressive and cardiovascular agents for treatment of diseases
INVENTOR(S): Kalleda, Srinivas; Padakanti, Srinivas; Kumar Swamy, Nalivela; Yeleswarapu, Koteswar Rao; Alexander, Christopher W.; Khanna, Ish Kumar; Iqbal, Javed; Pillarisetti, Sivaram; Pal, Manojit; Barange, Deepak
PATENT ASSIGNEE(S): Reddy US Therapeutics, Inc., USA
SOURCE: PCT Int. Appl., 336 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006034473	A2	20060330	WO 2005-US34243	20050923
WO 2006034473	A3	20061214		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005286592	A1	20060330	AU 2005-286592	20050923
CA 2581454	A1	20060330	CA 2005-2581454	20050923
US 2006084644	A1	20060420	US 2005-234257	20050923
US 2006084645	A1	20060420	US 2005-234695	20050923
EP 1796673	A2	20070620	EP 2005-799686	20050923
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				

PRIORITY APPLN. INFO.: US 2004-612374P P 20040923
WO 2005-US34243 W 20050923
OTHER SOURCE(S): MARPAT 144:350708
GI

L4 ANSWER 5 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AB The invention provides heterocyclic compds., particularly substituted pyrimidines of formula I, methods and compns. for making and using these heterocyclic compds., and methods for treating a variety of diseases and disease states, including atherosclerosis, arthritis, restenosis, diabetic nephropathy, or dyslipidemia, or disease states mediated by the low expression of Perlecan. Compds. of formula I wherein R1, R2 and R4 are independently (un)substituted (hetero)aryl or (un)substituted heterocyclyl; and their pharmaceutically acceptable salts, prodrugs, diastereoisomeric mixts., enantiomers, tautomers, and racemic mixts. thereof are claimed in this invention. Example compound II was prepared by acylation of 4-methoxyacetophenone with di-Et carbonate; the resulting Et 4-methoxybenzoylacetate underwent cyclization with guanidine carbonate to give 2-amino-6-(4-methoxyphenyl)pyrimidin-4-ol, which was converted to 4-chloro-6-(methoxyphenyl)pyrimidin-2-ylamine, which underwent amination with 3-chloro-4-methoxyaniline to give compound II. The invention compds. were evaluated for their antiinflammatory, proliferative, cardiovascular, and immunosuppressive activity (no data).

IT 881193-01-7P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate and intermediate; preparation of pyrimidine compds. and their use as antiinflammatory, proliferative, rheumatic, immunosuppressive and cardiovascular agents for treatment of diseases)

RN 881193-01-7 CAPLUS
CN 2,4-Pyrimidinediamine, N4-(3-chloro-4-methoxyphenyl)-6-phenyl- (9CI) (CA INDEX NAME)



IT 843608-32-2P 881193-00-6P 881193-02-8P
881193-03-9P 881193-04-0P 881193-05-1P
881193-06-2P 881193-07-3P 881193-10-8P
881194-21-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

L4 ANSWER 5 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 881193-05-1 CAPLUS
CN 2,4-Pyrimidinediamine, N4-(3-chloro-4-methoxyphenyl)-6-[4-(methylthio)phenyl]- (9CI) (CA INDEX NAME)



RN 881193-06-2 CAPLUS
CN 2,4-Pyrimidinediamine, N4-(3-fluoro-4-methoxyphenyl)-6-(4-methoxyphenyl)-(9CI) (CA INDEX NAME)



RN 881193-07-3 CAPLUS
CN Phenol, 4-[[2-amino-6-(4-methoxyphenyl)-4-pyrimidinyl]amino]-2-chloro-(9CI) (CA INDEX NAME)



RN 881193-10-8 CAPLUS
CN Phenol, 4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]-2-chloro- (9CI) (CA INDEX NAME)



RN 881194-21-4 CAPLUS
CN 2,4-Pyrimidinediamine, N4-(3-chloro-4-methoxyphenyl)-6-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(drug candidate; prepn. of pyrimidine compds. and their use as antiinflammatory, proliferative, rheumatic, immunosuppressive and cardiovascular agents for treatment of diseases)

RN 843608-32-2 CAPLUS
CN 2,4-Pyrimidinediamine, N4-(3-chloro-4-methoxyphenyl)-6-methyl- (9CI) (CA INDEX NAME)



RN 881193-00-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-(3-chloro-4-methoxyphenyl)-6-(4-methoxyphenyl)-(9CI) (CA INDEX NAME)



RN 881193-02-8 CAPLUS
CN 2,4-Pyrimidinediamine, N4-(3-chloro-4-methoxyphenyl)-6-(4-fluorophenyl)-(9CI) (CA INDEX NAME)



RN 881193-03-9 CAPLUS
CN 2,4-Pyrimidinediamine, N4-(3-chloro-4-methoxyphenyl)-6-(4-ethoxyphenyl)-(9CI) (CA INDEX NAME)



RN 881193-04-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-(3-chloro-4-methoxyphenyl)-6-(4-methylphenyl)-(9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1313901 CAPLUS
DOCUMENT NUMBER: 144:51598
TITLE: Preparation of amino-substituted pyrimidines as antitumor agents
INVENTOR(S): Dixon, Julie A.; Nagarathnam, Dhanapalan; Zhang, Lei; Wang, Chunguang; Yi, Lin; Chen, Yuanwei; Chen, Jianqing; Bear, Brian R.; Brands, Michael; Hillisch, Alexander; Bierer, Donald; Wang, Ming; Fu, Wenlang; Hentemann, Martin F.; Bullion, Ann-Marie; Patel, Manoj
PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 182 pp., Cont.-in-part of Appl. No. PCT/US04/033430.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005277640	A1	20051215	US 2005-78681	20050310
WO 2005035507	A2	20050421	WO 2004-US33430	20041008
WO 2005035507	A3	20060831		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-510804P P 20031010
WO 2004-US33430 A2 20041008
OTHER SOURCE(S): CASREACT 144:51598; MARPAT 144:51598
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = H, alkyl, cyclopropyl; R2 = alkyl, cyclopropyl, O-alkyl, etc.; R3 = H, halo; M = CH, N; L = carbonyl, O, (un)substituted alkylenyl, etc.; J and Y independently = substituted aryl, heteroaryl; A = halo, CF3, CN, etc.; m = 0-2] and their pharmaceutically acceptable salts, are prepared and disclosed as useful antitumor agents. Thus, coupling 6-chloro-N4-(4-([2-(trifluoromethyl)pyridin-4-yl]oxy)phenyl)pyrimidine-2,4-diamine with 1,3-dimethylphenylboronic acid afforded 56% II which showed IC50 of 62 nM in test for cytotoxic activity on HCT-116 cells.

IT 850247-06-2P 850247-12-0P 850247-26-6P
850247-28-8P 850247-38-0P 850247-41-5P
850248-80-5P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of amino-substituted pyrimidines as antitumor agents)

RN 850247-06-2 CAPLUS

L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 850247-41-5 CAPLUS
CN Phenol, 4-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 850248-80-5 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(4-aminophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



IT 850246-99-0P 850247-00-6P 850247-03-9P
850247-04-0P 850247-05-1P 850247-09-5P
850247-10-8P 850247-11-9P 850247-14-2P
850247-15-3P 850247-17-5P 850247-21-1P
850247-27-7P 850247-30-2P 850247-31-3P
850247-32-4P 850247-33-5P 850247-34-6P
850247-35-7P 850247-36-8P 850247-37-9P
850247-39-1P 850247-40-4P 850247-42-6P
850247-43-7P 850247-44-8P 850247-46-0P
850247-48-2P 850247-50-6P 850247-51-7P
850247-52-8P 850247-54-0P 850247-55-1P
850247-56-2P 850247-57-3P 850247-58-4P
850247-59-5P 850247-60-8P 850247-61-9P
850247-63-1P 850247-65-3P 850247-68-6P
850247-70-0P 850247-71-1P 850247-73-3P
850247-75-5P 850247-76-6P 850247-77-7P
850247-78-8P 850247-80-2P 850247-86-8P
850247-88-0P 850247-91-5P 850247-94-8P
850247-97-1P 850248-00-9P 850248-03-2P
850248-04-3P 850248-05-4P 850248-07-6P
850248-08-7P 850248-09-8P 850248-10-1P
850248-11-2P 850248-12-3P 850248-13-4P

L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 2-Pyridinecarbonitrile, 4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850247-12-0 CAPLUS
CN 2-Pyridinecarboxylic acid, 4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850247-26-6 CAPLUS
CN 2,4-Pyrimidinediamine, 6-phenyl-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850247-28-8 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-(aminomethyl)-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-38-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-chloro-4-pyridinyl)oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
850248-14-5P 850248-15-6P 850248-16-7P
850248-17-8P 850248-18-9P 850248-20-3P
850248-21-4P 850248-22-5P 850248-23-6P
850248-24-7P 850248-41-8P 850248-43-0P
850248-45-2P 850248-46-3P 850248-47-4P
850248-48-5P 850248-49-6P 850248-50-9P
850248-51-0P 850248-52-1P 850248-53-2P
850248-54-3P 850248-55-4P 850248-56-5P
850248-57-6P 850248-58-7P 850248-59-8P
850248-61-2P 850248-62-3P 850248-63-4P
850248-65-6P 850248-67-8P 850248-68-9P
850248-69-0P 850248-70-3P 850248-71-4P
850248-72-5P 850248-73-6P 850248-74-7P
850248-75-8P 850248-76-9P 850248-77-0P
850248-78-1P 850248-79-2P 850248-81-6P
850248-82-7P 850248-83-8P 850248-84-9P
850248-85-0P 850248-86-1P 850248-87-2P
850248-88-3P 850248-89-4P 850248-90-7P
850248-91-8P 850248-92-9P 850248-93-0P
850248-95-2P 850248-96-3P 850248-98-5P
850249-00-2P 850249-01-3P 850249-02-4P
850249-03-5P 850249-05-7P 850249-06-8P
850249-08-0P 850249-09-1P 850249-10-4P
850249-12-6P 850249-13-7P 850249-14-8P
850249-15-9P 850249-16-0P 850249-17-1P
850249-18-2P 850249-20-6P 850249-21-7P
850249-22-8P 850249-23-9P 850249-24-0P
850249-25-1P 850249-26-2P 850249-27-3P
850249-28-4P 850249-31-9P 850249-32-0P
850249-33-1P 850249-35-3P 850249-38-6P
850249-40-0P 850249-42-2P 850249-44-4P
850249-45-5P 850249-47-7P 850249-48-8P
850249-54-6P 850249-57-9P 850249-59-1P
850249-61-5P 850249-63-7P 850249-64-8P
850249-70-6P 850249-73-9P 850249-75-1P
850249-77-3P 850249-78-4P 850249-79-5P
850249-80-8P 850249-81-9P 850249-82-0P
850249-83-1P 850249-84-2P 850249-85-3P
850249-87-5P 850249-88-6P 850249-89-7P
850249-91-1P 850249-92-2P 850249-93-3P
850249-95-5P 850249-96-6P 850249-97-7P
850249-98-8P 850249-99-9P 850250-00-9P
850250-01-0P 850250-02-1P 850250-03-2P
850250-04-3P 850250-06-5P 850250-07-6P
850250-08-7P 850250-09-8P 850250-10-1P
850250-11-2P 850250-12-3P 850250-13-4P
850250-14-5P 850250-15-6P 850250-18-9P
850250-40-7P 850250-41-8P 850250-42-9P
850250-43-0P 850250-44-1P 850250-45-2P
850250-46-3P 850250-47-4P 850250-49-6P
850250-50-9P 850250-51-0P 850250-52-1P
850250-53-2P 850250-54-3P 850250-55-4P
850250-57-6P 850250-58-7P 850250-59-8P
850250-60-1P 850250-61-2P 850250-81-6P
850252-00-5P 850252-01-6P 871240-05-0P
871240-08-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of amino-substituted pyrimidines as antitumor agents)

L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 850246-99-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-ethyl-4-pyridinyl)oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-00-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-03-9 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(3,5-difluoro-4-pyridinyl)oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-04-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-(4-nitrophenoxy)phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-05-1 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[3-fluoro-4-[(2-methyl-4-pyridinyl)oxy]phenyl]-6-

L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CM 1

CRN 850247-13-1
CMF C26 H24 N6 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 850247-15-3 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 850247-17-5 CAPLUS
CN Piperazine, 1-[[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]carbonyl]-4-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850247-16-4
CMF C27 H27 N7 O2

L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
phenyl- (9CI) (CA INDEX NAME)



RN 850247-09-5 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-(4-chlorophenoxy)phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-10-8 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-(4-methoxyphenoxy)phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-11-9 CAPLUS
CN 2-Pyridinecarboxylic acid, 4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 850247-14-2 CAPLUS
CN Morpholine, 4-[[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]carbonyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 850247-21-1 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-[2-(4-morpholinyl)ethoxy]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-27-7 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[1-oxido-2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-30-2 CAPLUS
CN Methanesulfonamide, N-[[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CRN 850247-29-9
CMF C23 H22 N6 O3 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 850247-31-3 CAPLUS
CN Benzamide, N-[[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]methyl]-4-fluoro- (9CI) (CA INDEX NAME)



RN 850247-32-4 CAPLUS
CN Urea, N'-[[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]methyl]-N,N-diethyl- (9CI) (CA INDEX NAME)



L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 850247-37-9 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-(4,5-dihydro-1H-imidazol-2-yl)-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-39-1 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850247-40-4 CAPLUS
CN Propanamide, 2-amino-N-[4-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]phenyl]-3-hydroxy-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 850247-33-5 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[4-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-2-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 850247-34-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-[[(1-methylethyl)amino]methyl]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-35-7 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 850247-36-8 CAPLUS
CN 2,4-Pyrimidinediamine, 6-phenyl-N4-[4-[[2-(1H-tetrazol-5-yl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 850247-42-6 CAPLUS
CN Sulfamic acid, 4-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]phenyl ester (9CI) (CA INDEX NAME)



RN 850247-43-7 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-amino-4-pyridinyl)oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-44-8 CAPLUS
CN Phenol, 4-[2-amino-6-[[4-[(2-chloro-4-pyridinyl)oxy]phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 850247-46-0 CAPLUS
CN 3-Buten-1-ol, 4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]-, (3E)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CM 1

CRN 850247-45-9
CMF C25 H23 N5 O2

Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 850247-48-2 CAPLUS
CN 2-Pyridinemethanol, 4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 850247-47-1
CMF C22 H19 N5 O2



CM 2

L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CRN 850247-53-9
CMF C21 H16 F N5 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 850247-55-1 CAPLUS
CN 2(1H)-Pyridinone, 4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850247-56-2 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-chloro-4-pyridinyl)oxy]-2-fluorophenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-57-3 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[2-fluoro-4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CRN 76-05-1
CMF C2 H F3 O2

RN 850247-50-6 CAPLUS
CN 2,4-Pyrimidinediamine, 6-phenyl-N4-[4-(5-pyrimidinyloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 850247-51-7 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-(4-aminophenoxy)phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-52-8 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(4-bromo-2-pyridinyl)oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-54-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-fluoro-4-pyridinyl)oxy]phenyl]-6-phenyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 850247-58-4 CAPLUS
CN Benzonitrile, 4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850247-59-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850247-60-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 850247-61-9 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(4-fluorophenyl)-4-pyrimidinyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 850247-63-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(4-fluorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850247-65-3 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(4-fluorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850247-68-6 CAPLUS
CN 2-Pyridinecarboxylic acid, 4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 850247-70-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-N-1-azabicyclo[2.2.2]oct-3-yl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

RN 850247-69-7
CRN 850247-69-7
CMF C29 H29 N7 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 850247-71-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-N-(2,3-dihydroxypropyl)- (9CI) (CA INDEX NAME)



RN 850247-73-3 CAPLUS
CN Pyrrolidine, 1-[[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]carbonyl]-2-(methoxymethyl)-, (2S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850247-72-2
CMF C28 H28 N6 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 850247-75-5 CAPLUS
CN 3-Pyrrolidinol, 1-[[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]carbonyl]-, (3R)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 850247-74-4
CMF C26 H24 N6 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 850247-76-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-butoxy-4-pyridinyl)oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-77-7 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-(2-methoxyethoxy)-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-78-8 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-[2-(dimethylamino)ethoxy]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-80-2 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-ethoxy-4-pyridinyl)oxy]phenyl]-6-phenyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850247-79-9
CMF C23 H21 N5 O2

L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 850247-86-8 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-(aminomethyl)-4-pyridinyl]oxy]phenyl]-6-phenyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850247-28-8
CMF C22 H20 N6 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 850247-88-0 CAPLUS
CN 1H-Imidazole-4-sulfonamide, N-[[4-[4-[(2-amino-6-phenyl-4-

L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CRN 76-05-1
CMF C2 H F3 O2

RN 850247-94-8 CAPLUS
CN 2-Propanesulfonamide, N-[[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850247-93-7
CMF C25 H26 N6 O3 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 850247-97-1 CAPLUS
CN Benzenesulfonamide, N-[[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850247-96-0
CMF C28 H24 N6 O3 S

L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
pyrimidinyl)amino]phenoxy]-2-pyridinyl]methyl]-1-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850247-87-9
CMF C26 H24 N8 O3 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 850247-91-5 CAPLUS
CN Ethanesulfonamide, N-[[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850247-90-4
CMF C24 H24 N6 O3 S



CM 2

L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 850248-00-9 CAPLUS
CN Benzenesulfonamide, N-[[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]methyl]-4-methoxy-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850247-99-3
CMF C29 H26 N6 O4 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 850248-03-2 CAPLUS
CN Benzenesulfonamide, N-[[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]methyl]-4-fluoro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850248-02-1
CMF C28 H23 F N6 O3 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 850248-04-3 CAPLUS
CN Urea, N'-[[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]methyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 850248-05-4 CAPLUS

RN 850248-09-8 CAPLUS
CN Urea, N-[[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]methyl]-N',N'-diethyl-N-methyl- (9CI) (CA INDEX NAME)



RN 850248-10-1 CAPLUS
CN 4-Morpholinecarboxamide, N-[[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 850248-11-2 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[4-(4-morpholinyl)-2-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850248-12-3 CAPLUS
CN 2,4-Pyrimidinediamine, 6-phenyl-N4-[4-[[4-(1-piperidinyl)-2-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850248-13-4 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[4-(4-methyl-1-piperazinyl)-2-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)

CN 4-Morpholinecarboxamide, N-[[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 850248-07-6 CAPLUS
CN Urea, [[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850248-06-5
CMF C23 H21 N7 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 850248-08-7 CAPLUS
CN Urea, [[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]methyl]trimethyl- (9CI) (CA INDEX NAME)





RN 850248-14-5 CAPLUS
CN Ethanol, 2,2'-[[2-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-4-pyridinyl]imino]bis- (9CI) (CA INDEX NAME)



RN 850248-15-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[4-[bis(2-methoxyethyl)amino]-2-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850248-16-7 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-[[(1-ethylpropyl)amino]methyl]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850248-17-8 CAPLUS

L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 2,4-Pyrimidinediamine, N4-[4-[[2-[(cyclohexylamino)methyl]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850248-18-9 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(3,4-dichlorophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850248-20-3 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-chloro-4-pyridinyl)oxy]phenyl]-6-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 850248-21-4 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-chloro-4-pyridinyl)oxy]phenyl]-6-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 850248-22-5 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(4-aminophenyl)-N4-[4-[(2-chloro-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 850248-45-2 CAPLUS
CN 2,4-Pyrimidinediamine, 6-phenyl-N4-[4-[[2-[(phenylmethyl)amino]-4-pyridinyl]oxy]phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850248-44-1
CMF C28 H24 N6 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 850248-46-3 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 850248-23-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-chloro-4-pyridinyl)oxy]-3-fluorophenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850248-24-7 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(3-aminophenyl)-N4-[4-[(2-chloro-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850248-41-8 CAPLUS
CN Ethanol, 2,2'-[[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]imino]bis- (9CI) (CA INDEX NAME)



RN 850248-43-0 CAPLUS
CN 2,4-Pyrimidinediamine, 6-phenyl-N4-[4-[[2-[1-(phenylmethyl)hydrazino]-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 850248-47-4 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-(4-morpholinyl)-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850248-48-5 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-(4-methyl-1-piperazinyl)-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850248-49-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-[4-(2-methoxyethyl)-1-piperazinyl]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850248-50-9 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-[(2-methoxyethyl)methylamino]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850248-51-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-[[2-(dimethylamino)ethyl]amino]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850248-52-1 CAPLUS
CN 2,4-Pyrimidinediamine, 6-phenyl-N4-[4-[[2-(1-piperidinyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850248-53-2 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-[bis(2-methoxyethyl)amino]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850248-54-3 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-[[3-(diethylamino)propyl]amino]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)

RN 850248-58-7 CAPLUS
CN 2-Pyrrolidinemethanol, 1-[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850248-59-8 CAPLUS
CN 3-Pyrrolidinol, 1-[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850248-61-2 CAPLUS
CN Butanoic acid, 4-[[4-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]phenyl]amino]-4-oxo- (9CI) (CA INDEX NAME)



RN 850248-62-3 CAPLUS
CN Glycine, N-[(1,1-dimethylethoxy)carbonyl]-, 4-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]-2-methoxyphenyl ester (9CI) (CA INDEX NAME)



RN 850248-55-4 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-[[3-(4-morpholinyl)propyl]amino]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850248-56-5 CAPLUS
CN Phenol, 4-[2-amino-6-[[4-[[2-(4-morpholinyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 850248-57-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 850248-63-4 CAPLUS
CN Glycine, 4-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]-2-methoxyphenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 850248-65-6 CAPLUS
CN Glycine, 4-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]phenyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850248-64-5
CMF C24 H19 F3 N6 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 850248-67-8 CAPLUS

L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN Butanamide, 4-amino-N-[4-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850248-66-7
CMF C26 H24 F3 N7 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 850248-68-9 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(4-amino-3-methoxyphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850248-69-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-(aminomethyl)-4-pyridinyl]oxy]phenyl]-6-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 850248-70-3 CAPLUS

L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 850248-75-8 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(2,5-difluorophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850248-76-9 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[2-(trifluoromethoxy)phenyl]-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850248-77-0 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[2-(1-methylethyl)phenyl]-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850248-78-1 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-(aminomethyl)-4-pyridinyl]oxy]phenyl]-6-(2-ethylphenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 2,4-Pyrimidinediamine, 6-[2-(trifluoromethyl)phenyl]-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850248-71-4 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(2-ethylphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850248-72-5 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(2-ethoxyphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850248-73-6 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(2-fluoro-5-methylphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850248-74-7 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(2,3-difluorophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 850248-79-2 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(4-aminophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 850248-81-6 CAPLUS
CN Phenol, 4-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 850248-82-7 CAPLUS
CN Phenol, 3-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 850248-83-8 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(3-amino-4-methoxyphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850248-84-9 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(3-aminophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850248-85-0 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(3-aminophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 850248-86-1 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(4-hydroxy-3-methoxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850248-87-2 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(3-amino-4-methoxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850248-92-9 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(4-amino-3-fluorophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850248-93-0 CAPLUS
CN Carbamic acid, [4-[2-amino-6-[[4-[(2-cyano-4-pyridinyl)oxy]phenyl]amino]-4-pyrimidinyl]-2-methoxyphenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 850248-95-2 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(4-amino-3-methoxyphenyl)-4-pyrimidinyl]amino]phenoxy]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850248-94-1
CMF C23 H19 N7 O2





RN 850248-88-3 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(4-amino-3-methoxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850248-89-4 CAPLUS
CN Phenol, 4-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 850248-90-7 CAPLUS
CN Benzenemethanol, 2-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 850248-91-8 CAPLUS
CN Phenol, 4-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 850248-96-3 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(4-amino-3-methylphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850248-98-5 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(3-amino-4-chlorophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850249-00-2 CAPLUS
CN Benzonitrile, 2-amino-5-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 850249-01-3 CAPLUS
CN Sulfamic acid, 4-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]-2-methoxyphenyl ester (9CI) (CA INDEX NAME)



RN 850249-02-4 CAPLUS
CN Sulfamide, [4-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)



RN 850249-03-5 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[1,1'-biphenyl]-4-yl-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850249-05-7 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(3,4-dimethoxyphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850249-06-8 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(4-methoxyphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850249-13-7 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[3-(trifluoromethyl)phenyl]-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850249-14-8 CAPLUS
CN Benzonitrile, 3-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 850249-15-9 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[4-(dimethylamino)phenyl]-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850249-16-0 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(3-ethylphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850249-08-0 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(3-fluorophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850249-09-1 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(2-fluorophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850249-10-4 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(2-aminophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850249-12-6 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(4-fluorophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850249-17-1 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[2-methoxy-5-(1-methylethyl)phenyl]-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850249-18-2 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(2-methylphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850249-20-6 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(2,4-difluorophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850249-21-7 CAPLUS
CN Benzenemethanol, 3-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 850249-22-8 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(3-methoxyphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850249-23-9 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[4-(ethylthio)phenyl]-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850249-24-0 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(3-amino-4-methylphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850249-25-1 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[4-(1-methylethyl)phenyl]-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850249-32-0 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[3-(trifluoromethoxy)phenyl]-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850249-33-1 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[4-(trifluoromethoxy)phenyl]-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850249-35-3 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(3,5-difluorophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850249-38-6 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(4-butylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-26-2 CAPLUS
CN Benzeneacetonitrile, 4-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 850249-27-3 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(4-methylphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850249-28-4 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(3-methylphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850249-31-9 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(2,5-dimethoxyphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850249-40-0 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(2-fluoro[1,1'-biphenyl]-4-yl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-42-2 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-[3-(phenylmethoxy)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-44-4 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(3,4-dimethoxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-45-5 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(4-methoxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-47-7 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(3-hydroxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-48-8 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(4-hydroxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-54-6 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(4-aminophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-57-9 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-[4-(methylthio)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-70-6 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(3-aminophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-73-9 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(3-fluorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-75-1 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(2-fluorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-77-3 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(4-chlorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-59-1 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-[4-(dimethylamino)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-61-5 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(2,5-dimethoxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-63-7 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(3-methoxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-64-8 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-[4-(cyanomethyl)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-78-4 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(2-aminophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-79-5 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-80-8 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-[2-methoxy-5-(1-methylethyl)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-81-9 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(2-methylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-82-0 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(2,4-difluorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-83-1 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-[3-(hydroxymethyl)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-84-2 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(4-methylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-85-3 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(3-methylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-92-2 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(4-chlorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-93-3 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-95-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(4-butylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-96-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(2-fluoro[1,1'-biphenyl]-4-yl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)





RN 850249-87-5 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(3-amino-4-methylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-88-6 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(3,4-dichlorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-89-7 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(3-aminophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-91-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(3-fluorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)

RN 850249-97-7 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(3-ethylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-98-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-[2-methoxy-5-(1-methylethyl)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-99-9 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(2-methylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850250-00-9 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(2,4-difluorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850250-01-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-[3-(hydroxymethyl)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850250-02-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-[4-(1-methylethyl)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850250-03-2 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(4-methylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850250-04-3 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(3-methylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850250-06-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-[3-(1-methylethyl)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)





RN 850250-12-3 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(3,5-difluorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850250-13-4 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-[3-(trifluoromethoxy)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850250-14-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-[2-(trifluoromethoxy)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850250-15-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(3,5-difluorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)

RN 850250-07-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(3-amino-4-methylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850250-08-7 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(3,4-dichlorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850250-09-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(3-ethoxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850250-10-1 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-[3-(trifluoromethoxy)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850250-11-2 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-[2-(trifluoromethoxy)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850250-18-9 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(4-fluorophenyl)-N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850250-40-7 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]-6-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 850250-41-8 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[3-(dimethylamino)phenyl]-N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850250-42-9 CAPLUS
CN Phenol, 3-[2-amino-6-[[4-[(2-methyl-4-pyridinyl)oxy]phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 850250-43-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]-6-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 850250-44-1 CAPLUS
CN Acetamide, N-[4-[2-amino-6-[[4-[(2-methyl-4-pyridinyl)oxy]phenyl]amino]-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)



RN 850250-45-2 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]-6-[2-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 850250-46-3 CAPLUS
CN Phenol, 4-[2-amino-6-[[4-[(2-methyl-4-pyridinyl)oxy]phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 850250-47-4 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(3-methoxyphenyl)-N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850250-49-6 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(4-aminophenyl)-N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850250-50-9 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 850250-51-0 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(3-fluorophenyl)-N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850250-52-1 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(4-ethylphenyl)-N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850250-53-2 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[4-(dimethylamino)phenyl]-N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850250-54-3 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(3,4-dimethoxyphenyl)-N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850250-55-4 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(3-aminophenyl)-N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850250-57-6 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(2-aminophenyl)-N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850250-58-7 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(3-amino-4-methylphenyl)-N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850250-59-8 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[3-(1-methylethoxy)phenyl]-N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850250-60-1 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]-6-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 850250-61-2 CAPLUS
CN Sulfamic acid, 4-[2-amino-6-[[4-[(2-chloro-4-pyridinyl)oxy]phenyl]amino]-4-pyrimidinyl]phenyl ester (9CI) (CA INDEX NAME)



RN 850250-81-6 CAPLUS
CN Acetamide, 2-[[4-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]phenyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850250-80-5
CMF C24 H20 F3 N7 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 850252-00-5 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-phenyl-4-pyrimidinyl]amino]-3-fluorophenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

CN 2,4-Pyrimidinediamine, 6-chloro-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 871240-10-7 CAPLUS
CN 2,4-Pyrimidinediamine, 6-chloro-N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)





● HCl

RN 850252-01-6 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(2-methylphenyl)-N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 871240-05-0 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(2,6-dimethylphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 871240-08-3 CAPLUS
CN 2,4-Pyrimidinediamine, 6-phenyl-N4-[4-[[2-(trifluoromethyl)-4-pyrimidinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



IT 850250-76-9P 871240-10-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of amino-substituted pyrimidines as antitumor agents)
RN 850250-76-9 CAPLUS

ACCESSION NUMBER: 2005:1130634 CAPLUS
DOCUMENT NUMBER: 143:405919
TITLE: Preparation of heteroaryloxy-substituted phenylamino pyrimidines as Rho kinase inhibitors
INVENTOR(S): Schirok, Hartmut; Radtke, Martin; Mittendorf, Joachim; Kast, Raimund; Stasch, Johannes-Peter; Gnoth, Mark Jean; Muenter, Klaus; Lang, Dieter; Figueroa Perez, Santiago; Thutewohl, Michael; Bennabi, Samir; Ehmke, Heimo
PATENT ASSIGNEE(S): Bayer Healthcare A.-G., Germany
SOURCE: PCT Int. Appl., 82 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005097790	A1	20051020	WO 2005-EP3294	20050330
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 102004017438	A1	20051103	DE 2004-102004017438	20040408
CA 2563212	A1	20051020	CA 2005-2563212	20050330
EP 1751153	A1	20070214	EP 2005-740054	20050330
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRIORITY APPLN. INFO.:			DE 2004-102004017438A	20040408
			WO 2005-EP3294 W	20050330

OTHER SOURCE(S): MARPAT 143:405919
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = Cl, Br, CN, etc.; R2 = H or F; R3 = H, Cl, CF3, etc.] and their pharmaceutically acceptable salts, are prepared and disclosed as Rho kinase inhibitors. Thus, e.g., II was prepared by coupling of 3,5-difluoro-4-[(3-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]aniline (preparation given) with 4,6-dichloropyrimidin-2-amine. The inhibitory activity of I towards Rho kinase was evaluated using scintillation assay and it was revealed that selected compds. of the invention possessed IC50 values in the range of 2 up to 7 nM. I as Rho kinase inhibitors should prove useful in the treatment of cardiovascular disease and erectile dysfunction. Pharmaceutical compns. comprising I are disclosed.
IT 867017-68-3P 867017-69-4P 867017-70-7P
867017-71-8P 867017-72-9P 867017-73-0P
867017-74-1P 867017-75-2P 867017-76-3P
867017-77-4P 867017-78-5P 867017-79-6P

867017-80-9P 867017-81-0P 867017-82-1P
867017-83-2P 867017-84-3P 867017-85-4P
867017-86-5P 867017-87-6P 867017-88-7P
867017-89-8P 867017-90-1P 867017-91-2P
867017-92-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of heteroaryloxy-substituted phenylamino pyrimidines as Rho kinase inhibitors)

RN 867017-68-3 CAPLUS
CN 2,4-Pyrimidinediamine, 6-chloro-N4-[3,5-difluoro-4-[(3-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 867017-69-4 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[3,5-difluoro-4-[(3-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 867017-70-7 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[3,5-difluoro-4-[(3-methyl-1H-pyrrolo[2,3-

b]pyridin-4-yl)oxy]phenyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 867017-71-8 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(3-chloro-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 867017-72-9 CAPLUS
CN 2,4-Pyrimidinediamine, 6-chloro-N4-[3-fluoro-4-[(3-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 867017-73-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[3-fluoro-4-[(3-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 867017-74-1 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[3-fluoro-4-[(3-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 867017-75-2 CAPLUS
CN 2,4-Pyrimidinediamine, 6-chloro-N4-[4-[(3-chloro-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3-fluorophenyl]- (9CI) (CA INDEX NAME)



RN 867017-76-3 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(3-chloro-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3-fluorophenyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 867017-77-4 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(3-chloro-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3-fluorophenyl]- (9CI) (CA INDEX NAME)



RN 867017-78-5 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(3-cyclopropyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3-fluorophenyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 867017-79-6 CAPLUS
CN 2,4-Pyrimidinediamine, 6-chloro-N4-[4-[(3-ethyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3-fluorophenyl]- (9CI) (CA INDEX NAME)



RN 867017-80-9 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(3-ethyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3-fluorophenyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 867017-81-0 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-ethanol, 4-[4-[(2-amino-6-chloro-4-pyrimidinyl)amino]-2-fluorophenoxy]- (9CI) (CA INDEX NAME)



RN 867017-82-1 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-ethanol, 4-[4-[[2-amino-6-(trifluoromethyl)-4-pyrimidinyl]amino]-2-fluorophenoxy]- (9CI) (CA INDEX NAME)



RN 867017-83-2 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-ethanol, 4-[4-[(2-amino-4-pyrimidinyl)amino]-2-fluorophenoxy]- (9CI) (CA INDEX NAME)



RN 867017-84-3 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[3-fluoro-4-[[3-(2-methoxyethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 867017-85-4 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-carbonitrile, 4-[4-[[2-amino-6-(trifluoromethyl)-4-pyrimidinyl]amino]-2-fluorophenoxy]- (9CI) (CA INDEX NAME)



RN 867017-86-5 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-carbonitrile, 4-[4-[(2-amino-6-chloro-4-pyrimidinyl)amino]-2-fluorophenoxy]- (9CI) (CA INDEX NAME)



RN 867017-87-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-carbonitrile, 4-[4-[(2-amino-4-pyrimidinyl)amino]-2-fluorophenoxy]- (9CI) (CA INDEX NAME)



RN 867017-88-7 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-carbonitrile, 4-[4-[(2-amino-4-pyrimidinyl)amino]-2,6-difluorophenoxy]- (9CI) (CA INDEX NAME)



RN 867017-89-8 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(3-cyclopropyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 867017-90-1 CAPLUS
CN 2,4-Pyrimidinediamine, 6-chloro-N4-[4-[(3-chloro-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl]- (9CI) (CA INDEX NAME)



RN 867017-91-2 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(3-chloro-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl]- (9CI) (CA INDEX NAME)



RN 867017-92-3 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(3-bromo-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:902740 CAPLUS
DOCUMENT NUMBER: 143:263095
TITLE: Selective high-affinity polydentate ligands and methods of making such
INVENTOR(S): Denardo, Sally; Denardo, Gerald; Rodney, Balhorn
PATENT ASSIGNEE(S): The Regents of the University of California, USA
SOURCE: PCT Int. Appl., 106 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005077065	A2	20050825	WO 2005-US4134	20050208
WO 2005077065	A3	20051222		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2006084115	A1	20060420	US 2005-55181	20050209
PRIORITY APPLN. INFO.:			US 2004-543444P	P 20040209

AB This invention provides novel polydentate selective high affinity ligands (SHALs) that can be used in a variety of applications in a manner analogous to the use of antibodies. SHALs typically comprise a multiplicity of ligands that each bind different region of the target mol. The ligands are joined directly or through a linker thereby forming a polydentate moiety that typically binds the target mol. with high selectivity and avidity.
IT 339016-03-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(selective high-affinity polydentate ligands and methods of making such)
RN 339016-03-4 CAPLUS
CN 2,4-Pyrimidinediamine, 6-chloro-N4-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 9 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:460527 CAPLUS
DOCUMENT NUMBER: 143:153526
TITLE: Antileishmanial agents part-IV: synthesis and antileishmanial activity of novel terpenyl pyrimidines
AUTHOR(S): Chandra, Naveen; Ramesh; Ashutosh; Goyal, Neena; Suryawanshi, S. N.; Gupta, Suman
CORPORATE SOURCE: Division of Medicinal Chemistry, Central Drug Research Institute, Lucknow, 226001, India
SOURCE: European Journal of Medicinal Chemistry (2005), 40(6), 552-556
CODEN: EJMCA5; ISSN: 0223-5234
PUBLISHER: Elsevier Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 143:153526
GI



AB Some novel N- and O-substituted terpenyl pyrimidine derivs., I [R = NHC6H4OMe-4, NHC6H4Cl-4, piperazino, 4-Ph-piperazino, NHPh, N(CH2)5, morpholino, OMe, OEt, OBu], have been synthesized and screened for in vitro antileishmanial activity profile in promastigote model. Some of the compds. exhibited 100% inhibition at 10 μg ml-1 concentration
IT 860021-28-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antileishmanial activity of terpenyl pyrimidine derivs.)
RN 860021-28-9 CAPLUS
CN 2,4-Pyrimidinediamine, N4-(4-methoxyphenyl)-6-[(1E)-2-(2,6,6-trimethyl-2-cyclohexen-1-yl)ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:346995 CAPLUS
DOCUMENT NUMBER: 142:411371
TITLE: Preparation of pyrimidine derivatives as antitumor agents
INVENTOR(S): Dixon, Julie A.; Nagarathnam, Dhanapalan; Zhang, Lei; Wang, Chunguang; Yi, Lin; Chen, Yuanwei; Chen, Jianqing; Bear, Brian; Brands, Michael; Hillisch, Alexander; Bierer, Donald; Wang, Ming; Fu, Wenlang; Hentemann, Martin F.; Bullion, Ann-Marie
PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 276 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005035507	A2	20050421	WO 2004-US33430	20041008
WO 2005035507	A3	20060831		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2542031	A1	20050421	CA 2004-2542031	20041008
EP 1689722	A2	20060816	EP 2004-809919	20041008
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2007508321	T	20070405	JP 2006-534438	20041008
US 2005277640	A1	20051215	US 2005-78681	20050310
US 2007117817	A1	20070524	US 2006-573227	20060324
PRIORITY APPLN. INFO.:			US 2003-510804P	P 20031010
			WO 2004-US33430	W 20041008

OTHER SOURCE(S): MARPAT 142:411371
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = H, alkyl, cyclopropyl; R2 = alkyl, cyclopropyl, O-alkyl, etc.; R3 = H, halo; M = CH, N; L = carbonyl, O, (un)substituted-alkylenyl, etc.; J and Y independently = (un)substituted-aryl, -heteroaryl; A = halo, CF3, CN, etc.; m = 0-2] and their pharmaceutically acceptable salts, are prepared and disclosed as useful antitumor agents. Thus, e.g., II was prepared by etherification of 4-chloro-picoline with 4-aminophenol followed by amination of 4-chloro-6-phenylpyrimidin-2-amine (preparation given). The cytotoxic activity of I towards HCT116 cells was evaluated and selected compds. of the invention displayed IC50 values of less than or equal to 500 nM. I should

L4 ANSWER 10 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
prove useful in the treatment of hyperproliferative disorders.
IT 850247-06-2P 850247-12-0P 850247-26-6P
850247-28-8P 850247-38-0P 850247-41-5P
850248-80-5P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrimidine derivs. as antitumor agents)
RN 850247-06-2 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850247-12-0 CAPLUS
CN 2-Pyridinecarboxylic acid, 4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850247-26-6 CAPLUS
CN 2,4-Pyrimidinediamine, 6-phenyl-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850247-28-8 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-(aminomethyl)-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)

L4 ANSWER 10 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 850247-38-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-chloro-4-pyridinyl)oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-41-5 CAPLUS
CN Phenol, 4-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 850248-80-5 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(4-aminophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



IT 850246-99-0P 850247-00-6P 850247-03-9P
850247-04-0P 850247-05-1P 850247-09-5P
850247-10-8P 850247-11-9P 850247-14-2P
850247-15-3P 850247-17-5P 850247-21-1P
850247-27-7P 850247-30-2P 850247-31-3P
850247-32-4P 850247-33-5P 850247-34-6P
850247-35-7P 850247-36-8P 850247-37-9P

L4 ANSWER 10 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
850247-39-1P 850247-40-4P 850247-42-6P
850247-43-7P 850247-44-8P 850247-46-0P
850247-48-2P 850247-50-6P 850247-51-7P
850247-52-8P 850247-54-0P 850247-55-1P
850247-56-2P 850247-57-3P 850247-58-4P
850247-59-5P 850247-60-8P 850247-61-9P
850247-63-1P 850247-65-3P 850247-68-6P
850247-70-0P 850247-71-1P 850247-73-3P
850247-75-5P 850247-76-6P 850247-77-7P
850247-78-8P 850247-80-2P 850247-86-8P
850247-88-0P 850247-91-5P 850247-94-8P
850247-97-1P 850248-00-9P 850248-03-2P
850248-04-3P 850248-05-4P 850248-07-6P
850248-08-7P 850248-09-8P 850248-10-1P
850248-11-2P 850248-12-3P 850248-13-4P
850248-14-5P 850248-15-6P 850248-16-7P
850248-17-8P 850248-18-9P 850248-20-3P
850248-21-4P 850248-22-5P 850248-23-6P
850248-24-7P 850248-41-8P 850248-43-0P
850248-45-2P 850248-46-3P 850248-47-4P
850248-48-5P 850248-49-6P 850248-50-9P
850248-51-0P 850248-52-1P 850248-53-2P
850248-54-3P 850248-55-4P 850248-56-5P
850248-57-6P 850248-58-7P 850248-59-8P
850248-61-2P 850248-62-3P 850248-63-4P
850248-65-6P 850248-67-8P 850248-68-9P
850248-69-0P 850248-70-3P 850248-71-4P
850248-72-5P 850248-73-6P 850248-74-7P
850248-75-8P 850248-76-9P 850248-77-0P
850248-78-1P 850248-79-2P 850248-81-6P
850248-82-7P 850248-83-8P 850248-84-9P
850248-85-0P 850248-86-1P 850248-87-2P
850248-88-3P 850248-89-4P 850248-90-7P
850248-91-8P 850248-92-9P 850248-93-0P
850248-95-2P 850248-96-3P 850248-98-5P
850249-00-2P 850249-01-3P 850249-02-4P
850249-03-5P 850249-05-7P 850249-06-8P
850249-08-0P 850249-09-1P 850249-10-4P
850249-12-6P 850249-13-7P 850249-14-8P
850249-15-9P 850249-16-0P 850249-17-1P
850249-18-2P 850249-20-6P 850249-21-7P
850249-22-8P 850249-23-9P 850249-24-0P
850249-25-1P 850249-26-2P 850249-27-3P
850249-28-4P 850249-31-9P 850249-32-0P
850249-33-1P 850249-35-3P 850249-38-6P
850249-40-0P 850249-42-2P 850249-44-4P
850249-45-5P 850249-47-7P 850249-48-8P
850249-54-6P 850249-57-9P 850249-59-1P
850249-61-5P 850249-63-7P 850249-64-8P
850249-70-6P 850249-73-9P 850249-75-1P
850249-77-3P 850249-78-4P 850249-79-5P
850249-80-8P 850249-81-9P 850249-82-0P
850249-83-1P 850249-84-2P 850249-85-3P
850249-87-5P 850249-88-6P 850249-89-7P
850249-91-1P 850249-92-2P 850249-93-3P
850249-95-5P 850249-96-6P 850249-97-7P
850249-98-8P 850249-99-9P 850250-00-9P
850250-01-0P 850250-02-1P 850250-03-2P
850250-04-3P 850250-06-5P 850250-07-6P
850250-08-7P 850250-09-8P 850250-10-1P

L4 ANSWER 10 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
850250-11-2P 850250-12-3P 850250-13-4P
850250-14-5P 850250-15-6P 850250-18-9P
850250-40-7P 850250-41-8P 850250-42-9P
850250-43-0P 850250-44-1P 850250-45-2P
850250-46-3P 850250-47-4P 850250-49-6P
850250-50-9P 850250-51-0P 850250-52-1P
850250-53-2P 850250-54-3P 850250-55-4P
850250-57-6P 850250-58-7P 850250-59-8P
850250-60-1P 850250-61-2P 850250-81-6P
850252-00-5P 850252-01-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyrimidine derivs. as antitumor agents)
RN 850246-99-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-ethyl-4-pyridinyl)oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-00-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-03-9 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(3,5-difluoro-4-pyridinyl)oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-04-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-(4-nitrophenoxy)phenyl]-6-phenyl- (9CI) (CA

INDEX NAME)



RN 850247-05-1 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[3-fluoro-4-[(2-methyl-4-pyridinyl)oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-09-5 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-(4-chlorophenoxy)phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-10-8 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-(4-methoxyphenoxy)phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-11-9 CAPLUS
CN 2-Pyridinecarboxylic acid, 4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 850247-14-2 CAPLUS
CN Morpholine, 4-[[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]carbonyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850247-13-1
CMF C26 H24 N6 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 850247-15-3 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 850247-17-5 CAPLUS
CN Piperazine, 1-[[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]carbonyl]-4-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850247-16-4
CMF C27 H27 N7 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 850247-21-1 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-[2-(4-morpholinyl)ethoxy]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-27-7 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[1-oxido-2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-30-2 CAPLUS
CN Methanesulfonamide, N-[[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850247-29-9
CMF C23 H22 N6 O3 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 850247-31-3 CAPLUS
CN Benzamide, N-[[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]methyl]-4-fluoro- (9CI) (CA INDEX NAME)



RN 850247-32-4 CAPLUS
CN Urea, N'-[[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]methyl]-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 850247-33-5 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[4-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-2-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 850247-34-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-[[(1-methylethyl)amino]methyl]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)





RN 850247-40-4 CAPLUS
CN Propanamide, 2-amino-N-[4-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]phenyl]-3-hydroxy-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850247-42-6 CAPLUS
CN Sulfamic acid, 4-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]phenyl ester (9CI) (CA INDEX NAME)



RN 850247-43-7 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-amino-4-pyridinyl)oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)

RN 850247-35-7 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 850247-36-8 CAPLUS
CN 2,4-Pyrimidinediamine, 6-phenyl-N4-[4-[[2-(1H-tetrazol-5-yl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850247-37-9 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-(4,5-dihydro-1H-imidazol-2-yl)-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-39-1 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850247-44-8 CAPLUS
CN Phenol, 4-[2-amino-6-[[4-[(2-chloro-4-pyridinyl)oxy]phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 850247-46-0 CAPLUS
CN 3-Buten-1-ol, 4-[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]-, (3E)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 850247-45-9
CMF C25 H23 N5 O2

Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 850247-48-2 CAPLUS
CN 2-Pyridinemethanol, 4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 850247-47-1
CMF C22 H19 N5 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 850247-50-6 CAPLUS
CN 2,4-Pyrimidinediamine, 6-phenyl-N4-[4-(5-pyrimidinyloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 850247-51-7 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-(4-aminophenoxy)phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-56-2 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-chloro-4-pyridinyl)oxy]-2-fluorophenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-57-3 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[2-fluoro-4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-58-4 CAPLUS
CN Benzonitrile, 4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850247-59-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850247-52-8 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(4-bromo-2-pyridinyl)oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-54-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-fluoro-4-pyridinyl)oxy]phenyl]-6-phenyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850247-53-9
CMF C21 H16 F N5 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 850247-55-1 CAPLUS
CN 2(1H)-Pyridinone, 4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-



RN 850247-60-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 850247-61-9 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(4-fluorophenyl)-4-pyrimidinyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 850247-63-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(4-fluorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850247-65-3 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(4-fluorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850247-68-6 CAPLUS
CN 2-Pyridinecarboxylic acid, 4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 850247-70-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-N-1-azabicyclo[2.2.2]oct-3-yl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850247-69-7
CMF C29 H29 N7 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 850247-75-5 CAPLUS
CN 3-Pyrrolidinol, 1-[[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]carbonyl]-, (3R)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 850247-74-4
CMF C26 H24 N6 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 850247-76-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-butoxy-4-pyridinyl)oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)

RN 850247-71-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-N-(2,3-dihydroxypropyl)- (9CI) (CA INDEX NAME)



RN 850247-73-3 CAPLUS
CN Pyrrolidine, 1-[[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]carbonyl]-2-(methoxymethyl)-, (2S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850247-72-2
CMF C28 H28 N6 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 850247-77-7 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-(2-methoxyethoxy)-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-78-8 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-[2-(dimethylamino)ethoxy]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-80-2 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-ethoxy-4-pyridinyl)oxy]phenyl]-6-phenyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850247-79-9
CMF C23 H21 N5 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 850247-86-8 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-(aminomethyl)-4-pyridinyl]oxy]phenyl]-6-phenyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850247-28-8
CMF C22 H20 N6 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 850247-88-0 CAPLUS
CN 1H-Imidazole-4-sulfonamide, N-[[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]methyl]-1-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850247-87-9
CMF C26 H24 N8 O3 S

RN 850247-94-8 CAPLUS
CN 2-Propanesulfonamide, N-[[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850247-93-7
CMF C25 H26 N6 O3 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 850247-97-1 CAPLUS
CN Benzenesulfonamide, N-[[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850247-96-0
CMF C28 H24 N6 O3 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 850247-91-5 CAPLUS
CN Ethanesulfonamide, N-[[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850247-90-4
CMF C24 H24 N6 O3 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 850248-00-9 CAPLUS
CN Benzenesulfonamide, N-[[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]methyl]-4-methoxy-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850247-99-3
CMF C29 H26 N6 O4 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 850248-03-2 CAPLUS
CN Benzenesulfonamide, N-[[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]methyl]-4-fluoro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850248-02-1
CMF C28 H23 F N6 O3 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 850248-04-3 CAPLUS
CN Urea, N'-[[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]methyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 850248-05-4 CAPLUS

RN 850248-09-8 CAPLUS
CN Urea, N-[[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]methyl]-N',N'-diethyl-N-methyl- (9CI) (CA INDEX NAME)



RN 850248-10-1 CAPLUS
CN 4-Morpholinecarboxamide, N-[[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 850248-11-2 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[4-(4-morpholinyl)-2-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850248-12-3 CAPLUS
CN 2,4-Pyrimidinediamine, 6-phenyl-N4-[4-[[4-(1-piperidinyl)-2-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850248-13-4 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[4-(4-methyl-1-piperazinyl)-2-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)

CN 4-Morpholinecarboxamide, N-[[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 850248-07-6 CAPLUS
CN Urea, [[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850248-06-5
CMF C23 H21 N7 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 850248-08-7 CAPLUS
CN Urea, [[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]methyl]trimethyl- (9CI) (CA INDEX NAME)





RN 850248-14-5 CAPLUS
CN Ethanol, 2,2'-[[2-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-4-pyridinyl]imino]bis- (9CI) (CA INDEX NAME)



RN 850248-15-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[4-[bis(2-methoxyethyl)amino]-2-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850248-16-7 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-[[(1-ethylpropyl)amino]methyl]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850248-17-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[4-[[2-[(cyclohexylamino)methyl]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850248-18-9 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(3,4-dichlorophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850248-20-3 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-chloro-4-pyridinyl)oxy]phenyl]-6-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 850248-21-4 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-chloro-4-pyridinyl)oxy]phenyl]-6-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 850248-22-5 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(4-aminophenyl)-N4-[4-[(2-chloro-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850248-45-2 CAPLUS
CN 2,4-Pyrimidinediamine, 6-phenyl-N4-[4-[[2-[(phenylmethyl)amino]-4-pyridinyl]oxy]phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850248-44-1
CMF C28 H24 N6 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 850248-46-3 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850248-23-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-chloro-4-pyridinyl)oxy]-3-fluorophenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850248-24-7 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(3-aminophenyl)-N4-[4-[(2-chloro-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850248-41-8 CAPLUS
CN Ethanol, 2,2'-[[4-[[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]imino]bis- (9CI) (CA INDEX NAME)



RN 850248-43-0 CAPLUS
CN 2,4-Pyrimidinediamine, 6-phenyl-N4-[4-[[2-[1-(phenylmethyl)hydrazino]-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850248-47-4 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-(4-morpholinyl)-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850248-48-5 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-(4-methyl-1-piperazinyl)-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850248-49-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-[4-(2-methoxyethyl)-1-piperazinyl]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850248-50-9 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-[(2-methoxyethyl)methylamino]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850248-51-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-[[2-(dimethylamino)ethyl]amino]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850248-52-1 CAPLUS
CN 2,4-Pyrimidinediamine, 6-phenyl-N4-[4-[[2-(1-piperidinyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850248-53-2 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-[bis(2-methoxyethyl)amino]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850248-54-3 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-[[3-(diethylamino)propyl]amino]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)

RN 850248-58-7 CAPLUS
CN 2-Pyrrolidinemethanol, 1-[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850248-59-8 CAPLUS
CN 3-Pyrrolidinol, 1-[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850248-61-2 CAPLUS
CN Butanoic acid, 4-[[4-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]phenyl]amino]-4-oxo- (9CI) (CA INDEX NAME)



RN 850248-62-3 CAPLUS
CN Glycine, N-[(1,1-dimethylethoxy)carbonyl]-, 4-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]-2-methoxyphenyl ester (9CI) (CA INDEX NAME)



RN 850248-55-4 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-[[3-(4-morpholinyl)propyl]amino]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850248-56-5 CAPLUS
CN Phenol, 4-[2-amino-6-[[4-[[2-(4-morpholinyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 850248-57-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 850248-63-4 CAPLUS
CN Glycine, 4-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]-2-methoxyphenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 850248-65-6 CAPLUS
CN Glycine, 4-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]phenyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850248-64-5
CMF C24 H19 F3 N6 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 850248-67-8 CAPLUS

CN Butanamide, 4-amino-N-[4-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850248-66-7
CMF C26 H24 F3 N7 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 850248-68-9 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(4-amino-3-methoxyphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850248-69-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-(aminomethyl)-4-pyridinyl]oxy]phenyl]-6-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 850248-70-3 CAPLUS



RN 850248-75-8 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(2,5-difluorophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850248-76-9 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[2-(trifluoromethoxy)phenyl]-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850248-77-0 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[2-(1-methylethyl)phenyl]-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850248-78-1 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-(aminomethyl)-4-pyridinyl]oxy]phenyl]-6-(2-ethylphenyl)- (9CI) (CA INDEX NAME)

CN 2,4-Pyrimidinediamine, 6-[2-(trifluoromethyl)phenyl]-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850248-71-4 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(2-ethylphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850248-72-5 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(2-ethoxyphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850248-73-6 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(2-fluoro-5-methylphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850248-74-7 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(2,3-difluorophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850248-79-2 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(4-aminophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 850248-81-6 CAPLUS
CN Phenol, 4-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 850248-82-7 CAPLUS
CN Phenol, 3-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 850248-83-8 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(3-amino-4-methoxyphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850248-84-9 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(3-aminophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850248-85-0 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(3-aminophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 850248-86-1 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(4-hydroxy-3-methoxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850248-87-2 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(3-amino-4-methoxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850248-92-9 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(4-amino-3-fluorophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850248-93-0 CAPLUS
CN Carbamic acid, [4-[2-amino-6-[[4-[(2-cyano-4-pyridinyl)oxy]phenyl]amino]-4-pyrimidinyl]-2-methoxyphenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 850248-95-2 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(4-amino-3-methoxyphenyl)-4-pyrimidinyl]amino]phenoxy]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850248-94-1
CMF C23 H19 N7 O2





RN 850248-88-3 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(4-amino-3-methoxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850248-89-4 CAPLUS
CN Phenol, 4-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 850248-90-7 CAPLUS
CN Benzenemethanol, 2-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 850248-91-8 CAPLUS
CN Phenol, 4-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 850248-96-3 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(4-amino-3-methylphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850248-98-5 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(3-amino-4-chlorophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850249-00-2 CAPLUS
CN Benzonitrile, 2-amino-5-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 850249-01-3 CAPLUS
CN Sulfamic acid, 4-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]-2-methoxyphenyl ester (9CI) (CA INDEX NAME)



RN 850249-02-4 CAPLUS
CN Sulfamide, [4-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)



RN 850249-03-5 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[1,1'-biphenyl]-4-yl-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850249-05-7 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(3,4-dimethoxyphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850249-06-8 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(4-methoxyphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850249-08-0 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(3-fluorophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850249-09-1 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(2-fluorophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850249-10-4 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(2-aminophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850249-12-6 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(4-fluorophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME).



RN 850249-13-7 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[3-(trifluoromethyl)phenyl]-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850249-14-8 CAPLUS
CN Benzonitrile, 3-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 850249-15-9 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[4-(dimethylamino)phenyl]-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850249-16-0 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(3-ethylphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850249-17-1 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[2-methoxy-5-(1-methylethyl)phenyl]-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850249-18-2 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(2-methylphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850249-20-6 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(2,4-difluorophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850249-21-7 CAPLUS
CN Benzenemethanol, 3-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 850249-22-8 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(3-methoxyphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850249-23-9 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[4-(ethylthio)phenyl]-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850249-24-0 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(3-amino-4-methylphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850249-25-1 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[4-(1-methylethyl)phenyl]-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850249-26-2 CAPLUS
CN Benzeneacetonitrile, 4-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 850249-27-3 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(4-methylphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850249-28-4 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(3-methylphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850249-31-9 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(2,5-dimethoxyphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850249-32-0 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[3-(trifluoromethoxy)phenyl]-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850249-33-1 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[4-(trifluoromethoxy)phenyl]-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850249-35-3 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(3,5-difluorophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850249-38-6 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(4-butylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-40-0 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(2-fluoro[1,1'-biphenyl]-4-yl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-42-2 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-[3-(phenylmethoxy)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-44-4 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(3,4-dimethoxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-45-5 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(4-methoxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-47-7 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(3-hydroxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-48-8 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(4-hydroxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-54-6 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(4-aminophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-57-9 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-[4-(methylthio)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-70-6 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(3-aminophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-73-9 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(3-fluorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-75-1 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(2-fluorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-77-3 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(4-chlorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-59-1 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-[4-(dimethylamino)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-61-5 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(2,5-dimethoxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-63-7 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(3-methoxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-64-8 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-[4-(cyanomethyl)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-78-4 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(2-aminophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-79-5 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-80-8 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-[2-methoxy-5-(1-methylethyl)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-81-9 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(2-methylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-82-0 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(2,4-difluorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-83-1 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-[3-(hydroxymethyl)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-84-2 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(4-methylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-85-3 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(3-methylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-92-2 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(4-chlorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-93-3 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-95-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(4-butylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-96-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(2-fluoro[1,1'-biphenyl]-4-yl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)





RN 850249-87-5 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(3-amino-4-methylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-88-6 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(3,4-dichlorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-89-7 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(3-aminophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-91-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(3-fluorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)

RN 850249-97-7 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(3-ethylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-98-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-[2-methoxy-5-(1-methylethyl)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-99-9 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(2-methylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850250-00-9 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(2,4-difluorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850250-01-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-[3-(hydroxymethyl)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850250-02-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-[4-(1-methylethyl)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850250-03-2 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(4-methylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850250-04-3 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(3-methylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850250-06-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-[3-(1-methylethyl)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850250-07-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(3-amino-4-methylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850250-08-7 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(3,4-dichlorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850250-09-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(3-ethoxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850250-10-1 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-[3-(trifluoromethoxy)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850250-11-2 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-[2-(trifluoromethoxy)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850250-12-3 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(3,5-difluorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850250-13-4 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-[3-(trifluoromethoxy)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850250-14-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-[2-(trifluoromethoxy)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850250-15-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(3,5-difluorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850250-18-9 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(4-fluorophenyl)-N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850250-40-7 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]-6-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 850250-41-8 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[3-(dimethylamino)phenyl]-N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850250-42-9 CAPLUS
CN Phenol, 3-[2-amino-6-[[4-[(2-methyl-4-pyridinyl)oxy]phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 850250-43-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]-6-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 850250-44-1 CAPLUS
CN Acetamide, N-[4-[2-amino-6-[[4-[(2-methyl-4-pyridinyl)oxy]phenyl]amino]-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)



RN 850250-45-2 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]-6-[2-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 850250-46-3 CAPLUS
CN Phenol, 4-[2-amino-6-[[4-[(2-methyl-4-pyridinyl)oxy]phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 850250-47-4 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(3-methoxyphenyl)-N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850250-49-6 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(4-aminophenyl)-N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850250-50-9 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 850250-51-0 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(3-fluorophenyl)-N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850250-52-1 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(4-ethylphenyl)-N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850250-53-2 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[4-(dimethylamino)phenyl]-N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850250-54-3 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(3,4-dimethoxyphenyl)-N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850250-55-4 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(3-aminophenyl)-N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850250-57-6 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(2-aminophenyl)-N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850250-58-7 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(3-amino-4-methylphenyl)-N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850250-59-8 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[3-(1-methylethoxy)phenyl]-N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850250-60-1 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]-6-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 10 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 850250-61-2 CAPLUS
CN Sulfamic acid, 4-[2-amino-6-[[4-[(2-chloro-4-pyridinyl)oxy]phenyl]amino]-4-pyrimidinyl]phenyl ester (9CI) (CA INDEX NAME)



RN 850250-81-6 CAPLUS
CN Acetamide, 2-[[4-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]phenyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850250-80-5
CMF C24 H20 F3 N7 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 850252-00-5 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]-3-fluorophenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 10 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



● HCl

RN 850252-01-6 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(2-methylphenyl)-N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



IT 850250-76-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrimidine derivs. as antitumor agents)
RN 850250-76-9 CAPLUS
CN 2,4-Pyrimidinediamine, 6-chloro-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 11 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:120898 CAPLUS
DOCUMENT NUMBER: 142:219297
TITLE: Preparation of pyrimidine analogs as 5-HT2b receptor antagonists
INVENTOR(S): Borman, Richard Anthony; Coleman, Robert Alexander; Clark, Kenneth Lyle; Oxford, Alexander William; Hynd, George; Archer, Janet Ann; Aley, Amanda; Harris, Neil Victor
PATENT ASSIGNEE(S): Pharmagene Laboratories Limited, UK
SOURCE: PCT Int. Appl., 173 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005012263	A1	20050210	WO 2004-GB3184	20040723
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2532505	A1	20050210	CA 2004-2532505	20040723
EP 1648876	A1	20060426	EP 2004-743517	20040723
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
JP 2006528617	T	20061221	JP 2006-520897	20040723
PRIORITY APPLN. INFO.:			GB 2003-17346 A	20030724
			US 2003-490286P P	20030728
			WO 2004-GB3184 W	20040723

OTHER SOURCE(S): CASREACT 142:219297; MARPAT 142:219297
GI



AB Title compds. represented by the formula I [wherein X = O or NH; R1 = (un)substituted aryl; R2, R3 = independently H, (un)substituted (cyclo)alkyl, cycloalkylalkyl, phenylalkyl; R4, R5 = independently H, (un)substituted (phenyl)alkyl, sulfonylalkyl, carbonylalkyl, alkylamino or R4R5 = (un)substituted heterocyclic group; and pharmaceutically acceptable

L4 ANSWER 11 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

salts or solvates thereof], and 3 addnl. Markush structures, were prepd. as 5-HT2b receptor agonists. For example, reaction of 2-amino-4-chloro-6-methylpyrimidine with aniline in the microwave cavity gave II. I were tested for binding activity of 5-HT2A, 5-HT2B and 5-HT2C. Thus, I and their pharmaceutical comprns. are useful for the treatment of a condition alleviated by antagonism of a 5-HT2B receptor, such as digestive tract disease (no data).

IT 842154-19-2P 842154-21-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrimidinyl, imidazolyl, oxazolyl and triazolyl amine derivs. as 5-HT2b receptor antagonists)
RN 842154-19-2 CAPLUS
CN 2,4-Pyrimidinediamine, N4-(3-chloro-4-methoxyphenyl)-6-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 842154-21-6 CAPLUS
CN 2,4-Pyrimidinediamine, 6-methyl-N4-(4-phenoxyphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:857162 CAPLUS
DOCUMENT NUMBER: 141:350185
TITLE: Preparation of pyrimidine derivatives with lysophosphatidic acid acyltransferase β (LPAAT-β) inhibitory activity
INVENTOR(S): Bhatt, Rama; Gong, Baoqing; Hong, Feng; Jenkins, Scott A.; Klein, J. Peter; Kohm, Cory T.; Tulinsky, John
PATENT ASSIGNEE(S): Cell Therapeutics, Inc.; USA
SOURCE: U.S. Pat. Appl. Publ., 80 pp., which
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004204386	A1	20041014	US 2003-671070	20030924
PRIORITY APPLN. INFO.:			US 2002-419694P P	20021017
			US 2003-460776P P	20030404

OTHER SOURCE(S): MARPAT 141:350185
GI



I



II

AB The title compds. I [X, Y, Z = N, CH, or CR with the proviso that two of X, Y and Z are N; R = alkyl, alkoxy, Cl, Br, (substituted)amino; Q = NR', R'N-(CH2)n, (CH2)n-NR', O, O-(CH2)n, (CH2)n-O, S, S-(CH2)n, or (CH2)n-S; n = 1-10; R' = H or alkyl; R1 = H, OH, alkyl, alkoxy, Cl, F, Br, etc.; R2, R7 = H, OH, alkyl, alkoxy, Cl, F, Br, I, etc.; R3 = H, alkyl, alkoxy, Cl, CCl3, (substituted)amino; R4, R5, R6 = H, OH, alkyl, alkenyl, alkynyl, alkoxy, etc. or R4, R5 or R5, R6 are taken together with benzene ring to

L4 ANSWER 12 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 774606-32-5 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-methylphenyl)-N4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 774606-50-7 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-ethoxyphenyl)-N4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 774606-79-0 CAPLUS
CN Ethanol, 2-[4-[[2-amino-6-(5-chloro-2-ethoxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



L4 ANSWER 12 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

form a heterocycle) are prepd. as lysophosphatidic acid acyltransferase β (LPAAT-β) inhibitors for the treatment of diseases related to cell proliferation, such as cancer. For example, reaction of 6-chloro-N4-(4-methylphenyl)-pyrimidine-2,4-diamine (prepn. given) with 5-chloro-2-methoxy-Ph boronic acid yielded compd. II. The latter exhibits an IC50 = 0.12 μM in the LPAAT-β assay.

IT 774606-11-0P 774606-12-1P 774606-21-2P
774606-22-3P 774606-32-5P 774606-50-7P
774606-79-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrimidine derivs. with lysophosphatidic acid acyltransferase β (LPAAT-β) inhibitory activity)

RN 774606-11-0 CAPLUS
CN Phenol, 4-[[2-amino-6-(5-chloro-2-methoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 774606-12-1 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-methoxyphenyl)-N4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 774606-21-2 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(2,5-dichlorophenyl)-N4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 774606-22-3 CAPLUS
CN Phenol, 4-[[2-amino-6-(2,5-dichlorophenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 13 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:390240 CAPLUS
DOCUMENT NUMBER: 140:406815
TITLE: Preparation of phenylaminopyrimidines as Rho-Kinase II (ROKα) inhibitors for the treatment of cardiovascular diseases.
INVENTOR(S): Feurer, Achim; Bennabi, Samir; Heckroth, Heike; Schirok, Hartmut; Mittendorf, Joachim; Kast, Raimund; Stasch, Johannes-peter; Gnoth, Mark Jean; Muenter, Klaus; Lang, Dieter; Figueroa, Perez Santiago; Ehmke, Heimo
PATENT ASSIGNEE(S): Bayer Healthcare Ag, Germany; et al.
SOURCE: PCT Int. Appl., 203 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004039796	A1	20040513	WO 2003-EP11452	20031016
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10332232	A1	20040513	DE 2003-10332232	20030716
CA 2503646	A1	20040513	CA 2003-2503646	20031016
AU 2003278088	A1	20040525	AU 2003-278088	20031016
EP 1562935	A1	20050817	EP 2003-769398	20031016
EP 1562935	B1	20060906		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006506458	T	20060223	JP 2005-501803	20031016
US 2006241127	A1	20061026	US 2005-531889	20050419
PRIORITY APPLN. INFO.:			DE 2002-10250113 A	20021028
			DE 2003-10332232 A	20030716
			WO 2003-EP11452 W	20031016

OTHER SOURCE(S): MARPAT 140:406815
GI



I



II

AB Title compds. I [A = (un)substituted indazole, dihydrobenzofuran, indoline, etc.; R1 = H, halo, CN; R3, R4 = H, F, Cl; R5 = H, OH, halo, etc.] and their pharmaceutically acceptable salts were prepared For example, condensation of 5-(4-amino-2-fluorophenoxy)-1H-indazol, e.g., prepared from 5-hydroxyindazole in 2-steps, and 4-chloro-6-(4-pyridinyl)-2-pyrimidinamine, e.g., prepared from isonicotinic acid in 3-steps, afforded phenylaminopyrimidine II in 62% yield. In Rho-Kinase II (ROKα) inhibition assays, 13-examples of compds. I exhibited IC50 values ranging from 1-680 nM, e.g., the IC50 value of phenylaminopyrimidine II was 20 nM. Compds. I were claimed useful for the treatment of cardiovascular diseases.

IT 688779-56-8P 688779-61-5P 688780-14-5P
688781-25-1P 688781-29-5P 688781-33-1P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of phenylaminopyrimidines as Rho-Kinase II (ROKα) inhibitors for the treatment of cardiovascular diseases)

RN 688779-56-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[4-[(3-amino-1,2-benzisoxazol-4-yl)oxy]-3-fluorophenyl]-6-chloro- (9CI) (CA INDEX NAME)



RN 688779-61-5 CAPLUS

CN 2,4-Pyrimidinediamine, 6-chloro-N4-[3-fluoro-4-(1H-indazol-5-yloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 688780-14-5 CAPLUS

CN 2,4-Pyrimidinediamine, 6-chloro-N4-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 688781-25-1 CAPLUS

CN 4-Pyrimidineacetic acid, 2-amino-6-[[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 688781-29-5 CAPLUS

CN 4-Pyrimidinebutanoic acid, 2-amino-6-[[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]amino]-, hydrochloride (9CI) (CA INDEX NAME)



RN 688781-33-1 CAPLUS

CN 4-Pyrimidinebutanoic acid, 2-amino-6-[[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



IT 688779-62-6P 688779-63-7P 688779-71-7P
688779-77-3P 688779-78-4P 688779-79-5P
688779-82-0P 688779-86-4P 688779-87-5P
688779-88-6P 688779-89-7P 688779-90-0P
688779-93-3P 688779-95-5P 688779-96-6P
688779-97-7P 688779-98-8P 688780-01-0P
688780-02-1P 688780-05-4P 688780-06-5P
688780-07-6P 688780-08-7P 688780-10-1P
688780-11-2P 688780-12-3P 688780-13-4P
688780-15-6P 688780-73-6P 688780-75-8P
688780-77-0P 688780-79-2P 688780-81-6P
688780-83-8P 688781-01-3P 688781-03-5P
688781-05-7P 688781-07-9P 688781-09-1P
688781-11-5P 688781-13-7P 688781-15-9P
688781-17-1P 688781-19-3P 688781-21-7P
688781-23-9P 688781-27-3P 688781-31-9P
688781-35-3P 688781-51-3P 688781-53-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenylaminopyrimidines as Rho-Kinase II (ROKα) inhibitors for the treatment of cardiovascular diseases)

RN 688779-62-6 CAPLUS

CN 2,4-Pyrimidinediamine, 6-chloro-N4-[3-chloro-4-(1H-indazol-5-yloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 688779-63-7 CAPLUS
CN 2,4-Pyrimidinediamine, 6-chloro-N4-[3-fluoro-4-(1H-indazol-6-yloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 688779-71-7 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[3-fluoro-4-(1H-indazol-5-yloxy)phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 688779-77-3 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[3-fluoro-4-[(3-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl]-6-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 688779-78-4 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(4-fluorophenyl)-N4-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 688779-79-5 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[3,5-difluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-6-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 688779-82-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3-fluorophenyl]-6-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 688779-86-4 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[3-fluoro-4-(1H-indazol-5-yloxy)phenyl]-6-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 688779-87-5 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[3-chloro-4-(1H-indazol-5-yloxy)phenyl]-6-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 688779-88-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(3-amino-1-methyl-1H-indazol-6-yl)oxy]-3-chlorophenyl]-6-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 688779-89-7 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(3-amino-1H-indazol-6-yl)oxy]-3-chlorophenyl]-6-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 688779-90-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(3-amino-1H-indazol-4-yl)oxy]-3-chlorophenyl]-6-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 688779-93-3 CAPLUS
CN 2,4-Pyrimidinediamine, 6-cyclohexyl-N4-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 688779-95-5 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(2,4-difluorophenyl)-N4-[3-fluoro-4-(1H-indazol-5-yloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 688779-96-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[3-fluoro-4-(1H-indazol-5-yloxy)phenyl]-6-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 688779-97-7 CAPLUS
CN Benzonitrile, 3-[2-amino-6-[[3-fluoro-4-(1H-indazol-5-yloxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 688779-98-8 CAPLUS
CN Benzonitrile, 4-[2-amino-6-[[3-fluoro-4-(1H-indazol-5-yloxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 688780-01-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[3-fluoro-4-(1H-indazol-5-yloxy)phenyl]-6-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 688780-02-1 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(4-bromophenyl)-N4-[3-chloro-4-(1H-indazol-5-yloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 688780-05-4 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(3-bromophenyl)-N4-[3-chloro-4-(1H-indazol-5-yloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 688780-06-5 CAPLUS
CN 4-Pyrimidinecarboxylic acid, 2-amino-6-[[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 688780-07-6 CAPLUS
CN 4-Pyrimidinecarboxylic acid, 2-amino-6-[[3-fluoro-4-(1H-indazol-5-yloxy)phenyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 688780-08-7 CAPLUS
CN Piperazine, 1-[[2-amino-6-[[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]amino]-4-pyrimidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 688780-10-1 CAPLUS
CN 6-Oxa-2,9-diazaspiro[4.5]decane, 2-[[2-amino-6-[[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]amino]-4-pyrimidinyl]carbonyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 688780-09-8
CMF C25 H25 F N8 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 688780-11-2 CAPLUS
CN Piperidine, 1-[[2-amino-6-[[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]amino]-4-pyrimidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 688780-12-3 CAPLUS
CN 4-Pyrimidinecarboxamide, 2-amino-6-[[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]amino]-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 688780-13-4 CAPLUS
CN Piperazine, 1-[[2-amino-6-[[3-fluoro-4-(1H-indazol-5-yloxy)phenyl]amino]-4-pyrimidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 688780-77-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[3-fluoro-4-(1H-indazol-5-yloxy)phenyl]-6-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 688780-79-2 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-6-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 688780-81-6 CAPLUS
CN Benzenemethanol, 2-[2-amino-6-[[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 688780-15-6 CAPLUS
CN 2,4-Pyrimidinediamine, 6-chloro-N4-[3,5-difluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 688780-73-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[3-fluoro-4-(1H-indazol-5-yloxy)phenyl]-6-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 688780-75-8 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[4-(dimethylamino)phenyl]-N4-[3-fluoro-4-(1H-indazol-5-yloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 688780-83-8 CAPLUS
CN Benzenemethanol, 4-[2-amino-6-[[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 688781-01-3 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[[(1,1-dimethylethyl)amino]methyl]-N4-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 688781-03-5 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-6-(1-piperidinylmethyl)- (9CI) (CA INDEX NAME)



RN 688781-05-7 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-6-[[(1-methylcyclopentyl)amino]methyl]- (9CI) (CA INDEX NAME)



RN 688781-11-5 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[(cyclopropylamino)methyl]-N4-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 688781-13-7 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[[bis(1-methylethyl)amino]methyl]-N4-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 688781-07-9 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-6-[[(1,1,3,3-tetramethylbutyl)amino]methyl]- (9CI) (CA INDEX NAME)



RN 688781-09-1 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-6-[(2-methyl-1-piperidinyl)methyl]- (9CI) (CA INDEX NAME)



RN 688781-15-9 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[(2,6-dimethyl-1-piperidinyl)methyl]-N4-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 688781-17-1 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[[(4-fluorophenyl)amino]methyl]-N4-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 688781-19-3 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-6-[(propylamino)methyl]- (9CI) (CA INDEX NAME)



RN 688781-21-7 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[[[(1,1-dimethylethyl)amino]methyl]-N4-[3-fluoro-4-(1H-indazol-5-yloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 688781-23-9 CAPLUS
CN 4-Pyrimidinemethanol, 2-amino-6-[[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 688781-27-3 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 688781-31-9 CAPLUS
CN Piperidine, 1-[4-[2-amino-6-[[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]amino]-4-pyrimidinyl]-1-oxobutyl]- (9CI) (CA INDEX NAME)



RN 688781-35-3 CAPLUS
CN 4-Pyrimidinebutanol, 2-amino-6-[[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 688781-51-3 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[3-fluoro-4-(1H-indazol-5-yloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 688781-53-5 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (9CI) (CA INDEX NAME)



IT 688782-22-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of phenylaminopyrimidines as Rho-Kinase II (ROKα) inhibitors for the treatment of cardiovascular diseases)
RN 688782-22-1 CAPLUS
CN Phenol, 4-[(2-amino-6-chloro-4-pyrimidinyl)amino]-2-chloro- (9CI) (CA INDEX NAME)



IT 91241-38-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of phenylaminopyrimidines as Rho-Kinase II (ROKα) inhibitors for the treatment of cardiovascular diseases)
RN 91241-38-2 CAPLUS
CN 2,4-Pyrimidinediamine, 6-chloro-N4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 13 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L4 ANSWER 14 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:20322 CAPLUS
DOCUMENT NUMBER: 140:87658
TITLE: Peptidomimetic modulators of cell adhesion
INVENTOR(S): Gour, Barbara J.; Blaschuk, Orest W.; Ali, Anmar; Ni, Feng; Chen, Zhigang; Michaud, Stephanie Denise; Wang, Shaomeng; Hu, Zengjian
PATENT ASSIGNEE(S): Can.
SOURCE: U.S. Pat. Appl. Publ., 280 pp., Cont.-in-part of U.S. Ser. No. 6,982.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 15
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004006011	A1	20040108	US 2003-425557	20030428
US 6031072	A	20000229	US 1997-893534	19970711
US 6326352	B1	20011204	US 2000-507102	20000217
US 2002168761	A1	20021114	US 2001-769145	20010124
US 2002151475	A1	20021017	US 2001-6982	20011204
US 6914044	B2	20050705		
PRIORITY APPLN. INFO.:			US 1996-21612P	P 19960712
			US 1997-893534	A1 19970711
			US 2000-491078	B2 20000124
			US 2000-507102	A1 20000217
			US 2001-769145	B2 20010124
			US 2001-6982	A2 20011204

OTHER SOURCE(S): MARPAT 140:87658

AB Peptidomimetics of cyclic peptides, and compns. comprising such peptidomimetics are provided. The peptidomimetics have a three-dimensional structure that is substantially similar to a three-dimensional structure of a cyclic peptide that comprises a cadherin cell adhesion recognition sequence HAV. Methods for using such peptidomimetics for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.

IT 339016-03-4, 2,4-Pyrimidinediamine, 6-chloro-N4-(4-phenoxyphenyl)-
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

RN 339016-03-4 CAPLUS
CN 2,4-Pyrimidinediamine, 6-chloro-N4-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 15 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:1006976 CAPLUS
DOCUMENT NUMBER: 140:59653
TITLE: Preparation of phenylaminopyrimidines as rho-kinase inhibitors
INVENTOR(S): Feurer, Achim; Bennabi, Samir; Heckroth, Heike; Erqueden, Jens; Schenke, Thomas; Bauser, Markus; Kast, Raimund; Stasch, Johannes-Peter; Stahl, Elke; Muenter, Klaus; Lang, Dieter; Ehmke, Heimo
PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 116 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003106450	A1	20031224	WO 2003-EP5827	20030604
WO 2003106450	A8	20050203		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10226943	A1	20040108	DE 2002-10226943	20020617
CA 2489452	A1	20031224	CA 2003-2489452	20030604
AU 2003232848	A1	20031231	AU 2003-232848	20030604
EP 1515965	A1	20050323	EP 2003-759908	20030604
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005538962	T	20051222	JP 2004-513282	20030604
PRIORITY APPLN. INFO.:			DE 2002-10226943 A	20020617
			WO 2003-EP5827 W	20030604

OTHER SOURCE(S): MARPAT 140:59653
GI

L4 ANSWER 15 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)





AB Title compds. [I; R1 = amino, OH; R2 = H, alkyl, cycloalkyl; R3, R4 = cyano, H, F, Cl; A = Q1-Q3; R5, R6 = H, F, Cl; D = (substituted) Ph, (iso)quinoline, indole, etc.], were prepared for treating cardiovascular diseases. Thus, 4-chloro-6-quinolin-6-yl-pyrimidin-2-amine (preparation given) and 3-fluoro-4-(4-pyridinylsulfanyl)aniline (preparation given) were treated with 37% HCl followed by stirring for over night at 100° to give 12% N-[2-amino-6-(6-quinolinyl)-4-pyrimidinyl]-N-[3-fluoro-4-(4-pyridinylsulfanyl)phenyl]amine. The latter inhibited Rho-kinase II (ROKα) with IC50 = 7 nM.

IT 637039-06-6P 637039-07-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenylaminopyrimidines as rho-kinase inhibitors)

RN 637039-06-6 CAPLUS
CN Phenol, 4-[2-amino-6-[[3-fluoro-4-(5-isoquinolinyloxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 637039-07-7 CAPLUS
CN Acetamide, N-[3-[2-amino-6-[[3-fluoro-4-(5-isoquinolinyloxy)phenyl]amino]-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)



IT 570415-44-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of phenylaminopyrimidines as rho-kinase inhibitors)
RN 570415-44-0 CAPLUS
CN 2,4-Pyrimidinediamine, 6-chloro-N4-[3-fluoro-4-(5-isoquinolinyloxy)phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:	2003:591171 CAPLUS
DOCUMENT NUMBER:	139:149645
TITLE:	Preparation of pyrimidine derivatives for use in pharmaceutical compositions as Rho-kinase inhibitors
INVENTOR(S):	Nagarathnam, Dhanapalan; Dumas, Jacques; Hatoum-Mokdad, Holia; Boyer, Stephen; Pluempe, Hans
PATENT ASSIGNEE(S):	Bayer Corporation, USA
SOURCE:	PCT Int. Appl., 69 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003062227	A1	20030731	WO 2003-US1840	20030123
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2473910	A1	20030731	CA 2003-2473910	20030123
US 2004002507	A1	20040101	US 2003-349176	20030123
US 6943172	B2	20050913		
EP 1470122	A1	20041027	EP 2003-705859	20030123
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005523894	T	20050811	JP 2003-562105	20030123
MX 2004PA07196	A	20050608	MX 2004-PA7196	20040723
US 2005209261	A1	20050922	US 2005-111704	20050422
PRIORITY APPLN. INFO.:			US 2002-349986P	P 20020123
			US 2003-349176	A3 20030123
			WO 2003-US1840	W 20030123

GI



AB Pyrimidine derivs., such as I [R = H, Ph; R1 = H, alkyl, aryl, heteroaryl,

halogen; R2 = H, alkyl, halogen; R1R2 = (CH2)3-5; R3 = heteroaryl, such as pyridinyl, quinolinyl or isoquinolinyl; X = O, S; R4, R5 = H, Cl, F], were prepd. for therapeutic use as Rho-kinase inhibitors. These pyrimidine derivs. are useful for inhibiting tumor growth in cancer of the breast, colon, prostate, ovaries, brain or lung, and for treatment of other disorders mediated by Rho-kinase, such as erectile dysfunction, coronary heart disease, hypertension, atherosclerosis, restenosis, cerebral ischemia, cerebral vasospasm, neurpnal degeneration, spinal cord injury, asthma, glaucoma and osteoporosis. Thus, II was prepd. in 18% yield by reacting 2-amino-4-chloro-6-methylpyrimidine with 3-fluoro-4-(4-pyridinylthio)aniline using K2CO3 in o-xylene at 100° overnight. The prepd. pyrimidine derivs. were assayed for inhibition of ROCK-I phosphorylation of myelin basic protein.

IT 570415-18-8P 570415-24-6P 570415-31-5P
570415-33-7P 570415-44-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrimidine derivs. for use in pharmaceutical compns. as Rho-kinase inhibitors)
RN 570415-18-8 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-(5-isoquinolinyloxy)phenyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 570415-24-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[3-fluoro-4-(5-isoquinolinyloxy)phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 570415-31-5 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[3-fluoro-4-(5-isoquinolinyloxy)phenyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 570415-33-7 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[3,5-dichloro-4-(5-isoquinolinyloxy)phenyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 570415-44-0 CAPLUS
CN 2,4-Pyrimidinediamine, 6-chloro-N4-[3-fluoro-4-(5-isoquinolinyloxy)phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:591169 CAPLUS
DOCUMENT NUMBER: 139:149643
TITLE: Preparation of pyrimidinamines as Rho-kinase inhibitors for inhibiting tumor growth, treating erectile dysfunction, and other therapeutic uses
INVENTOR(S): Nagarathnam, Dhanapalan; Dumas, Jacques; Hatoum-mokdad, Holia; Boyer, Stephen; Wang, Chunguang; Pluempe, Hans; Feurer, Achim; Bennabi, Samir
PATENT ASSIGNEE(S): Bayer Corporation, USA
SOURCE: PCT Int. Appl., 91 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003062225	A1	20030731	WO 2003-US1839	20030123
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2473510	A1	20030731	CA 2003-2473510	20030123
US 2004002508	A1	20040101	US 2003-349177	20030123
US 6924290	B2	20050802		
EP 1470121	A1	20041027	EP 2003-705858	20030123
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005521659	T	20050721	JP 2003-562103	20030123
MX 2004PA07191	A	20050331	MX 2004-PA7191	20040723
US 2005192304	A1	20050901	US 2005-107793	20050418
PRIORITY APPLN. INFO.:			US 2002-349987P	P 20020123
			US 2003-349177	A3 20030123
			WO 2003-US1839	W 20030123

OTHER SOURCE(S): MARPAT 139:149643
GI



AB Disclosed are pyrimidinamines (shown as I; variables defined below; e.g. 4-[[4-[(2-amino-6-ethyl-4-pyrimidinyl)amino]phenyl]sulfanyl]phenol), their synthesis, and their use as Rho-kinase inhibitors (no data). These compds. are useful for inhibiting tumor growth, treating erectile dysfunction, and treating other indications mediated by Rho-kinase, e.g., coronary heart disease. For I: R1 and R2 = H, halo, alkyl (un)substituted

by halo up to perhalo, cycloalkyl, alkenyl, alkynyl, NO2, NH2, NR6R7, or furyl, thienyl, pyridyl, trifluoromethyl or Ph each (un)substituted with NH2, NO2 trifluoromethyl or alkoxy; or R1 and R2 may be taken together to form a ring of = 5-7 members optionally interrupted by N and (un)substituted on N by benzyl. R3 = NH2 or -NH- Ph (un)substituted with halo, C1-C4 alkyl, trifluoromathyl, nitro or amino; R4 = X-A- and R5n-substituted Ph, R5n-substituted 6-X-Apyridin-3-yl or indol-5-yl (un)substituted on N with pyridyl; X is a linker substituted at the 3 or 4 position of the ring and is O, S, -S-CH2-, -(CH2)m-, or -C(O)-; A is Ph (un)substituted with alkylthio or OH, pyridyl, quinolyl or isoquinolyl. Each R5 independently is halo, alkyl (un)substituted by halo up to perhalo, cycloalkyl, alkoxy, alkenyl, alkynyl, NO2, NH2, or trifluoromethyl; n is 0-4; m is 1 or 2; and R6 and R7 are each independently H, alkyl, cycloalkyl, or Ph (un)substituted with halo, CF3, alkyl, nitro or amino; or R6 and R7 may form, together with the N atom to which they are attached, a heterocyclic ring (un)substituted with alkyl, optionally interrupted by O, or optionally fused to phenyl; addnl. details including provisos are given in the claims. More than 30 example prepns. of I plus many prepns. of intermediates are included. For example, 4-[[4-[(2-amino-6-ethyl-4-pyrimidinyl)amino]phenyl]mercapto]phenol (0.11 mmol, 51% yield) was prepd. from 2-amino-4-chloro-6-ethylpyrimidine (0.23 mmol) and 4-[(4-aminophenyl)sulfanyl]phenol (0.25 mmol) suspended in a mixt. of 0.01M aq. HCl (230 μL) and 1-butanol (230 μL); the mixt. was refluxed overnight.

IT 569658-24-8P, 4-[[4-(4-Hydroxyphenoxy)phenyl]amino]-6-methylpyrimidin-2-amine 569658-28-2P, N-(2-Amino-6-methyl-4-pyrimidinyl)-N-[4-[(5-quinolinyl)oxy]phenyl]amine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of pyrimidinamines as Rho-kinase inhibitors for inhibiting tumor growth, treating erectile dysfunction, and other therapeutic uses)

RN 569658-24-8 CAPLUS
CN Phenol, 4-[4-[(2-amino-6-methyl-4-pyrimidinyl)amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 569658-28-2 CAPLUS
CN 2,4-Pyrimidinediamine, 6-methyl-N4-[4-(5-quinolinyloxy)phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 17 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 18 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:927396 CAPLUS
DOCUMENT NUMBER: 138:13955
TITLE: Preparation of phenol and hydroxynaphthalene based inhibitors of protein kinase for the treatment of disease
INVENTOR(S): Cao, Sheldon Xiaodong; Bounaud, Pierre-Yves; Chen, Xiaohua; Chung, Hyun-Ho; Dumas, David Paul; Kc, Sunil Kumar; Min, Changhee; Yang, Jae Young; Long, Melissa C.
PATENT ASSIGNEE(S): LG Biomedical Institute, USA
SOURCE: PCT Int. Appl., 286 pp.
CODEN: PIXXD2.
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002096867	A2	20021205	WO 2002-US16920	20020528
WO 2002096867	A3	20040304		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002310187	A1	20021209	AU 2002-310187	20020528
US 2003187007	A1	20031002	US 2002-158030	20020528
US 2003208067	A1	20031106	US 2002-158103	20020528
EP 1412327	A2	20040428	EP 2002-737248	20020528
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004534779	T	20041118	JP 2003-500047	20020528
KR 2004026657	A	20040331	KR 2003-715388	20031125
PRIORITY APPLN. INFO.:			US 2001-294792P	P 20010530
			WO 2002-US16920	W 20020528

OTHER SOURCE(S): MARPAT 138:13955
GI

L4 ANSWER 18 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I



II

AB Phenol and hydroxynaphthalene derivs. I [X = O, S, amine, alkylamine, alkynylamine, arylamine, and heteroarylamine; R1 = (un)substituted 5- or 6-membered aromatic or heteroarom. ring, -(X1)mCOX2-, wherein X1 = alkylene, alkenylene, alkynylene, aryl and heteroaryl, X2 = H, alkyl, aryl, heteroaryl, OH, alkoxy, amino, substituted amine, m = 0 or 1, or R1 = -C(X3)=N-NX4-C(=E)-NX5X6 wherein X3 = H, alkyl, aryl, alkylaryl, heteroaryl, and amino and E = O, S, and substituted amine with X4, X5, and X6 independently equal to H, alkyl, aryl, and heteroaryl; R2, R3, and R4 = H, alkyl, alkylene, halo, alkoxy, etc.; or R2 and R3 or R3 and R4 may be taken together to form an (un)substituted aromatic or heteroarom. ring; R5 = H, (un)substituted-alkyl, -aryl, -heterocycle, etc.; R6 = H, alkyl, alkene, alkyne, aryl, and heteroaryl] are prepared and disclosed as inhibitors of protein kinase. Thus, II was prepared by cyclocondensation of 5'-bromo-2'-methoxyacetophenone with N,N-dimethylformamide di-Et acetal with subsequent Suzuki coupling with 4-methoxyphenylboronic acid. In assays to determine cyclin dependent kinase activity, specifically against CDK2 and CDK5, II possessed IC50 values of.0-0.5 μM. II proved highly specific for CDK2 and CDK5 and was further evaluated by in vitro tumor cell efficacy tests against numerous cancers. The present invention is directed in part towards methods of modulating the function of protein kinases with phenol- and hydroxynaphthalene-based compds. The methods incorporate cells that express a protein kinase. In addition, the invention describes methods of preventing and treating protein kinase-related abnormal conditions in organisms with a compound identified by the invention. Furthermore, the invention pertains to phenol- and hydroxynaphthalene-based compds. and pharmaceutical compns. comprising these compds.

IT 477727-07-4P 477727-28-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of phenol and hydroxynaphthalene based inhibitors of protein kinase)

RN 477727-07-4 CAPLUS
CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[(4-methoxyphenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 18 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 477727-28-9 CAPLUS
CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[(2-fluoro-4-hydroxyphenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 19 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:869496 CAPLUS
DOCUMENT NUMBER: 137:363033
TITLE: Peptidomimetic modulators of cell adhesion
INVENTOR(S): Gour, Barbara J.; Blaschuk, Orest W.; Ali, Anmar; Ni, Feng; Chen, Zhigang; Michaud, Stephanie D.; Wang, Shoameng; Hu, Zenjian
PATENT ASSIGNEE(S): Can.
SOURCE: U.S. Pat. Appl. Publ., 309 pp., Cont.-in-part of U.S. Ser. No. 491,078.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 15
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002168761	A1	20021114	US 2001-769145	20010124
US 2004058864	A1	20040325	US 2003-412701	20030410
US 2004006011	A1	20040108	US 2003-425557	20030428
PRIORITY APPLN. INFO.:			US 2000-491078 A2	20000124
			US 1996-21612P P	19960712
			US 1997-893534 A1	19970711
			US 2000-507102 A1	20000217
			US 2001-769145 B1	20010124
			US 2001-6982 A2	20011204

OTHER SOURCE(S): MARPAT 137:363033
AB Peptidomimetics of cyclic peptides, and compns. comprising such peptidomimetics are provided. The peptidomimetics have a three-dimensional structure that is substantially similar to a three-dimensional structure of a cyclic peptide that comprises a cadherin cell adhesion recognition sequence HAV. Methods for using such peptidomimetics for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.
IT 339016-03-4, 2,4-Pyrimidinediamine, 6-chloro-N4-(4-phenoxyphenyl)-
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)
RN 339016-03-4 CAPLUS
CN 2,4-Pyrimidinediamine, 6-chloro-N4-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 20 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:545724 CAPLUS
DOCUMENT NUMBER: 135:147398
TITLE: Peptidomimetic modulators of cell adhesion
INVENTOR(S): Gour, Barbara J.; Blaschuk, Orest W.; Ali, Anmar; Ni, Feng; Chen, Zhigang; Michaud, Stephanie Denise; Wang, Shoameng; Hu, Zengjian
PATENT ASSIGNEE(S): Adherex Technologies, Inc., Can.
SOURCE: PCT Int. Appl., 416 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 15
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001053331	A2	20010726	WO 2001-US2508	20010124
WO 2001053331	A3	20020711		
WO 2001053331	A9	20021031		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2000-491078 A 20000124
OTHER SOURCE(S): MARPAT 135:147398
AB Peptidomimetics of cyclic peptides, and compns. comprising such peptidomimetics are provided. The peptidomimetics have a three-dimensional structure that is substantially similar to a three-dimensional structure of a cyclic peptide that comprises a cadherin cell adhesion recognition sequence HAV. Methods for using such peptidomimetics for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.
IT 339016-03-4
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(peptidomimetic modulators of cell adhesion)
RN 339016-03-4 CAPLUS
CN 2,4-Pyrimidinediamine, 6-chloro-N4-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 21 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1992:651318 CAPLUS
DOCUMENT NUMBER: 117:251318
TITLE: Novel piperazinyl-substituted pyrimidines as antihypertensive and vasodilators
AUTHOR(S): Badran, M. M.; Youssef, K.
CORPORATE SOURCE: Fac. Pharm., Cairo Univ., Cairo, Egypt
SOURCE: Revue Roumaine de Chimie (1992), 37(2), 283-8
CODEN: RRCHAX; ISSN: 0035-3930
DOCUMENT TYPE: Journal
LANGUAGE: English
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Three series of piperazinyl-substituted pyrimidine derivs. having the general formulas I, II, and III (R = 2-EtOC6H4, 2-MeOC6H4, 2-ClC6H4, 4-ClC6H4, 3-CF3C6H4, PhCH2) were synthesized. Reaction of 2-amino-4-chloro-6-methylpyrimdine (IV) with a number of 1-arylpiperazines afforded the corresponding 4-aryl-1-piperazinyl-substituted pyrimidines I. The second series was prepared by treating 2-amino-4-(p-carboxyanilino)-6-methylpyrimidine (V, R1 = CO2H), prepared via reaction of IV and p-aminobenzoic acid, with thionyl chloride to give the corresponding key intermediate V (R1 = COCl). The latter was treated with the appropriate 1-arylpiperazines to furnish the desired products II. Addnl., the third series of target compds. III was prepared by reacting IV with 4-aminophenol to give V (R1 = OH). Application of the acid-catalyzed Mannich reaction to V (R1 = OH), using formaldehyde and different 1-arylpiperazines gave the corresponding Mannich bases III.
IT 131555-97-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and Mannich reaction of, with formaldehyde and arylpiperazines)
RN 131555-97-0 CAPLUS
CN Phenol, 4-[(2-amino-6-methyl-4-pyrimidinyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L4 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1991:81760 CAPLUS
DOCUMENT NUMBER: 114:81760
TITLE: Novel piperazinyl-substituted pyrimidines as possible antihypertensives and vasodilators
AUTHOR(S): Badran, M. M.; Youssef, K.
CORPORATE SOURCE: Fac. Pharm., Cairo Univ., Cairo, Egypt
SOURCE: Egyptian Journal of Pharmaceutical Sciences (1990), 31(1-4), 407-15
CODEN: EJPSBZ; ISSN: 0301-5068
DOCUMENT TYPE: Journal
LANGUAGE: English
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The preparation of 3 series of title compds. I (Z = bond, R = 3-EtO, 4-Cl, 2-Cl, 3-CF3; Z = CH2, R = H), II (Z = bond, R = 2-MeO, 4-Cl, 2-Cl, 3-CF3; Z = CH2, R = H) and III (Z = bond, R = 2-Cl, 4-Cl, 2-EtO; Z = CH2, R = H) from 2-amino-4-chloro-6-methylpyrimidine is reported.
IT 131555-97-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and Mannich reaction of, with arylpiperazines and formaldehyde)
RN 131555-97-0 CAPLUS
CN Phenol, 4-[(2-amino-6-methyl-4-pyrimidinyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L4 ANSWER 23 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1991:62037 CAPLUS
DOCUMENT NUMBER: 114:62037
TITLE: Synthesis of some Mannich bases of 2- and 4-amino- and 2,4-diamino-6-methylpyrimidines as potential biodynamic agents
AUTHOR(S): Ghoneim, Khadiga M.; El-Telbany, Faraq A.; Youssef, Khairia
CORPORATE SOURCE: Fac. Pharm., Cairo Univ., Cairo, Egypt
SOURCE: Egyptian Journal of Chemistry (1989), Volume Date 1987, 30(6), 295-304
CODEN: EGJCA3; ISSN: 0367-0422
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The synthesis of certain Mannich bases of 2- and 4-amino- and 2,4-diamino-6-methylpyrimidines and their antimicrobial and antileukemic activities are described. Likewise, application of the Mannich conditions to 2-amino-4-(p-hydroxyanilino)-, 4-amino-2-(p-hydroxyanilino)-, and 2-amino-4-(p-acetylanilino)-6-methylprimidines using piperazine as the secondary amine afforded the corresponding bis-Mannich bases.
IT 131554-44-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and anitleukemia activity of)
RN 131554-44-4 CAPLUS
CN Phenol, 4-[(2-amino-6-methyl-4-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)



IT 131555-97-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and antibacterial and antifungal activity of)
RN 131555-97-0 CAPLUS
CN Phenol, 4-[(2-amino-6-methyl-4-pyrimidinyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L4 ANSWER 24 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1975:579000 CAPLUS
DOCUMENT NUMBER: 83:179000
TITLE: Purine Antagonists. II. Synthesis of 2,6-disubstituted 9-arylpurines and 9-aryl-8-azapurines and some related 5-phenylazopyrimidines
AUTHOR(S): Sen, D.; Sengupta, Purnendu
CORPORATE SOURCE: Univ. Coll. Sci. Technol., Calcutta Univ., Calcutta, India
SOURCE: Indian Journal of Chemistry (1975), 13(6), 549-51
CODEN: IJOCAP; ISSN: 0019-5103
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 83:179000
GI For diagram(s), see printed CA Issue.
AB 2-Amino-6-hydroxy-9-arylpurines I (R = Me, MeO; R = H2N) were prepared by the cyclization of 2,5-diamino-6-arylamino-4-hydroxypyrimidines with HCONH2. 9-Aryl-2,6-dihydroxypurine I (R = MeO, R1 = OH) were prepared by the deamination of 2-amino-9-aryl-6-hydroxypurine with NaNO2 and concentrate HCl. 9-Aryl-8-azapurines II (R = Me, MeO) were prepared by the cyclization of 2,5-diamino-6-arylamino-4-hydroxypyrimidines with NaNO2 and HOAc. 2,5-Diamino-6-arylamino-4-hydroxypyrimidines were obtained by the reduction of
2-amino-6-arylamino-4-hydroxy-5-phenylazopyrimidines with sodium dithionite. The preparation of 5-phenylazopyrimidines III (R = Me, R2 = MeO)
involves the reaction of appropriate 2-amino-6-arylamino-4-hydroxypyrimidines with benzenediazonium chloride.
IT 57493-60-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with benzenediazonium chloride)
RN 57493-60-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-amino-6-[(4-methoxyphenyl)amino]- (9CI) (CA INDEX NAME)



L4 ANSWER 25 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1964:464427 CAPLUS
DOCUMENT NUMBER: 61:64427
ORIGINAL REFERENCE NO.: 61:11197f-g
TITLE: Growth inhibition of Clostridium feseri by carcinostatic purine and pyrimidine analogs. I. Effect of medium on growth inhibition
AUTHOR(S): Cappuccino, James G.; George, Marilyn; Merker, Philip C.; Tarnowski, George S.
CORPORATE SOURCE: Sloan-Kettering Inst., New York, NY
SOURCE: Cancer Research (1964), 24, 1243-8
CODEN: CNREA8; ISSN: 0008-5472
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
AB C. feseri grows well, in semisynthetic basal medium devoid of purine bases and folic acid. Growth inhibition of this organism is pronounced in such a medium by carcinostatic purine analogs; with pyrimidine analogs, inhibition is also marked. Purines in the medium block the growth inhibition caused by purine analogs. Greater agreement occurs between the growth inhibition of the organism and that of adenocarcinoma 755 when carcinostatic purine and pyrimidine analogs are studied in purineless media as compared with complex thioglycolate medium.
IT 93001-35-5, Pyrimidine, 2-amino-4-p-anisidino-6-methyl-
(Clostridium feseri growth inhibition by)
RN 93001-35-5 CAPLUS
CN Pyrimidine, 2-amino-4-p-anisidino-6-methyl- (7CI) (CA INDEX NAME)

L4 ANSWER 26 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1962:429651 CAPLUS
DOCUMENT NUMBER: 57:29651
ORIGINAL REFERENCE NO.: 57:5916d-i,5917a
TITLE: Pyrimidines. VII. 2-Amino-4-(substituted anilino)pyrimidines
AUTHOR(S): O'Brien, Darrell E.; Baiocchi, Fred; Robins, Roland K.; Cheng, C. C.
CORPORATE SOURCE: Midwest Res. Inst., Kansas City, MO
SOURCE: Journal of Organic Chemistry (1962), 27, 1104-7
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
OTHER SOURCE(S): CASREACT 57:29651
GI For diagram(s), see printed CA Issue.
AB An appropriate chloropyrimidine (0.1 mole) and 0.1 mole suitable aniline mixed with 1 ml. concentrated HCl in a round-bottom flask and immersed in an oil
bath at 175° (exothermic reaction at 155° with rise of temperature to 185°), the mixture heated 20 min. at 185° and the cooled glass-like mass taken up in 200 ml. dilute HCl, the clarified (C) solution filtered and made alkaline with NH4OH, the precipitate dried at 80° and recrystd. from H2O and alc. gave the alkylaminopyrimidines (I, Z = NH2, Me, Cl). HOCH2CH2OH (150 ml.), 10 g. NaOH, and 10 g. I (Z = Cl) in a round-bottom flask heated at 160° (preheated oil bath) with exothermic reaction, heated 30 min. at 175° and the cooled solution taken up in 500 ml. H2O, the clarified filtrate heated and acidified with AcOH, filtered hot and the dried product recrystd. gave I(Z = OH). A similar procedure using NaSH in place of NaOH gave I (Z = SH). The compds. synthesized are tabulated (R = H except where indicated) (series, X, Y, % yield, and m.p. given): Z = NH2: H, H, 78, 172-4°; H, H, Me, 72, 193-4°; H, 2-Me, 79, 182-3°; H, 3-Me, 76, 129-30°; H, 4-Me, 84, 172-3°; H, 4-MeO, 87, 179-80°; H, 4-HOC2H4, 81, 146-8°; H, 4-F, 81, 175-7°; H, 2-Cl, 71, 175-6°; H, 3-Cl, 78, 1601°; H, 4-Br, 90, 175-6°; 3-Me, 4-Me, 83, 163-4°; 4-Me, 3-Cl, 87, 172-3°; 3-Cl, 4-Cl, 92, 185-6°. Z = Me: H, H, Me, 74, 148-9°; H, H, HOC2H4, 67, 162-3°; H, 3-Me, 83, 142-3°; H, 4-Me, 91, 224-5°; H, 4-MeO, 89, 222-3°; H, 3-EtO, 64, 159-60°; H, 4-HOCH2CH2, 80, 204-5°; H, 2-Cl, 67, 175-7°; H, 3-Cl, 59, 147-8°; H, 2-Br, 78, 1723°; H, 4-Br, 88, 227-8°; H, 4-CN, 53, 215-16°; 2-Me, 5-Me, 67, 191-2°; 3-Me, 4-Me, 88, 213-14°; 4-Me, 3-Cl, 81, 185-6°; 3-Cl, 4-Cl, 96, 206-7°. Z = Cl: H, H, Me, 68, 177-8°; H, 2-Me, 54, 230-1°; H, 3-Me, 66, 166-7°; H, 4-Me, 78, 236-8°; H, 4-MeO, 74, 213-15°; H, 2-EtO, 77, 153-4°; H, 4-HOC2H4, 73, 191-2°; H, 2-Cl, 76, 1889°; H, 3-Cl, 74, 154-5°; H, 2-Br, 63, 194-5°; H, 4-Br, 84, 246-8°; H, 4-CN, 52, 279-81°; 3-Me, 4-Me, 78, 2279°; 4-Me, 3-Cl, 78, 197-9°; 3-Cl, 4-Cl, 81, 216-17°. Z = OH: H, 2-Me, 70, 264-5°; H, 4-Me, 83, 262-3°; H, 4MeO, 80, 295-7°; H, 2-Cl, 71, 273-4°; H, 3-Cl, 73, 25960°; H, 4-Br, 82, 296-8°; 3-Me, 4-Me, 87, 218-20°; 4-Me, 3-Cl, 81, 307-9°; 3-Cl, 4-Cl, 85, 258-9°. Z = SH: H, 2Me, 63, 259-60°; H, 3-Me, 81, 224-6°; H, 4-Me, 85, 284-5°; H, 4-MeO, 79, 238-9°; H, 2-Cl, 67, 237-8°; H, 3-Cl, 80, 285-6°; 3-Me, 4-Me, 83, 220-2° (decomposition); 4-Me, 3-Cl, 80, 261-2° (decomposition); 3-Cl, 4-Cl, 85, 288-9° (decomposition). Ultraviolet spectral data were tabulated.
IT 57493-60-4P, 4-Pyrimidinol, 2-amino-6-p-anisidino-
91241-38-2P, Pyrimidine, 2-amino-4-p-anisidino-6-chloro-

L4 ANSWER 26 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
93001-35-5P, Pyrimidine, 2-amino-4-p-anisidino-6-methyl-
RL: PREP (Preparation)
(prepn. of)
RN 57493-60-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-amino-6-[(4-methoxyphenyl)amino]- (9CI) (CA INDEX NAME)



RN 91241-38-2 CAPLUS
CN 2,4-Pyrimidinediamine, 6-chloro-N4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 93001-35-5 CAPLUS
CN Pyrimidine, 2-amino-4-p-anisidino-6-methyl- (7CI) (CA INDEX NAME)



L4 ANSWER 27 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1962:73486 CAPLUS
DOCUMENT NUMBER: 56:73486
ORIGINAL REFERENCE NO.: 56:14277f-i,14278a-i,14279a-i,14280a
TITLE: v-Triazolo[4,5-d]pyrimidines. I. Synthesis and nucleophilic substitution of 7-chloro derivatives of 3-substituted v-triazolo[4,5-d]pyrimidines
AUTHOR(S): Shealy, Y. Fulmer; Struck, Robert F.; Clayton, Joe D.; Montgomery, John A.
CORPORATE SOURCE: Southern Research Inst., Birmingham, AL
SOURCE: Journal of Organic Chemistry (1961), 26, 4433-40
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
GI For diagram(s), see printed CA Issue.
AB 3-Substituted 5-amino-7-chloro-v-triazolo[4,5-d]pyrimidines were synthesized from the appropriate 2,5-diamino-4-chloro-6-alkyl (or aryl)aminopyrimidines. Retention of the Cl group until the v-triazolo[4,5-d]pyrimidine ring had been formed permitted introduction, by nucleophilic displacement, of a wide variety of substituents at position 7. (All m.ps. are corrected unless otherwise noted.) BuNH2 (6.14 g.), 6.56 g. 2-amino-4,6-dichloropyrimidine (I), and 120 ml. absolute EtOH refluxed and stirred 6 hrs., the solution concentrated in vacuo to 40 ml., treated slowly with 40 ml. H2O with stirring, seeded, treated dropwise with an addnl. 40 ml. H2O with stirring, the precipitate collected, washed with 35% aqueous EtOH and H2O, and dried in vacuo at 40° gave 7.3 g. II (R = Bu), m. 97-8° (cyclohexane). I (56.1 g.), 250 ml. absolute EtOH, and 250 ml. EtOH-EtNH2 (prepared from 148 g. anhydrous EtNH2 and 830 ml. absolute EtOH) refluxed 2 hrs. (in a flask equipped with a H2O-cooled condenser surmounted by a Dewar-type condenser containing solid CO2, and the reaction mixture was protected from moisture), treated with the remainder of the EtNH2 solution, the solution refluxed 4 hrs., concentrated in vacuo to 175 ml., and chilled gave 43.6 g. (an addnl. 10.1 g. was isolated from the filtrate by dilution with H2O) II (R = Et), m. 149° and 154° (after cooling and then remelting) (iso-PrOH), λ (EtOH) 239 and 284 mμ (ε × 10-3 10.8 and 8.5). Fusion of equimolar amts. I, p-MeOC6H4NH2 (III) and AcOH gave 53% II (R = C6H4OMe-p) (IIIa), m. 223-4°. I (10 g.), 30 g. III, and 200 ml. EtOH refluxed 5.5 hrs., the precipitate filtered off, washed several times with N HCl, boiled briefly with 150 ml. N HCl, and dried in vacuo gave (in 2 crops) 19.5 g. IV (R = OMe) HCl salt (V.HCl), m. 257-61° (uncor.) (EtOH with C). Crude V.HCl in EtOH made alkaline with aqueous NaOH, concentrated, and the precipitate leached with hot EtOAc gave V, m. 195-6° and 203-4° (after cooling and then remelting) (EtOAc). Similarly, with a 10-fold excess p-ClC6H4NH2 (VI), was prepared IV (R = Cl) HCl salt monoethanolate (VII.HCl.EtOH), m. 298-301° (uncor.); VII m. 193° (EtOAc). A cold (0-5°) solution of p-ClC6H4N2Cl (VIII) (prepared from 39.4 g. VI, 23.8 g. NaNO2, 86 ml. concentrated HCl, and 245 ml H2O) added dropwise during 6.5 hrs. to 48.7 g. II (R = Et), 424 g. NaOAc, 1410 ml. AcOH, and 1175 ml. H2O with stirring under N, and stirred 11.5 hrs. at room temperature under N gave 73.2 g. IX (R = Et), m. 263-4° (decomposition) (uncor.) (EtOAc-Me2CO-C6H6, then EtOAc). Similarly was prepared 70-92% IX (R = Bu), m. 197-8° (uncor.) (iso-PrOH). IIIa (7.0 g.) and 140 ml. pyridine

L4 ANSWER 27 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
in 700 ml. cold EtOH added dropwise during 3 hrs. to VIII (from 14.3 g. VI, 50 ml. concd. HCl, 200 ml. EtOH, 80 ml. H2O, and 9.52 g. NaNO2) at 0-5° with stirring, stirred 3 hrs. more, stored overnight at 5°, the ppt. filtered off, washed twice with 50-ml. portions H2O, and dried 5 hrs. in vacuo at 80° gave 7.0 g. IX (R = C6H4OMe-p) (X), m. 282-3° (uncor.) (EtOH-MeOCH2CH2OH). IX (R = Et) (25.2 g.), 625 ml. EtOH, 625 ml. H2O, and 62.5 ml. AcOH heated to 70° with stirring under N, the mixt. treated portionwise during 1 hr. with 60 g. Zn dust, heated 1 hr. at 70°, filtered while hot, the filter cake washed with 3 20-ml. portions EtOH, the combined filtrate and washings concd. in vacuo under N to 350 ml., and cooled to room temp. gave 11.3 g. XI (R = Et), m. 207-8° (uncor.) (EtOH). IX (R = Et) (1.0 g.) in 20 ml. EtOH treated dropwise during 15 min. with 2.75 g. SnCl2.2H2O in 20 ml. concd. HCl with stirring under N, the mixt. heated 45 min. at 55-60°, the resulting soln. cooled to room temp., treated with 16 g. NaOH in 40 ml. H2O, and kept 1 hr. gave 710 mg. crude X (R = Et); sublimation of 200 mg. crude product gave 130 mg. XI (R = Et), m. 208-9° (uncor.) (EtOH). Redn. of IX (R = Et) with Fe powder and HCl in EtOH-AcOH-H2O gave 71% XI (R = Et), m. 209-12°. IX (R = Bu) (50.4 g.) reduced as above with 120 g. Zn dust in 1260 ml. EtOH, 1260 ml. H2O, and 126 ml. AcOH, the mixt. filtered under N, the filtrate cooled in an ice bath, made alk. to pH 9-10 with 420 ml. 6N NaOH, treated with C and Celite, filtered through Celite under N, the filtrate neutralized to pH 7 with 32 ml. AcOH, concd. in vacuo at below 40° to 1.5 l., cooled at 5°, the ppt. collected, washed with 2 30-ml. portions H2O, and stirred twice with 100-ml. portions 1:1 cyclohexane-iso-Pr2O gave 29.2 g. crude XI (R = Bu), m. 106-7°. Crude XI (R = Bu) (10.6 g.) dissolved in 120 ml. N HCl, the filtered soln. adjusted to pH 5, treated with C, filtered, the filtrate adjusted to pH 9 with 6N NaOH, and chilled gave 6.7 g. XI (R = Bu), m. 125-6° (sublimation in vacuo). Redn. of X with Zn as above gave (in 2 crops) 75% XI (R = C6H4OMe-p) (XII), m. 158-60° (decompn.). XI (R = Et) (11.3 g.) in 900 ml. H2O and 180 ml. AcOH treated dropwise during 1 hr. with 4.65 g. NaNO2 in 20 ml. H2O at 0-5° with stirring and the mixt. stirred 1 hr. at 0-5° gave 9.4 g. XIII (R' = Cl, R = Et) (XIV), m. 159-60°. Similarly was prepd. 82% XIII (R' = Cl, R = Bu) (XV), m. 88-9° (iso-Pr2O-cyclohexane). Redn. of IX (R = Bu) with Zn, the excess Zn filtered off, and the filtrate treated with 2.05 g. equivs. NaNO2 at 0-5° gave a red product from which some XV was obtained after laborious purification; a small amt. of XIII (R' = NHC6H4Cl-p, R = Bu) (XVI) was also isolated. A soln. of XII (prepd. by reducing 2.5 g. X and removing the excess Zn by filtration under N) treated during 1 hr. with 945 mg. NaNO2 and 6.5 ml. AcOH at 0-5° under N gave 1.21 g. XIII (R' = Cl, R = C6H4OMe-p), m. 267-9° (decompn.) (EtOAc with C). XIV (3.1 g.), 250 ml. EtOH, and 75 ml. N NaOH refluxed and stirred 7 hrs., the soln. concd. to 100 ml., and acidified (pH 4.8) with concd. HCl gave 2.3 g. XVII (R = Et), m. 296-7° (decompn.) (uncor.) (EtOH). Similarly was prepd. 86% XVII (R = Bu), m. 290-2° (decompn.) (uncor.) (obtained by acidification of the reaction mixt.), and another form m. 284-5° (decompn.) (uncor.) (EtOH); the 2 forms were identical (by paper chromatography and ultraviolet absorption spectra in EtOH). XIV (7.0 g.) in 400 ml. dry EtOH added to NaOEt soln. (prepd. from 1.214 g. Na and 80 ml. dry EtOH), the mixt. heated to 70°, kept 10 min. at 70°, cooled, acidified (pH 4-5) with concd. HCl, evapd. in vacuo, the residue leached with 2 500-ml. portions hot C6H6, and the combined C6H6 solns. evapd. gave 4.9 g. XIII (R' = OEt, R = Et), m. 120° (1:1 C6H6-cyclohexane). Na (5.75 g.) in 300 ml. abs. EtOH satd. with H2O during 1.5 hrs., the soln. treated with 6.5 g. XIV, refluxed 2 hrs. (the reaction was conducted in a flask equipped with a H2O-cooled condenser surmounted by a Dewar-type condenser contg. solid CO2 and moisture was

L4 ANSWER 27 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
excluded), dild. with 100 ml. H2O, treated with C, filtered, the filtrate acidified to pH 2, the ppt. filtered off, washed with H2O, and dried in vacuo at 50° gave crude 4.1 g. XIII (R' = SH, R = Et) (XVIII), m. 200-2° (decompn.) (uncor.); anal. sample (by repptn. from 0.5N NaOH with acid, then EtOH) m. 210° (uncor.) (Kofler) and 199-201° (uncor.) (capillary). Similarly was prepd. 82% XIII (R' = SH, R = Bu), m. 193° [by repptn. from 0.5N NaOH with acid, or MeOCH2CH2OH - (XIX)-EtOH]. To 5.67 g. XVIII, 4.39 g. K2CO3, and 100 ml. HCONMe2 was added 3.65 ml. PhCH2Cl in 3 portions, the mixt. heated to 50°, kept 1 hr. at 50-5°, cooled, poured into 600 ml. H2O, the resulting oil induced to crystallize, the solid (7.8 g.) dissolved in 60 ml. hot EtOH, the soln. treated with C, filtered, the hot filtrate dild. with 40 ml. H2O, and allowed to cool to give 5.25 g. XIII (R' = SCH2Ph, R = Et), m. 102° (EtOH-H2O). N2H4.H2O (2.80 g.) added to 6.00 g. XV in 400 ml. anhyd. EtOH with stirring, the mixt. stirred 1 hr. at room temp., and chilled in an ice bath gave 5.10 g. XIII (R' = NHNH2, R = Bu) (XX), m. 195° (uncor.) (EtOH). XIV (400 mg.) and 8 ml. (iso-PrO)3P heated 7 hrs. at 168°, kept 3 days at 0-5°, the ppt. filtered off, slurried twice with 25-ml. portions hexane, dried in vacuo at 55°, and recrystd. from 1:1 C6H6-cyclohexane gave 423 mg. XIII [R' = PO(OPr-iso)2, R = Et)] (XXI), m. 119-20° (C6H6-cyclohexane). XXI (100 mg.) and 5 ml. N HCl refluxed 1 hr., freeze-dried, and the residue treated with 3 ml. EtOH gave 20 mg. XIII [R' = PO(OH)2, R = Et], m. 284-5° (uncor.) (3:1 EtOH-H2O). XIV (500 mg.) and 25 ml. EtOH satd. with NH3 heated 4 hrs. at 95-100° in a 40 ml. stainless steel bomb gave 330 mg. XIII (R' = NH2, R = Et) (XXII), m. 263-4° (uncor.) (EtOH). XIV (500 mg.), 40 g. 25% aq. Me2NH, and 50 ml. EtOH refluxed 2.5 hrs. (the app. was topped by a Dewar-type condenser contg. solid CO2) and the soln. concd. to 20 ml. gave 470 mg. XIII (R' = NMe2, R = Et) (XXIII), m. 198-9° (EtOH). By procedures used to prep. XXII and XXIII was prepd. 91% and 88%, resp., XIII (R' = NH2, R = Bu) (XXIV), m. 256-8° (uncor.) (XIX-EtOH). XV (300 mg.), 300 mg. (HOCH2CH2)2NH, and 15 ml. anhyd. EtOH refluxed 4 hrs., the soln. treated with C, filtered, the filter cake washed with 5 ml. EtOH, the combined filtrate and washing evapd. in vacuo, the residual sirup evapd. twice with 10 ml. portions EtOH, the resulting solid residue triturated with 10 ml. H2O, filtered off, washed with 5 ml. H2O, and dried in vacuo at 100° gave 325 mg. XIII [R' = N(CH2CH2OH)2, R = Bu], m. 124-5° (EtOAc). Similarly were prepd. 96% XIII (R' = NHCH2CH2OH, R = Et), m. 210° (HCONMe2-EtOH) (45 min. reflux period used); 78% XIII (R' = NHCH2CH2NEt2, R = Et), m. 168-9° (EtOH) (excess Et2NCH2CH2NH2 used); and 89% XIII (R' = NHBu, R = Bu) (XXV), m. 160° (50% EtOH) (the reaction time was 1.75 hrs.). XV (6.0 g.), 5.08 g. histamine di-HCl salt, 8.4 g. Et3N, and 250 ml. anhyd. EtOH refluxed 4 hrs. under anhyd. conditions, the mixt. dild. with 50 ml. H2O, chilled, filtered, and the filtrate concd. to 40 ml. gave 6.65 g. XIII (R' = histaminyl, R = Bu) (XXVI), m. 193-4° (50% EtOH). Similarly was prepd. 84% XVI, m. 233° (EtOH). Ultraviolet absorption data for the 3H-v-triazolo[4,5-d]pyrimidines were tabulated. Preliminary tests indicated that XX, XXV, and XXVI had moderate activity against sarcoma 180 in mice and that XV and XXIV were active against adenocarcinoma 755.
IT 91241-38-2P, Pyrimidine, 2-amino-4-p-anisidino-6-chloro-
RL: PREP (Preparation)
(preparation of)
RN 91241-38-2 CAPLUS
CN 2,4-Pyrimidinediamine, 6-chloro-N4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 27 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1960:87613 CAPLUS
DOCUMENT NUMBER: 54:87613
ORIGINAL REFERENCE NO.: 54:16655a-d
TITLE: The schistosomicidal and toxic effects of some N-(p-aminophenoxyalkyl)amides
AUTHOR(S): Collins, R. F.; Davis, M.; Edge, N. D.; Hill, J.; Reading, H. W.; Turn bull, Eleanor R.
CORPORATE SOURCE: May & Baker Ltd., Dagenham, UK
SOURCE: British Journal of Pharmacology and Chemotherapy (1959), 14, 467-75
CODEN: BJPCAL; ISSN: 0366-0826
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable

AB Compds. related to N-(p aminophenoxyalkyl)amide were prepared, and 102 were screened for schistosomicidal activity. Two of these compds., N-[5-(p-aminophenoxy)pentyl]phthalimide (I) and N-[5-(p-aminophenoxy)pentyl]benzamide (II) were investigated in detail. Given orally, I was inactive against Schistosoma mansoni in monkeys, but both I and II were effective in mice and hamstars. II was more toxic in rats, guinea pigs, and monkeys than I. Visual impairment in monkeys and cats by both compds. was considered to be less than other e-p-aminophenoxyalkyl derivs. not containing an amide group. Results of absorption studies of the 2 compds. in rats and mice show lower blood concentration after 4 hrs. Most of the drug was excreted in the 1st 24 hrs. I has been found to be moderately effective against S. haematobium infections in Africans.

IT 103758-22-1, Phthalimide, N-[5-[p-[(2-amino-6-methyl-4-pyrimidinyl)amino]phenoxy]pentyl]-
(pharmacology of)
RN 103758-22-1 CAPLUS
CN Phthalimide, N-[5-[p-[(2-amino-6-methyl-4-pyrimidinyl)amino]phenoxy]pentyl]- (6CI) (CA INDEX NAME)



L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1960:38924 CAPLUS
DOCUMENT NUMBER: 54:38924
ORIGINAL REFERENCE NO.: 54:7613f-i,7614a-i,7615a-i,7616a-i,7617a-i,7618a-d
TITLE: Chemotherapy of schistosomiasis. III. N-(p-amino-phenoxyalkyl)amides, -imides, and -sulfonamides
AUTHOR(S): Ashley, J. N.; Collins, R. F.; Davis, M.; Sirett, N. E.
CORPORATE SOURCE: May & Baker, Dagenham, UK
SOURCE: Journal of the Chemical Society (1959) 3880-94
CODEN: JCSOA9; ISSN: 0368-1769
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable

AB cf. C.A. 53, 17942c. Many acyl- and diacylaminoalkyl ethers of p-aminophenol (I) were prepared by a number of routes. Some of these compds. were effective against schistosomicides. K p-nitrophenoxide and 2-phthalimidoethyl bromide gave 22% 1-(p-nitrophenoxy)-2-phthalimidoethane, m. 152-4° (AcOH). Similarly prepared in either alc. or EtOCH2-CH2OH were: 44% 1-(p-nitrophenoxy)-3-phthalimidopropane, m. 189-91.5° (dioxane); 64% 1-(p-nitrophenoxy)-4-phthalimidobutane, m. 119° (AcOH); 60% 1-(p-nitrophenoxy)-10-phthalimidodecane, m. 102-3° (AcOH); and 55% 1-(p-nitrophenoxy)-6-phthalimido-3-hexene [from 6-phthalimido-1-(p-toluenesulfonyloxy)-3-hexene], m. 118-19° (aqueous AcOH). 1-(p-Nitrophenoxy)-5-phthalimidopentane (Ia) treated with aqueous N2H4.H2O in alc. and the amine liberated by shaking the complex with CHCl3 and warm 2N NaOH gave 1-amino-5-(p-nitrophenoxy)pentane (II), b0.02 160-5°. Similarly prepared were: 94% 1-amino-5-(p-aminophenoxy)pentane, m. 67-9° (ligroine) (dimethanesulfonate m. 244-6°); and 91% 1-(p-acetamidophenoxy)-5-aminopentane (IIa) m. 137-9° (C6H6) (methanesulfonate m. 155-7°). II (22.4 g.) and 28.6 g. tetrachlorophthalic anhydride heated 2 hrs. at 180-90°, cooled, and dissolved in 150 ml. hot EtOCH2CH2OH gave 96 % 1-(p-nitrophenoxy)-5-tetrachlorophthalimidopentane, m. 165-7°. Similarly prepared were: 84% 1-(p-nitrophenoxy)-5-(3-nitrophthalimido)pentane, m. 163-4.5°; 67% 1-(p-acetamidophenoxy)-5-(3-nitrophthalimido)pentane, m. 132-4°(alc.); and 65% 1-homophthalimido-5-(p-nitrophenoxy)pentane, m. 144-5° (Me2CO). 1-(p-Nitrophenoxy)-5-ureidopentane (61 g.), 24 g. CH2(CO2H)2, and 55 ml. AcOH heated to 70-80°, treated dropwise with 45 ml. Ac2O, left 8 hrs. at 90°, cooled, diluted with 84 ml. H2O, and filtered gave a solid, m. 178.5-80.0°, possibly an Ac derivative. Further dilution with 240 ml. H2O gave 1-[5-(p-nitrophenoxy)pentyl]barbituric acid, m. 149-51° (alc.). II (45 g.) and 15.2 g. Me salicylate heated 5 hrs. at 120°, dissolved in CHCl3, washed with 2N HCl, dried, and evaporated gave 73% 1-(p-nitrophenoxy)-5-(salicylylamido)pentane (III), m. 123-5°(C6H6). ClCO2Et (12 g.) slowly added to a cold solution of 35 g. III in 120 ml. C6H6, the mixture heated 2 hrs. at 100°, cooled, and diluted with H2O gave 86% 3,4-dihydro-3-[5-(p-nitrophenoxy)pentyl]-2,4-dioxo-5,6-benz-1,2-oxazine, m. 145-6° (AcOH and alc.). 5-(p-Nitrophenoxy)pentyl bromide (IIIa) (16.15 g.), 10.15 g. (±)-camphorimide, 5.4 ml. 10.4N KOH, and 25 ml. EtOCH2CH2OH refluxed 2 hrs. and the product crystallized gave 71% 1-camphorimido-5-(p-nitrophenoxy)pentane, m. 66-7° (aqueous alc.). N-[5-(p-Nitrophenoxy)pentyl]phthalhydrazide was similarly obtained in 23% yield, m. 160-2° (PhMe). II (22.4 g.) in 100 ml. CHCl3 refluxed 1 hr. with 9.8 g. maleic anhydride in 100 ml. CHCl3 gave 53% 1-[β-carboxyacrylamido)-6-(p-nitrophenoxy)pentane (IV), m. 91-3° (alc.). Similarly prepared were: 63% 1-(p-acetamidophenoxy)-5-(β-carboxyacrylamido)pentane, m. 161-3° (aq. AcOH); 1-(β-carboxymethyl-β-methylvaleramido)-5-(p-nitrophenoxy)pentane (not obtained cryst.); and 92% 1-(γ-carboxybutyramido)-5-(p-nitrophenoxy)pentane (V), m. 116-17°. IV (17.2 g.), 18 ml. Ac2O, and 1.8 g. freshly fused NaOAc stirred 1 hr. at 100° gave 51% 1-maleimido-5-(p-nitrophenoxy)pentane, m. 105-7° (ligroine). The glutaramic acid (37.3 g.) and 100 ml. AcCl refluxed 20 min., evapd., and the residue crystd. gave 84% 1-glutarimido-5-(p-nitrophenoxy)pentane, m. 87-8°(MeOH). 1-(β-Ethyl-β-methylglutarimido)-5-(p-nitrophenoxy)pentane was made similarly, but was not obtained cryst. Glutarimide (11.3 g.) and 28.8 g. 5-(p-nitrophenoxy)pentyl bromide refluxed 20 hrs. with 2.3 g. Na in 150 ml. alc., dild. with H2O, and extd. with CHCl3 gave 39% 1-(γ-ethoxycarbonylbutyramido)-5-(p-nitrophenoxy)pentane (VI), m. 90-1.5° (C6H6). Hydrolysis of VI with 1 equiv. 2N NaOH gave 93% V. When a similar condensation was carried out by using 1 equiv. of NaOH in aq. alc. 33% 5-(p-nitrophenoxy)pentyl glutaramate (VII), m. 93-5°(C6H6), was obtained identical with a specimen prepd. in 34% yield from 5-(p-nitrophenoxy)pentyl bromide and Ag glutaramate in dry dioxane. Its structure was confirmed by catalytic redn. of VII to 81% 5-(p-aminophenoxy)pentyl glutaramate, m. 116-18°, and subsequent hydrolysis to 5-(p-aminophenoxy)pentanol, m. 94-5°. The following p-RC6H4O(CH2)nNHR1 (VIII) were prepd. from IIa, 1-amino-4-(p-nitrophenoxy)butane, II, or 1-amino-8-(p-nitrophenoxy)octane with the appropriate acid chloride or anhydride either in C5H5N or under Schotten-Baumann conditions (n, R, R', % yield, m.p., and solvent of recrystn. given): 4, NO2, Bz, 82, 102-3°, aq. AcOH; 5, NO2, p-BrC6H4CO, 81, 153-4°, alc.; 5, NO2, p-MeC6H4CO, 73, 132-3°, AcOH; 5, NO2, p-O2NC6H4CO, 49, 148-50°, Me2CO; 5, NO2, p-AcOC6H4CO, 54, 131-3°, Me2CO; 5, NO2, p-HOC6H4CO, 91, 147-50°, PhMe; 5, NO2, o-MeO2CC6H4CO, 61, 140-1°, C6H6; 5, NO2, p-MeO2CC6H4CO, 56, 164-6°, alc.; 5, NO2, p-MeSO2C6H4CO, 22, 169-71°, AcOH; 5, NO2, hexahydrobenzoyl, 87, 123°, AcOH; 5, NO2, EtCO, 69, 79-80°, aq. alc.; 5, NO2, C5H11CO, 60, 59-60°, Et2O; 5, NO2, Ph2CHCO, 53, 104-6°, aq. Me2CO; 5, NO2, Ph(CH2)4CO, 82, 87-9°, aq. alc.; 5, NO2, 2,4-Cl2C6H3OCH2CO, 37, 112-14°, alc.; 5, NO2, C6H4(CO)2NCH2CO, 68, 183.5-5.0°, EtO(CH2)2OH; 5, AcNH, p-O2NC6H4CO, -, 214-17.5°, alc. or EtO(CH2)2OH; 8, NO2, PhSO2, 71, 73-5°, alc.; 5, NO2, p-MeC6H4SO2, 93, 154-6°, aq. alc.; 5, NO2, p-AcNHC6H4SO2, 77, 129-31°, aq. alc. N,N'-Bis[5-(p-nitrophenoxy)pentyl]terephthalamide (58%), m. 154-7° (alc.), and 39% N,N'-bis[5-(p-nitrophenoxy)pentyl]glutaramide, m. 127-9°(Me2CO), were similarly prepd. II and NCCH2CO2Et in refluxing alc. gave 68% 1-cyanoacetamido-5-(p-nitrophenoxy)pentane, m. 85-6° (aq. alc.). Similarly obtained in the absence of solvent was 73% N,N'-bis[5-(p-nitrophenoxy)pentyl]oxamide, m. 163.5-4.5° (CHCl3-alc.). Ethoxalyl chloride (13.65 g.) slowly added to 21.4 g. II in 100 ml. C5H5N, the soln. kept overnight at room temp., dild. with H2O and Et2O, and filtered gave 27% 1-ethoxalylamino-5-(p-nitrophenoxy)pentane, m. 85-7° (ligroine). II (36.4 g.), 13.95 ml. concd. HCl, and 64.5 g. HCONH2 heated 0.5 hr. at 145°, cooled, evapd., 100 ml. H2O added, and the crude product extd. with Et2O in a Soxhlet app. gave 78% 1-formamido-5-(p-nitrophenoxy)pentane, m. 71-2°. 2-Phenyloxazolone (8.2 g.) added to 12 g. II in CHCl3, the solvent evapd., and the residue heated 0.5 hr. at 100° gave 80% 1-hippuramido-5-(p-nitrophenoxy)pentane, m. 145-7°(alc.). Ia (17.7 g.) refluxed 15 min. with 50 ml. N NaOH gave 1-[o-carboxybenzamido)-5-(p-nitrophenoxy)pentane, m. 118-22° (CHCl3-ligroine). Tetra-Et pyrophosphate (2.7 ml.) added to 2.24 g. II and 1.79 g. p-acetamidobenzoic acid in 7 ml. di-Et phosphite, the mixt. heated 1 hr. at 100°, dild. with H2O, and cooled gave 55% 1-(p-acetamidobenzamido)-5-(p-

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
nitrophenoxy)pentane (IX), m. 187-8°(EtOCH2CH2OH). II (11.2 g.) added to 17.9 g. p-acetamidobenzoic acid and 9.52 g. p-MeC6H4SO2Cl in 40 ml. C5H5N, left 0.5 hr. at room temp., and the mixt. treated with 10 g. NaOH and 5 g. Na metabisulfite in 200 ml. H2O gave 60% IX. II (2.54 g.) in 10 ml. C5H5N refluxed 1.5 hrs. with 5 ml. BzCl gave 83% 1-dibenzoylamino-5-(p-nitrophenoxy)pentane, m. 119-20° (alc.). Benzyloxycarbonyl-β-alanine (24 g.) and 24 g. II in 75 ml. diethyl phosphite heated 0.5 hr. at 100° with 30 ml. tetraethyl pyrophosphite gave 90% 1-(N-benzyloxycarbonyl-β-alanylamino)-5-(p-nitrophenoxy)pentane (X), m. 137-8° (aq. alc.). X (35.05 g.) left 20 min. with 60 ml. 33% HBr with evolution of CO2, the soln. treated with Et2O, the hygroscopic hydrobromide filtered off, the salt dissolved in H2O, basified, and extd. with CHCl3 gave 1-(β-alanylamino)-5-(p-nitrophenoxy)pentane (XI), m. 93-5°(C6H6). XI (10.36 g.) and 4.56 g. DL-pantolactone in 50 ml. alc. refluxed 20 hrs., evapd., and washed with 2N NaOH, 2N HCl, and H2O gave 14.6 g. 1-(p-nitrophencxy)-5-(DL-pantothenamido)pentane, oil. 5-(p-Nitrophenoxy)pentyl bromide (XII) (43.2 g.) and 19.8 g. cyclohexylamine in 50 ml. alc. refluxed 19 hrs., cooled, and filtered gave 76% 1-cyclohexyl-amino-5-(p-nitrophenoxy)pentane-HBr, m. 221-3°(alc.); benzoyl deriv. m. 78-9° (aq. alc.). XII (44.5 g.) and 35 g. N-benzyloxybenzamide refluxed 24 hrs. with 3.5 g. Na and 300 ml. alc. gave 46% 1-(N-benzyloxybenzamido)-5-(p-nitrophenoxy)pentane, m. 77-8°. XII (57.6 g.), 50 ml. PhNH2, and 200 ml. alc. refluxed 20 hrs., concd., dild. with H2O, and crystd. gave 98% 1-anilino-5-(p-nitrophenoxy)pentane, m. 87-9° (alc.); Ac deriv. noncryst.; methanesulfonyl deriv. (XIII) (64%) m. 73-4° (C6H6-ligroine). XIII (42.7 g.), 5 ml. H2O, and 17.4 ml. MeI added to 3.5 g. Na in 300 ml. alc., the mixt. refluxed 3 hrs., concd., and dild. with H2O gave 78% 1-(N-methylmethanesulfonamido)-5-(p-nitrophenoxy)pentane, m. 61-3°(Et2O). XII (28.8 g.) and 22.4 g. II in 250 ml. alc. refluxed 20 hrs. and the 69% crude HBr shaken with BzCl in Me2CO-2N NaOH gave 66% N-benzoylbis[4-(p-nitrophenoxy)pentyl]amine, m. 114-15.5° (Me2CO-Et2O). Condensation of K p-nitrophenoxide with 4-benzoylbutyl bromide in EtOCH2CH2OH gave 89% 1-benzoyl-4-(p-nitrophenoxy)butane (XIV), m. 122-3° (AcOH). XIV (63 g.) and 25.2 g. (iso-PrO)3Al in 3 l. iso-PrOH slowly distd. 2 hrs., the soln. evapd., and the residue treated with dil. HCl gave 94% 1-hydroxy-5-(p-nitrophenoxy)-1-phenylpentane (XV), m. 61-2° (aq. alc.). PBr3 (21.6 ml.) added slowly under cooling at 10° to 54 g. XV in 500 ml. C6H6, the mixt. kept overnight at room temp., treated with H2O, the C6H6 layer sepd., the aq. layer extd. with Et2O, the combined org. layers dried, evapd., the mixt. refluxed 48 hrs. with 54 g. K phthalimide and 250 ml. Me2CO, and the product isolated gave 66% 5-(p-nitrophenoxy)-1-phenyl-1-phthalimidopentane (XVI), m. 131-2°(alc.). Hydrolysis of XVI with N2H4 and subsequent benzoylation afforded 69% 1-benzamido-5-(p-nitrophenoxy)-1-phenylpentane, m. 116-18°(C6H6). 1-(2-Hydroxyethoxy)-5-(p-nitrophenoxy)pentane was converted by p-MeC6H4SO2Cl in C5H5N into 81% p-toluenesulfonyl deriv., m. 49-50°, which condensed with K phthalide gave 65% 1-(p-nitrophenoxy)-5-(2-phthalimidoethoxy)pentane, m. 78-9° (MeOH). 5-(p-Nitrophenoxy)pentyl iodide (102 g.), 36 g. Na deriv. of 2-pyridone, 400 ml. alc., and 200 ml. H2O refluxed 24 hrs. gave 47% 1-(1,2-dihydro-2-oxo-1-pyridyl)-5-(p-nitrophenoxy)pentane, m. 103° (Me2CO), and a small amt. of 1-(p-nitrophenoxy)-5-(2-pyridyloxy)pentane. XII (2.88 g.), 1.73 g. Na deriv. of 2,3-dihydro-3-oxobenzisothiazole (XVII), and 10 ml. EtOCH2CH2OH refluxed 20 hrs. gave 39% 1-(2,3-dihydro-3-oxobenzisothiazol-2-yl)-5-(p-nitrophenoxy)pentane, m. 109-11° (alc.). Oxidn. with 30% H2O2 in AcOH at 100° gave the known saccharin deriv., m. 126-7°. XII (3.15 g.) condensed with 1.65 g. XVII by use of 0.76 g. K2CO3 in 50 ml. Me2CO gave 1.9 g. 1-(p-nitrophenoxy)-5(3-benzisothiazolyloxy)pentane, m. 97-9°

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
177-9°, alc.Et2O; 5, NHCHO, base, 89, 74-6°, C6H6; 5, NHCO2Et, base, 70, 77.5-9.0°, C6H6; 5, NHCOEt, CHPh3, -, 122.5-3.5°, -; 5, NHCOC5H11, base, 74, 86-7°, alc.Et2O; 5, NHCO(CH2)4Ph, base, 87, 92% CHCl3-ligroine; 5, NHCOCO2Et, base, 85, 78-80°, CHCl3-ligroine; 5, NHCOCO2Et, MeSO3H, -, 142-3°, alc.-Et2O; 5, NHCOCHPh2, base, 80, 101-2.5°, alc.-ligroine; 5, NHCOCH2C6H3Cl2-1,2,4, base, 84, 104.5-6.5°, alc.; 5, NHCOCH2N(CO2)C6H4-o, base, 98, 156.5-8.5°, alc.; 5, NHCOCH2NHCOPh, base, 81, 119-21°, alc.; 5, pantothenamido, base, 86, -, -; 5, hexahydrobenzamido, base, 85, 103-4°, C6H6; 5, N(COPh)2, base, 87, 92 3°, alc.; 4, NHCOPh, base, 80, 108°, alc.; 5, NHCOC6H4Me-p, base, 84, 123-4°, CHCl3-ligroine; 5, NHCOC6H4Br-p, base, 47, 118-20°, alc.; 5, NHCOC6H4Br-p, CHPh3, -, 154-5°, alc.; 5, NHCOC6H4OH-p, base, 67, 192.5-4.0°, alc.; 5, NHCOC6H4OH-o, base, 80, 122-3°, aq. MeOH; 5, NHCOC6H4CO2Me-p, base, 77, 141-3°, PhMe; 5, NHCOC6H4CO2H-p, base, 93, 242-4°, aq. HCONMe2; 5, NHCOC6H4SO2Me-p, base, 77, 144-5°, alc.; 5, NHCOC6H4NO2-p, base, 75, 139-41°, EtOAc; 5, NHCOC6H4NHAc-p, base, 89, 173.5-4.5°, alc.; 5, NHCOC6H4NH2-p, base, 80, 121-3°, alc.; 5, NHCOC6H4NH2-p, 2MeSO3H, -, 272-4°, alc.-Et2O; 5, NPhAc, base, 62, 66-8°, Et2O-ligroine; 5, N-cyclohexyl-benzamido, base, 80, 72-5°, Et2O-ligroine; 5, N(OCH2Ph)Bz, base, 96, 77-8°, aq. alc.; 5, N(OH)Bz, base 78, 105-7°, alc.; 5, NBz(CH2)5OC6H4NH2-p, 2MeSO3H, 82, 137-9°, alc.-Et2O; 5, 1,2-dihydro-2-oxopyridyl, base, 96, 114-15°, alc.; 5, 2-oxopiperidino, base, 56, 97-8°, H2O; 5, 2,3-dihydro-3-oxobenzisothiazol-2-yl, base, 78, 117-19°, C6H6; 5, 2-phthalimidoethoxy, base, 94, 104-6°, alc.; 2, 4-phthalimidobut-1-enyl, base, -, 101-3°, aq. alc.; 5, NHCONH (bis compd.), base, 72, 160-2°, alc.; 5, NHCOCONH (bis compd.), base, 79, 150-2°, EtOCH2CH2OH; 5, p-NHCOC6H4CONH (bis compd.), base, 53, 176-8°, xylene; 5, NHCO(CH2)3 CONH (bis compd.), base, 94, 133-5° and 140-1°, alc.; 5, NHCO(CH2)3CONH (bis compd.), MeSO3H, -, 227-30°, alc.; 8, NHSO2Ph, base, 79, 121-2°, alc.; 5, NHSO2C6H4Me-p, base, 67, 168-9°, alc.; 5, NHSO2C6H4NHAc-p, base, 79, 117-19°, aq. MeOH; 5, NHSO2C6H4NHAc-p, H2SO4, -, 198-201°, -; 5, NHSO2C6H4NH2-p, base, 64, 125-8°, aq.alc.; 5, NHSO2C6H4NH2-p, 2MeSO3H, -, 235-7°, -; 5, NPhSO2Me, base, 81, 67-8°, MeOH; 5, NMeSO2Me, base, 81, 76-7°, alc.-Et2O; 5, tetrahydro-1,1-dioxo-1,2-thiazin-2-yl, base, 60, 73°, Et2O; 5, 1,1-dioxonaphtho[1.8a.8-cd]isothiazol-2-yl, base, 92, 106-7°, alc. 1-(p-Aminophenoxy)-3-phthalimidopropane (m. 92-3°) converted to the MeI salt in 100% yield, m. 203-6° (H2O), and pyrolyzed under reduced pressure gave 100% 1-(p-dimethylaminophenoxy)-3-phthalimidopropane, m. 121-2°(alc.). 1-Benzenesulfonamido-5-(p-dimethylaminophenoxy)pentane, m. 71-2.5° (Et2O), similarly obtained (96%) from its MeI salt (96%), m. 183-5° (H2O). p-(N-Methylacetamido)phenol, 5-phthalimidopentyl bromide, and NaOEt in alc. gave 53% 1-[p-(N-methylacetamido)phenoxy]-5-phthalimidopentane (XIX), m. 83-5° (CHCl3-Et2O). 1-[p-(N-Methylbenzamido)phenoxy]-5-phthalimidopentane, m. 121-4°(MeOH), was similarly obtained. Refluxing XIX with concd. HCl gave 1-amino-5-(p-methylaminophenoxy)pentane, m. 76-9°(ligroine), decompd. on storage. The corresponding 5-phthalimido compd. treated with aq. alc.-N2H4 and the amine hydrolyzed gave 61% 1-benzamido-5-[p-(N-methylacetamido)phenoxy]pentane, m. 110-12° (Me2CO-ligroine). 1-Benzamido-5-[(p-(N methylformamido)phenoxy]pentane, m. 115-16° (Me2CO-Et2O), was similarly prepd. in 12% yield. Partial hydrolysis of either the N-formyl or the N-Ac deriv. with aq. HCl gave 60% 1-benzamido-5-(p-methylaminophenoxy)pentane, m. 91-2°

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(AcOH). CS2 (8.4 ml.) and 60 ml. HCONMe2 added successively to 32 g. II in 100 ml. PhMe, the mixt. left 0.5 hr., cooled, shaken 0.5 hr. with 32 g. HgO, filtered, the filtrate treated with 7.3 g. 90% mercaptoacetic acid, the soln. heated 0.5 hr. at 100°, concd., and dild. with Et2O gave 68% 3-[5-(p-nitrophenoxy)pentyl]rhodanine (XVIII), m. 112-13° (alc.). XVIII (30 g.) heated 3 hrs. at 100° with 20 ml. BzH, 200 ml. AcOH, and 40 ml. H2SO4 gave 96% 5-benzylidene deriv., m. 143-4° (AcOH). Thiazolidine-2,4-dione (14.1 g.) and 49.7 g. 5-(p-nitrophenoxy)pentyl iodide added successively to 3.43 g. Na and 200 ml. alc., the mixt. refluxed 20 hrs., cooled, and filtered gave 46% 3-[5-(p-nitrophenoxy)pentyl]thiazolidine-2,4-dione, m. 118-19° (alc.). Butane-1,4-sultam (2 g.) in 0.35 g. Na and 10 ml. alc. and refluxed 3 hrs. with 4.3 g. XII in 10 ml. alc. gave 79% N-[5-(p-nitrophenoxy)pentyl]butane-1,4-sultam, m. 89-90° (MeOH). N-[5-(p-Nitrophenoxy)pentyl]naphthalene-1,8-sultam (59%) was similarly prepd. from naphthalene-1,8-sultam, m. 1190 (alc.). 1-(p-Nitrophenoxy)-7-phthalimidoheptane (43.8 g.) reduced at 70°/56 lb./sq. in. in 350 ml. alc. over 2% PtO2 gave 55% 1-(p-aminophenoxy)-7-phthalimidoheptane, m. 107-9°. Concn. of the mother liquor gave 27% 1-(p-aminophenoxy)-7-hexahydrophthalimidoheptane, m. 73-5° (CHCl3-ligroine). 1-Maleimido-5-(p-nitrophenoxy)pentane (5.9 g.) kept 5 min. at 100° in 18 g. SnCl2.2H2O and 27 ml. concd. HCl, poured into 50% NaOH and 100 ml. CHCl3 at 0°, the soln. immediately sepd., and crystd. gave 71% 1-(p-aminophenoxy)-5-maleimidopentane, m. 122-4° (EtOAc-ligroine); methanesulfonate m. 194-5°. 3-[5-(p-Aminophenoxy)pentyl]rhodanine (40%), m. 104-6°(alc.), and 73% 3-[5-(p-aminophenoxy)pentyl]-5-benzylidenerhodanine, m. 133-5° (AcOH), were similarly prepd. 3-[5-(p-Aminophenoxy)pentyl]thiazolidine-2,4-dione was prepd. in 54% yield by reducing the corresponding NO2 compd. with SnCl2, or preferably with reduced Fe powder and aq. AcOH, m. 107-9° (alc.). 1-Amino-5-(p-aminophenoxy)pentane (14.55 g.), 8.36 g. CNCH2CO2Et, and 20 ml. MeOH kept 5 days gave 81% 1-(p-aminophenoxy)-5-(cyanoacetamido)pentane, m. 92-30 (alc.). The Ac deriv. was obtained directly from 1-(p-acetamidophenoxy)-5-aminopentane and NCCH2CO2Et. Similarly prepd. were 13% 1-(p-aminophenoxy)-5(dichloroacetamido)pentane, m. 81-2° (C6H6-ligroine), and 66% 1-(p-aminophenoxy)-5-(trichloroacetamido)pentane, m. 97-9° (Et2O). Concd. HCl (100 ml.) added during 1 hr. to a refluxing mixt. of 32.4 g. 1-(p-aminophenoxy)-5-phthalimidopentane (XVIIIa), 25 g. Sn, and 200 ml. alc., left 17 hrs., filtered, and the filtrate added to 200 ml. 50% NaOH gave 63% 1-(p-aminophenoxy)-5-phthalimidinopentane, m. 143-4°. Except where stated, the amines, p-H2NC6H4O(CH2)nR, were prepd. by catalytic redn. of the corresponding NO2 compds., usually over Raney Ni in alc., EtOCH2CH2OH, or HCONMe2 (n, R, deriv., % yield, m.p., and solvent given): 2, phthalimido, base, 59, 159-60°, alc.; 2, phthalimido, MeSO3H, -, 198-9°, -; 3, phthalimido, base, 94, 67-8° (or 92-3°), CHCl3-Et2O; 3, phthalimido, MeSO3H, -, 163-5°, EtOH-Et2O; 4, phthalimido, base, 59, 124-5°, alc.; 10, phthalimido, base, 70, 98°, alc.; 5, tetrachlorophthalimido, base, 55, 180-2°, EtOCH2CH2OH; 5, 3-nitrophthalimido, base, 30, 117-18°, alc.; 5, 3-nitro phthalimido, MeSO3H, -, 183-5°, alc.-Et2O; 5, 3-aminophthalimido, base, 87, 105-7°, alc.; 5, homophthalimido, MeSO3H, 85, 187-9°, MeOH; 5, 3,4-dihydro-2,4-dioxo-5,6-benz-1,3-oxazin-3-yl, base, 95, 136-8°, alc.; 5, camphorimido, 0.5H2SO4, 54, 183-5°, alc.-Et2O; 5, 1,2,3,4-tetrahydro-11,4-dioxophthalazin-2-yl, base, 43, 169-71°, alc.; 5, glutarimido, base, 93, 109°, alc.; 5, β-ethyl-Bmethylglutarimido, base, 57, 99-100°, C6H6; 5, hexahydro-2,4,6-trioxopyrimidin-1-yl, base, 78, 211-14° (effervescent), Me2NCHO-alc.; 4, α-phthalimidobenzyl, base, 73, 112-13°, alc.; 4, α-benzamidobenzyl, MeSO3H, 63,

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(Me2CO-ligroine); N-Bz deriv. m. 111-13°(C6H6-Et2O). 1-Benzenesulfonamido-5-[p-(N-methylacetamido)phenoxy]pentane, m. 109-11° (PhMe-ligroine), was similarly prepd. and was hydrolyzed to 62% 1-benzenesulfonamido-5-(p-methylaminophenoxy)pentane (XX), m. 83-5° (alc.). XX with HOCH2CH2Cl and CaCO3 in refluxing H2O gave 76% 1-benzenesulfonamido-5-[p-(2-hydroxy-N-methylethylamino)phenoxy]pentane, m. 76-8° (C6H6-ligroine). 1-(p-Aminophenoxy)-5-benzamidopentane (XXa) (14.9 g.), 4.7 g. (CH2Br)2, and 25 ml. alc. refluxed 20 hrs. gave 3.3 g. piperazine deriv. and 24% 1,2-bis[p-(5-benzamidopentyloxy)anilino]ethane (XXI), m. 155-7°(alc.). XXI (8.1 g.), 4.7 g. (CH2Br)2, and 4.2 g. NaHCO3 refluxed 20 hrs. in 30 ml. EtOCH2CH2OH gave 1,4-bis[p-(5-benzamidopentyloxy)phenyl]piperazine, m. 231-3°(EtOCH2CH2OH). POCl3 (2.74 g.) added to 4.12 g. 1-[p-bis(2-hydroxyethyl)aminophenoxy]-5-phthalimidopentane in 15 ml. C6H6, the mixt. refluxed 2 hrs., poured on ice, and extd. with C6H6 gave 81% 1-[p-bis(2-chloroethyl)aminophenoxy]-5-phthalimidopentane (XXII), m. 107-8° (alc.). XXII (17.96 g.), 5.66 g. 3-chloro-p-toluidine, 4.24 g. Na2CO3, and 75 ml. EtOCH2CH2OH refluxed 20 hrs. gave 63% 1-(3-chloro-p-tolyl)-4-[p-(5-phthalimidopentyloxy)phenyl]piperazine, m. 149-50° (CHCl3-alc.). 2-Amino-4-chloro-6-methylpyrimidine (14.35 g.), 32.4 g. XVIIIa, 100 ml. N HCl, and 500 ml. H2O refluxed 1 hr., and made alk. gave 67% 1-[p-(2-amino-6-methylpyrimid-4-ylamino)phenoxy]-5-phthalimidopentane, m. 211-13° (EtOCH2CH2OH); 1-methomethylsulfate (75%) m. 186-8° (alc.). NaNO2 (91.43 g.) in 24 ml. H2O added slowly at 0-5° to 4.16 g. p-aminobenzamidine-2HCl and 2.9 ml. concd. HCl in 17 ml. H2O, 6.28 g. XVIIIa in 20 ml. AcOH added quickly followed by NaOAc, and the product sepd. gave 68% 4-amidino-4'-[(5-phthalimido)pentyloxydiazoamino]benzene acetate, m. 210-12°(alc.). XXa (19.7 g.), 6.18 g. chloracetamide, 3.5 g. Na2CO3, and 200 ml. alc. refluxed 20 hrs. gave 61% 5-benzamido-1 (p-carbamoylmethylaminophenoxy)pentane, m. 161-3° (alc.). XVIIIa (3.24 g.), 1.8 g. D-glucose, and 0.5 ml. 5% alc. CaCl2 in 20 ml. alc. refluxed 1.5 hrs. gave 86% 1-(p-D-glucosylaminophenoxy)-5-phthalimidopentane, m. 110-15°. 1-Benzamido-5-(p-D-glucosylamino)pentane (83%) was similarly prepd., m. 119-20° (aq. MeOH). IIIa (14.6 g.), 10.65 g. 1-(3-chloro-p-tolyl)piperazine, and 75 ml. alc. refluxed 40 hrs. gave 76% 4-(3-chloro-p-tolyl) 1-[5-(p-nitrophenoxy)pentyl]piperazine (XXIII).HBr, m. 170-2°(alc.). Free XXIII m. 101-3°(alc.). Redn. of XXIII with Na2S gave 86% 1-[5-(p-aminophenoxy)pentyl]-4-(3-chloro-p-tolyl)piperazine, m. 95-6° (alc.). IIIa (5.76 g.) and 1.94 g. piperazine-6H2O heated 40 hrs. at 100° and the residue refluxed with alc. gave 92% 1,4-bis[5-(p-nitrophenoxy)pentyl]piperazine-2HBr, m. 253-5°; free base m. 122-3° (alc.). Catalytic redn. gave 92% 1,4-bis[5-(p-aminophenoxy)pentyl]piperazine, m. 124-6° (alc.-ligroine). The following RC6H4O(CH2)5R' were prepd. (R, R', m.p., and solvent for recrystn. given): p-NHCHO, NHBz, 163-4°, alc.; p-NHAc, NHBz, 165-7°, alc.; p-NHAc, NHAc, 155-7°, H2O; p-HO2C(CH2)2CONH, o-C6H4(CO)2N, 185-7°, AcOH; p-NH4O2C(CH2)2CONH, o-C6H4(CO)2N, 174-6°, -; p-(5-nitrofurfurylidene)amino, o-C6H4(CO)2N, 138-9°, CHCl3-alc.; p-PhCH:N, NHBz, 133-4° alc.; p-MeN(NO), o-C6H4(CO)2N, 104-5°, alc.; o-NO2, o-C6H4(CO)2N, 99.5°, alc.; o-NH2, o-C6H4(CO)2N, 94-5°, alc.; m-NHAc, o-C6H4(CO)2N, 127.5-9.0°, alc.; m-NH2, o-C6H4(CO)2N, 102-3°, alc.

IT 103758-22-1P, Phthalimide, N-[5-[p-[(2-amino-6-methyl-4-pyrimidinyl)amino]phenoxy]pentyl]- 111978-34-8P, 2-[5-[p-[(2-Amino-6-methyl-4-pyrimidinyl)amino]phenoxy]pentyl]-2-methyl-1,3-dioxoisoindolinium methyl sulfate
RL: PREP (Preparation)
(preparation of)

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 103758-22-1 CAPLUS
CN Phthalimide, N-[5-[p-[(2-amino-6-methyl-4-pyrimidinyl)amino]phenoxy]pentyl]- (6CI) (CA INDEX NAME)



RN 111978-34-8 CAPLUS
CN 2-[5-[p-[(2-Amino-6-methyl-4-pyrimidinyl)amino]phenoxy]pentyl]-2-methyl-1,3-dioxoisoindolinium methyl sulfate (6CI) (CA INDEX NAME)

CM 1

CRN 111978-33-7
CMF C25 H28 N5 O3



CM 2

CRN 21228-90-0
CMF C H3 O4 S

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1957:61796 CAPLUS
DOCUMENT NUMBER: 51:61796
ORIGINAL REFERENCE NO.: 51:11197e-g
TITLE: Geology of the Nokia region, Southwest Finland
AUTHOR(S): Marmo, Vladi
CORPORATE SOURCE: Geol. tutkimuslaitos, Otaniemi
SOURCE: Bull. comm. geol. Finlande (1957), No. 176, 38 pp.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The rocks of the Nokia area comprise phyllites and related rocks, Ca-rich schists, limestone, and dikes of diabase and tremolite-actinolite rock. Many aspects of the geology of the region are reviewed. The occurrence of trace elements (Zn, Ni, V, Cu, Mo, Cr, B) in the schists and other rocks is discussed. An account is given of the manner of origin of the rocks and their metamorphic facies. Two new chemical analyses of a tremolite-actinolite vein rock are given. 37 references.
IT 93001-35-5
(Derived from data in the 6th Collective Formula Index (1957-1961))
RN 93001-35-5 CAPLUS
CN Pyrimidine, 2-amino-4-p-anisidino-6-methyl- (7CI) (CA INDEX NAME)



L4 ANSWER 31 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1957:17528 CAPLUS
DOCUMENT NUMBER: 51:17528
ORIGINAL REFERENCE NO.: 51:3675b-d
TITLE: 1-(4-Anilino-2-pyrimidino)-3-alkylureas
INVENTOR(S): Burtner, Robert R.
PATENT ASSIGNEE(S): G.D. Searle and Co.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2748124		19560529	US 1954-428136	19540506

AB 1-[4-(N,4-Disubstituted anilino)-2-pyrimidino]-3-ethylureas (I) (the substituents = R and Y, resp., where Y is H and lower alkoxyl radicals containing less than 3 C atoms, and R is H and lower alkyl radicals containing less than 3 C atoms) are prepared from a 2-amino-4-halopyrimidine treated with aniline or a substituted aniline to give the 4-anilino-2-aminopyrimidine (II), and II is treated with an alkyl isocyanate in PhMe or dioxane at 85-120° to yield I. The I are useful in the field of cardiac pathology, showing digitalis-like activity. 2-Amino-4-chloropyrimidine (III) 43, PhNHEt 133, HCl 13, and in H2O 1100 parts (all by weight) refluxed 30 min., the mixture cooled, made alkaline with an excess of 50% aqueous NaOH, and the solidified oil rinsed with H2O, dried at 75°, and crystallized from approx. 5 vols. PhMe with decolorizing C yield 2-amino-4-(N-ethylanilino)pyrimidine (IV), white crystals, m. 142-4°. IV 41, EtNCO approx. 14, and dry PhMe 435 parts refluxed 12 hrs., the mixture chilled, filtered, and the crystalline product rinsed with PhMe, dried at 75° and recrystd. from 10 vols. EtOH yield white I (Y = H, R = Et), m. 186-7°. Similarly III, p-phenetidine, and HCl yield colorless 2-amino-4-(p-phenetidino)pyrimidine (V), m. approx. 163° (from EtOH). V and EtNCO in dioxane yield I (Y = EtO, R = H), feathery white needles, m. approx. 218° (from EtOH).
IT 100120-45-4P, Pyrimidine, 2-amino-4-p-phenetidino-
RL: PREP (Preparation)
(preparation of).
RN 100120-45-4 CAPLUS
CN Pyrimidine, 2-amino-4-p-phenetidino- (6CI) (CA INDEX NAME)



L4 ANSWER 32 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1955:60839 CAPLUS
DOCUMENT NUMBER: 49:60839
ORIGINAL REFERENCE NO.: 49:11726h-i,11727a-b
TITLE: 2-Amino-4-substituted amino-6-arylpyrimidines
INVENTOR(S): Hitchings, Geo. H.; Russell, Peter B.
PATENT ASSIGNEE(S): Burroughs Wellcome and Co. (U.S.A.) Inc.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2691655		19541012	US 1952-289907	19520524

AB 2-Amino-4-substituted amino-6-arylpyrimidines, useful as growth inhibitors for rapidly growing virus are prepared from the corresponding 4-hydroxypyrimidine by conversion to the-4-chloropyrimidine and subsequent reaction with the appropriate amine. Thus, 47 g. BzCHPrCO2Et, refluxed 6 hrs. with 12 g. guanidine carbonate in 200 ml. EtOH, gives 2-amino-4-hydroxy-5-propyl-6-phenylpyrimidine (I), m. 311-13°, obtained by dilution of the reaction mixture with 500 ml. H2O and recrystn. of the precipitate from EtOH; the 5-benzyl analog (II), m. 340°, was prepared similarly from BzCH(CH2Ph)CO2Et. Refluxing 10 g. I with 50 ml. POCl3 until solution was achieved, removing the excess POCl3, and suspending the residue in iced aqueous NH4OH gave 2-amino-4-chloro-5-propyl-6-phenylpyrimidine (III). Similarly, II yields the 5-benzyl analog (IV) of III; heating 5 g. III with 100 ml. of a saturated solution of MeNH2 in EtOH in a bomb for 16 hrs. at 150° gives 4.2 g. 4-MeNH analog of III, m. 198°, and IV gives the 4-MeNH analog of IV, m. 177°. Refluxing 5 g. III with 25 ml. of PhNH2 5 hrs., cooling, and recrystg. the precipitate from EtOH, gives needles of the 4-PhNH analog of III, m. 171°; 4-PhNH analog of IV, m. 211°. The following compds. are obtained by analogous procedures: 2-amino-4-methylamino-6-(2-naphthyl)pyrimidine, m. 238-9°; 2-amino-4-methylamino-6-phenylpyrimidine, m. 195-6°, and its 4-PhNH, m. 305-6° (decomposition), 4-(p-ClC6H4NH), m. 304-5°, and 4-(p-MeOC6H4NH) analogs, m. 259-63°.
IT 875233-37-7P, Pyrimidine, 2-amino-4-p-anisidino-6-phenyl-
RL: PREP (Preparation)
(preparation of)
RN 875233-37-7 CAPLUS
CN Pyrimidine, 2-amino-4-p-anisidino-6-phenyl- (5CI) (CA INDEX NAME)



L4 ANSWER 33 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1954:7533 CAPLUS
DOCUMENT NUMBER: 48:7533
ORIGINAL REFERENCE NO.: 48:1445e-i
TITLE: Therapeutically useful pyrimidines
PATENT ASSIGNEE(S): Burroughs Wellcome & Co. (U.S.A.) Inc.; Wellcome Foundation Ltd.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 681712		19521029	GB 1949-23768	19490914

GI For diagram(s), see printed CA Issue.

AB Physiologically active compds. were prepared, represented by N:C(NH2)N:CR3.CR2:CR1 (I) where R1 is Ph, 2-C10H7, p-ClC6H4, p-BrC6H4, or p-O2NC6H4; R2 is H, PhCH2, or straight- or branched-chain alkyl radical of not more than 7 C atoms; and R3 is NH2, straight- or branched-chain alkyl amino of not more than 7 C atoms, or a MeC6H4NH, PhCH2NH, PhNH, p-ClC6H4NH, p-BrC6H4NH, p-MeOC6H4NH, or p-EtOC6H4NH, Cl, or HO. The compds. were prepared from the p-HO derivs. (prepared by refluxing guanidine carbonate in alc. with the appropriate oxo ester), which were converted to the corresponding Cl derivs. with POCl3, and the Cl derivative, treated with the corresponding amine gave I (R3 = NHR). The following I (R1, R2; R3, and m.p. given) are disclosed: Ph, H, Cl, 148° (from aqueous EtOH); Ph, H, NH2, 162° (from EtOH); Ph, Me, HO, 287°; Ph, Me, Cl, 127-8°; Ph, Me, NH2, 196-7° (from EtOH); Ph, Pr, HO, decompose 311-13°; Ph, Pr, Cl, -; Ph, Pr, NH2, 165-6° (from aqueous EtOH); Ph, PhCH2, HO, decompose 334° (from EtOH); Ph, PhCH2, Cl, -; Ph, PhCH2, NH2, 222-3° (from aqueous EtOH); Ph, H, NHMe, 195-6° (from H2O); Ph, H, NHPh, decompose 305-6° (from HOAc); Ph, H, p-ClC6H4NH, 304-5° (from HOAc); Ph, H, p-MeOC6H4NH, 259-63° (from HOAc); p-ClC6H4, H, HO, decompose 344-7° (from HOAc); p-ClC6H4, H, Cl, -; p-ClC6H4, H, NH2, 161-2° (from aqueous EtOH); p-ClC6H4, Me, HO, 331-3° (from aqueous EtOH); p-ClC6H4, Me, Cl, -; p-ClC6H4, Me, NH2, 184-5° (from aqueous EtOH); p-O2NC6H4, H, HO, decompose 334° (from HOAc); p-O2NC6H4, H, Cl, -; p-O2NC6H4, H, NH2, decompose 239° (from EtOH); 2-C10H7, H, HO, -; 2-C10H7, H, Cl, -; 2-C10H7, H, NH2, 205-6° (from aqueous EtOH); 2-C10H7, H, NHMe, 238-9° (from aqueous MeOH).

IT 875233-37-7P, Pyrimidine, 2-amino-4-p-anisidino-6-phenyl-
RL: PREP (Preparation)
(preparation of)

RN 875233-37-7 CAPLUS

CN Pyrimidine, 2-amino-4-p-anisidino-6-phenyl- (5CI) (CA INDEX NAME)



L4 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1948:5794 CAPLUS
DOCUMENT NUMBER: 42:5794
ORIGINAL REFERENCE NO.: 42:1272i,1273a-i,1274a-i,1275a-h
TITLE: Synthetic antimalarials. XXI. 4-Arylamino-6-(aminoalkylamino)pyrimidines. Further variations
AUTHOR(S): Basford, F. R.; Curd, F. H. S.; Hoggarth, E.; Rose, F. L.
CORPORATE SOURCE: Imperial Chem. Industries Ltd., Manchester, UK
SOURCE: Journal of the Chemical Society (1947) 1354-64
CODEN: JCSOA9; ISSN: 0368-1769
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable

GI For diagram(s), see printed CA Issue.

AB cf. C.A. 42, 187c. This is a continuation of the work reported in C.A. 41, 131b. In that work it was pointed out that, in compds. of type I (R = dialkylaminoalkyl, R' = p-ClC6H4NH), there do not exist 2 amidine units capable of independent tautomerism as are found in the 2 isomeric types (II and III). Since one important development (C.A. 41, 134b) was in part based on the recognition of the possible significance of this difference, it was desirable to demonstrate, with as much certainty as possible, that antimalarial activity could not be developed in compds. of type I. 4-Chloro-6-hydroxy-2-methylpyrimidine (IV) (14.4 g.) and 11.6 g. Et2NCH2CH2NH2, heated 8 hrs. at 150-60°, give the 4-(2-diethylaminoethylamino) derivative, whose HCl salt (V) (with 1 mol. H2O, lost at 100°) m. 193-5°; 20 g. V and 75 cc. POCl3, refluxed 3 hrs., give 9.9 g. 4-chloro-6-(2-diethylaminoethylamino)-2-methylpyrimidine (VI), b0.15 136-7° (dipicrate, yellow, m. 144-5°). 4-(3-Diethylaminopropylamino) analog of V (with 1.5 mols. H2O, 1 of which is lost at 100°) m. 87-9° (air-dried) or 186-8° (dried at 100°); 6-(3-diethylaminopropylamino) analog (VII) of VI b0.15 143-5° (dipicrate, yellow, m. 158-9°). VI (4.85 g.), 2.55 g. p-ClC6H4NH2, 25 cc. H2O, and 2.2 cc. 10 N HCl, refluxed 6 hrs., give 86.2% 4-p-chloroanilino-6-(2-diethylaminoethylamino)-2-methylpyrimidine (VIII), m. 148° (C.A. 41, 131b); VII gives the 6-(3-diethylaminopropylamino) analog, m. 129-31°. IV (28.9 g.) and 31.6 g. Et2N(CH2)3CHMeNH2, heated 8 hrs. at 150-60°, 180 cc. POCl3 added to the cooled residue, and the mixture refluxed 3 hrs., give 36.4 g. 4-chloro-6-(4-diethylamino-1-methylbutylamino)-2-methylpyrimidine, b0.125 168-70° (dipicrate, yellow, m. 171-3°); treated with p-ClC6H4NH2 as above, this yields the 6-(4-diethylamino-1-methylbutylamino) analog of VIII, b0.15 220-5°; the dipicrate m. 159-61° (previously reported as 149-51°; the 2 compds. are probably dimorphous; the conditions for obtaining the 2 forms were not fully elucidated). 2-Chloro-4-amino-6-methylpyrimidine (7.2 g.), 6.4 g. p-ClC6H4NH2, 25 cc. H2O, and 0.5 cc. 10 N HCl, refluxed 1 hr., give 2-amino-2-p-chloroanilino-6-methylpyrimidine, b0.5 190-2°, m. 121-2°; this also results on heating 10 g. 4-chloro-2-p-chloroanilino-6-methylpyrimidine and 30 cc. NH4OH 12 hrs. at 140-50°. Similarly 4-chloro-2-amino-6-methylpyrimidine yields the 4-p-chloroanilino analog, m. 216-18°; this results also on heating 5 g. 4-chloro-2-(p-chlorophenylguanidino)-6-methylpyrimidine and 25 cc. saturated EtOH-NH3 12 hrs. at 175°. 4-Chloro-6-amino-2-methylpyrimidine (7.2 g.), 6.4 g. p-ClC5H4NH2, 25 cc. H2O, and 0.5 cc. 10 N HCl, refluxed 1 hr., give 4-amino-6-p-chloroanilino-2-methylpyrimidine, m. 192-4°. 4,6-Dichloro-2,5-dimethylpyrimidine (IX) (8.85 g.), 6.4 g. p-ClC6H4NH2, 40 cc. H2O, and 2 cc. 10 N HCl, refluxed 2 hrs., give 9 g. 4-chloro-6-p-chloroanilino-2,5-dimethylpyrimidine (X), m. 176-7°; X results also on heating 5.3 g. IX and 4.2 g. p-ClC6H4NH2 in 30 cc. AcOH containing a crystal of KI 20 hrs. at 40°. IX (25 g.), 250 cc. H2O,

L4 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

and 100 cc. HCl, refluxed 1 hr., give 16.3 g. 4-chloro-6-hydroxy-2,5-dimethylpyrimidine (XI), m. 225°. XI (25 g.) and 18.3 g. Et2NCH2CH2NH2, heated 8 hrs. at 150-60°, give 4-(2-diethylaminoethylamino)-6-hydroxy-2,5-dimethylpyrimidine (characterized as the dipicrate, yellow, m. 154°); refluxed 5 hrs. with POCl3, there results 21.9 g. 4-chloro-6-(2-diethylaminoethylamino)-2,5-dimethylpyrimidine (XII), b0.085 139°; hydrate m. 80°; dipicrate, yellow, m. 143°. XI (31.7 g.) and 31.6 g. Et2N(CH2)3CHMeNH2, heated 8 hrs. at 150-60°, give 4-(4-diethylamino-1-methylbutylamino)-6-hydroxy-2,5-dimethylpyrimidine, whose HCl salt (XIII) could not be crystd.; dipicrate m. 163-4°; 62 g. crude XIII and 225 cc. POCl3, refluxed 4 hrs., give 22.05 g. 4-chloro-6-(4-diethylamino-1-methylbutylamino)-2,5-dimethylpyrimidine, b0.055 144-5° (a cryst. deriv. could not be prepd.). X (14.6 g.), 15 g. Et2NCH2CH2NH2, and a trace of KI, heated 6 hrs. at 150-60°, give 11.6 g. 4-p-chloroanilino-6-(2-diethylaminoethylamino)-2,5-dimethylpyrimidine (XIV), b0.07 209°; di-HCl salt m. 263-4°; it results also (5.7 g. yield) on heating 5.13 g. XII, 3.28 g. p-ClC6H4NH2.HCl, and 0.25 cc. HCl 6 hrs. at 150-60°. 6-(3-Diethylaminopropylamino) analog of XIV m. 105°; di-HCl salt m. 275-6° (decompn.). 6-(4-Diethylamino-1-methylbutylamino) analog of XIV b0.55 208° (cryst. derivs. could not be prepd.). XII (10.26 g.), 6.9 g. p-BrC6H4NH2.HCl, and a few drops HCl, heated 6 hrs. at 150-60°, give 4-p-bromoanilino-6-(2-diethylaminoethylamino)-2,5-dimethylpyrimidine, whose di-HCl salt m. 265-6°. IX (5.31 g.), 4.5 g. p-MeOC6H4NH2, 30 cc. AcOH, and 0.2 g. 10 N HCl, stirred 20 hrs. at 40-5°, 4 g. AcONa added, and the soln. dild. with 300 cc. H2O, give 6.4 g. 4-chloro-6-p-methoxyanilino-2,5-dimethylpyrimidine (XV), m. 201°; XV results in 9.5-g. yield from 8.85 g. IX, 6.15 g. p-MeOC6H4NH2, 40 cc. H2O, 20 cc. Me2CO, and 1 cc. 10 N HCl on refluxing 3 hrs. XV (10 g.), 14 g. Et2NCH2CH2NH2, and a trace of KI, heated 6 hrs. at 150-60°, give 8.9 g. 4-p-methoxyanilino-6-(2-diethylaminoethylamino)-2,5-dimethylpyrimidine, b0.5 203°; di-HCl salt, with 1 mol. H2O, m. 254-5°. IX (5.22 g.), 4.55 g. p-O2NC6H4NH2, 50 cc. AcOH, and a little KI, heated 18 hrs. at 55-60°, give 5.2 g. 4-chloro-6-p-nitroanilino-2,5-dimethylpyrimidine (XVI), yellow, m. 208-10°. XII (1 g.) and 0.68 g. p-O2NC6H4NH2.HCl, heated 6 hrs. at 150-60°, give 4-p-nitroanilino-6-(2-diethylaminoethylamino)-2,5-dimethylpyrimidine, yellow, m. 104-6°; di-HCl salt, yellow, m. 254-6°; the base results in 1.8-g. yield on heating 1.8 g. XVI, 1.8 g. Et2NCH2CH2NH2, and a trace of KI 5 hrs. at 155-65°. 4,6-Dihydroxy-2-methyl-5-ethylpyrimidine (30 g.) and 110 cc. POCl3, refluxed 2 hrs., give 4,6-dichloro-2-methyl-5-ethylpyrimidine (XVII), b. 212-14°; 25 g. XVII, 100 cc. HCl, and 250 cc. H2O, refluxed 2.5 hrs., give 19.2 g. 4-chloro-6-hydroxy-2-methyl-5-ethylpyrimidine (XVIII), m. 200°. XVIII (8.63 g.), 9.6 g. p-ClC6H4NH2, and 0.5 cc. HCl, heated 8 hrs. at 160-70°, give 8.1 g. 4-p-chloroanilino-6-hydroxy-2-methyl-5-ethylpyrimidine (XIX), m. 275°; XVII (5.73 g.) and 4.3 g. p-ClC6H4NH2 in 30 cc. AcOH contg. a crystal of KI, stirred 20 hrs. at 35-45°, give 4-chloro-6-p-chloroanilino-2-methyl-5-ethylpyrimidine (XX), m. 166°; XX was prepd. also by refluxing 8.9 g. XIX and 45 cc. POCl3 1.5 hrs. XVIII (34.5 g.) and 26 g. Et2N(CH2)3NH2, heated 8 hrs. at 150-60°, give 4-(3-diethylaminopropylamino)-6-hydroxy-2-methyl-2-ethylpyrimidine (XXI), characterized as the dipicrate, yellow, m. 188°; 59.5 g. of the HCl salt of XXI and 225 cc. POCl3, refluxed 15 hrs., give 4-chloro-6-(3-diethylaminopropylamino)-2-methyl-5-ethylpyrimidine, b0.095 142° (dipicrate yellow, m. 147-8°). XX (2 g.), 2 g. Et2NCH2CH2NH2, and a little KI, heated 6 hrs. at 140-50°, give 4-p-chloroanilino-6-(2-diethylaminoethylamino)-2-

L4 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

methyl-5-ethylpyrimidine (XXII), whose di-HCl salt m. 268-70° (decompn.); the 6-(3-dimethylaminopropylamino) analog of XXII was characterized as the dipicrate, yellow, m. 171-3°, and the di-HCl salt, with 2 mols. H2O, m. 278-9° (decompn.). The 6-(3-diethylaminopropylamino) analog of XXII (prepd. from XX and p-ClC6H4NH2) b0.065 210° (di-HCl salt, with 1 mol. H2O, m. 162°), XVIII (17.25 g.), 12.3 g. p-MeOC6H4NH2, and 1 cc. HCl, heated 3 hrs. at 160-70°, give 4-p-methoxyanilino-6-hydroxy-2-methyl-5-ethylpyrimidine (XXIII), m. 199-200°. XVII (5.73 g.) and 4.1 g. p-MeOC6H4NH2 in 30 cc. AcOH contg. a little KI, stirred 20 hrs. at 40-5°, give 4-chloro-6-p-methoxyanilino-2-methyl-5-ethylpyrimidine (XXIV), m. 157°; it results also from XXIII and POCl3 on refluxing 1.5 hrs. XXIV (2.75 g.) and 2.5 g. Et2NCH2CH2NH2, heated 8 hrs. at 155-65°, give 4-p-methoxyanilino-6-(2-diethylaminoethylamino)-2-methyl-5-ethylpyrimidine (XXV), whose di-HCl salt m. 250-1° (decompn.); the 6-(3-dimethylaminopropylamino) analog of XXV m. 106-7°. 4,6-Dihydroxy-5-phenyl-2-methylpyrimidine (40 g.) and 140 cc. POCl3, refluxed 2 hrs., give 4,5-dichloro-5-phenyl-2-methylpyrimidine (XXVI), m. 160°; 11.95 g. XXVI, 6.4 g. p-ClC6H4NH2, and 3 cc. AcOH, heated 1 hr. at 110-15°, give 9.5 g. 4-chloro-6-p-chloroanilino-5-phenyl-2-methylpyrimidine, m. 155-6°; this yields 4-p-chloroanilino-6-(2-diethylaminoethylamino)-5-phenyl-2-methylpyrimidine, m. 88-9°; the 6-(3-diethylaminopropylamino) analog m. 77-8°; these compds. did not form cryst. HCl salts. 4,6-Dichloro-2-aminopyrimidine (12.3 g.) and 9.6 g. p-ClC6H4NH2 in 9 g. AcOH, heated to 110°, boiled 1.5 hrs. with 150 cc. EtOH contg. NH4OH, and dild. with H2O, give 11.6 g. 4-chloro-2-amino-6-p-chloroanilinopyrimidine (XXVII), m. 242-3° (di-HCl salt, with 1 mol. H2O, m. 252-4°); this results also on refluxing the reactants in H2O, Me2CO, and 10 N HCl 2 hrs.; 6-p-methoxyanilino analog m. 224-5° (HCl salt, m. 236° (decompn.)); 6-p-toluidino analog, m. 239-41° (HCl salt, m. 259-60° (decompn.). The HCl salt of XXVII (9.7 g.) and 4.84 g. Et2NCH2CH2NH2, heated 5 hrs. at 150-60°, give 8 g. 2-amino-4-p-chloroanilino-6-(2-diethylaminoethylamino)-pyrimidine, m. 135°; 6-(2-dimethylaminoethylamino) analog m. 139-40°; 6-(3-dimethylaminopropylamino) analog m. 132-4°; 6-(3-diethylaminopropylamino) analog m. 109-11°; 6-(4-diethylamino-1-methylbutylamino) analog m. 128-30°; 2-amino-4-p-methoxyanilino-6-(2-diethylaminoethylamino)pyrimidine m. 123-5°; 4-p-toluidino analog m. 108-9°. 4,6-Dichloro-2-amino-5-ethylpyrimidine (XXVIII) (19.2 g.), 12.75 g. p-ClC6H4NH2, and 6 g. AcOH, heated 0.5 hr. at 100-10°, give 19.25 g. 4-chloro-2-amino-6-p-chloroanilino-5-ethylpyrimidine, m. 158-60° (HCl salt, m. above 290°); 12.8 g. XXVIII and 7.86 g. p-NCC6H4NH2 with 4 g. AcOH, heated 1 hr. at 120-30°, give 10 g. 4-chloro-2-amino-6-p-cyanoanilino-5-ethylpyrimidine, m. 230-2°. HN:C(NH2)2.HNO3 (24.4 g.), added to 9.2 g. Na in 250 cc. MeOH and, after refluxing 0.5 hr., treated with 47.2 g. PhCH(CO2Et)2 and boiled 3 hrs., gives 25.6 g. crude 2-amino-4,6-dihydroxy-5-phenylpyrimidine; refluxed with POCl3 3 hrs., this yields 4,6-dichloro-2-amino-5-phenylpyrimidine, m. 221-2°; with p-ClC6H4NH2 and AcOH (1.5 hrs. at 120-30°) there results 4-chloro-2-amino-6-p-chloroanilino-5-phenylpyrimidine, m. 228-9°. The following were prepd. by heating the appropriate amine and pyrimidine with a trace of KI 6 hrs. at 160-5°: 2-amino-4-p-chloroanilino-6-(2-diethylaminoethylamino)-5-ethylpyrimidine (XXIX), m. 71-2°; 6-(3-dimethylaminopropylamino) analog (XXX), m. 130-2°; 6-(3-diethylaminopropylamino) analog (XXXI), m. 102-3°; 4-p-cyanoanilino analog of XXIX, m. 151-2°; 5-Ph analog of XXIX, m. 170-1°; 5-Ph analog of XXX, m. 172-3°; 5-Ph analog of XXXI,

L4 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
m. 157-8°. The following compds. were prepd. from the requisite 4,6-dichloro-2-aminopyrimidine and 1 mol. each of the amine and AcOH by heating 3 hrs. at 100-10° (115-20° for the Ph derivs.).
4-Chloro-2-amino-6-(2-diethylaminoethylamino)pyrimidine m. 93-5°; 5-Et deriv. m. 105-6°; 5-Ph deriv. m. 138-9°.
4-Chloro-2-amino-6-(3-diethylaminopropylamino)pyrimidine m. 86-7°; 5-Et deriv. m. 115-16°; 5-Ph deriv. m. 131-2°.
4-Chloro-2-amino-5-ethyl-6-[3-(1-piperidyl)propylamino]-pyrimidine m. 170-1°; 5-Ph analog m. 151-2°. None of the compds. contg. an NH2 group in the 2-position of the pyrimidine nucleus exhibited any antimalarial activity, nor did any of the several 5-Et or 5-Ph derivs. which were prepd.

IT 91241-38-2P, Pyrimidine, 2-amino-4-p-anisidino-6-chloro- 856971-31-8P, Pyrimidine, 2-amino-4-p-anisidino-6-chloro-, hydrochloride
RL: PREP (Preparation)
(preparation of)

RN 91241-38-2 CAPLUS
CN 2,4-Pyrimidinediamine, 6-chloro-N4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 856971-31-8 CAPLUS
CN Pyrimidine, 2-amino-4-p-anisidino-6-chloro-, hydrochloride (5CI) (CA INDEX NAME)



● HCl

L4 ANSWER 35 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



● HCl

L4 ANSWER 35 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1944:33307 CAPLUS
DOCUMENT NUMBER: 38:33307
ORIGINAL REFERENCE NO.: 38:4952h-i,4953a-b
TITLE: Arylaminoheterocyclic compounds. II. Arylaminopyrimidines
AUTHOR(S): Banks, C. Kenneth
SOURCE: Journal of the American Chemical Society (1944), 66, 1131
CODEN: JACSAT; ISSN: 0002-7863
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable

AB PhNH2 and 2-amino-4-chloropyrimidine (0.1 mol each) and 1 mL. HCl in 100 mL. H2O, refluxed 30 min. and the product made strongly alkaline with 10 N NaOH, give 92% of 2-amino-4-anilinopyrimidine, m. 155-6° (m. ps. corrected); solution in glacial AcOH and precipitation with ether give the diacetate, m. 170°; heating, in vacuo, or solution of the base in dilute AcOH gives the monoacetate, m. 176-8°; alc. HCl with addition of 5 vols. AcOBu gives the HCl salt, m. 184-5°. The following 4 substituted 2-aminopyrimidines were similarly prepared: 2,6-dimethylanilino, m. 186-7°; 4-phenylanilino, m. 193-5°; 2-isomer, m. 130-2°; 1-naphthylamino, m. 133-4°; morpholino, m. 157-61°; 4-acetylanilino-HCl, m. 275-6°; 4-acetamidoanilino-HCl, m. 299-300°; 3,4-dimethoxyanilino-HCl, m. 270°; 4-methoxyanilino-HCl, m. 276-8°; 2,6-dihydroxyanilino-2HCl, m. 123-4°; 2-hydroxyanilino-2HCl, m. above 200°; 3-isomer-HCl, m. 178-80°; 4-isomer, m. 245-7° (decomposition) (HCl salt, m. 275-7°); 4-carboxyanilino, m. 295-7° (decomposition) (diethylaminoethanol ester-3HCl, m. above 250°); 2-carboxyanilino (Na salt), m. above 250°. 4-Amino-2-anilinopyrimidine-HCl, m. 149-50°; 2-amino-4-anilino-6-methylpyrimidine, m. 170-2°; 2,4-dianilinopyrimidine, m. 136-8° (HCl salt, m. 194-5°).

IT 857628-04-7, Phenol, p-(2-amino-4-pyrimidylamino)- (hydrochlorides)

RN 857628-04-7 CAPLUS
CN Phenol, p-(2-amino-4-pyrimidylamino)- (4CI) (CA INDEX NAME)



IT 861031-85-8P, Pyrimidine, 2-amino-4-p-methoxyanilino-, -HCl
RL: PREP (Preparation)
(preparation of)

RN 861031-85-8 CAPLUS
CN Pyrimidine, 2-amino-4-p-methoxyanilino-, -HCl (4CI) (CA INDEX NAME)

```
=> d his

     (FILE 'HOME' ENTERED AT 11:44:44 ON 26 JUL 2007)

     FILE 'REGISTRY' ENTERED AT 11:44:56 ON 26 JUL 2007
L1                STRUCTURE UPLOADED
L2             18 S L1
L3            411 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 11:46:03 ON 26 JUL 2007
L4             35 S L3

=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   185.86     358.62

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                   -27.30     -27.30

STN INTERNATIONAL LOGOFF AT 11:48:04 ON 26 JUL 2007
```